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This thesis describes two approaches for studying of lipoprotein metabolism in sheep. 
The first approach involves the assay of lipoprotein lipase (LPL) activity to determine the role of 
lipoprotein-triacylglycerol fatty acids in fat deposition in sheep. This enzyme is the rate limiting 
enzyme in the hydrolysis of fatty acids from lipoprotein-triacylglycerol. The second approach 
was to characterize and quantify in vivo lipoprotein metabolism using iodinated very low density 
lipoprotein e25I-VLDL) and low density lipoprotein (131I_LDL). 
Cross-bred lambs were divided into two treatment groups and either weaned early at 5 
weeks of age or remained suckling. Lambs were slaughtered at 12 or 23 weeks at which time the 
body composition and adipose tissue LPL activity were determined. The differences in rearing 
led to differences in body composition. The suckled lambs were larger and fatter than weaned 
lambs. The increased fatness in the suckled lambs was associated with increased LPL activity 
(U/mg protein) in subcutaneous adipose tissue and was reflected in higher LPL activity in post-
heparin plasma (PHP) taken 2 days prior to slaughter. 
The role of insulin in the regulation of LPL activity was investigated by either infusing 
a subset of the weaned and suckled lambs with insulin for 7 or 18 weeks or using the euglycemic 
clamp technique to study the effect of short insulin infusions. The long term infusion of insulin 
had no significant effect on PHP LPL or on adipose tissue LPL (U/g tissue). However. after 
infusing insulin for 6h at 6.3 mU.kg-·7s.h·! during the euglycemic clamps, a two fold increase in 
LPL activity in biopsied subcutaneous adipose tissue was observed. 
In the second approach, in vivo lipoprotein metabolism was investigated in 4 lambs 
using apolipoprotein B as a marker. Following the simultaneous injection of 125I VLDL and 1311 
LDL, the specific activities of apoB in VLDL, IDL and LDL fractions were determined. ApoB 
specific activity curves demonstrated that VLDL is metabolised to IDL and subsequently to LDL. 
The turnover of VLDL-B (3.45mg.d-1.kg-1) and LDL-B (4.8mg.d-1.kg-1) was calculated by fitting 
the VLDL-l25I-B and LDL_131I_B specific activity data to a mono-exponential equation. The 
metabolism of lipoproteins, inferred from the study of apoB, was shown to be similar in sheep to 
that reported in other animals although the amount of lipoprotein synthesised was low. 
A model to describe the kinetics of apoB metabolism in sheep was developed using 
SAAM. The proposed model features a three pool delipidation chain for VLDL, and subsystems 
containing two pools for IDL and LDL. IDL may be catabolised to LDL or cleared directly from 
the plasma. The developed model can now be used to compare the metabolism of lipoproteins in 
different physiological states and to design new experiments to study lipoprotein metabolism 
further. 
Keywords: sheep, lipoprotein, apolipoprotein B metabolism, lipoprotein lipase, kinetics, body 
composition, insulin. 
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1. GENERAL INTRODUCTION. 
The current health directives to reduce the fat content of the diet as a means of 
decreasing the risk of heart disease and cancer, has lead to consumers demanding leaner cuts of 
meat. Consequently there has been an upsurge of interest in manipulating carcass composition 
and in particular, the deposition of fat in ruminants. The latter are the primary meat animals in 
New Zealand and as such a profitable export commodity. To reduce fat content, especially in 
subcutaneous fat deposits, requires an understanding of the underlying mechanisms of fat 
deposition. 
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Although the interest in fat metabolism in sheep has been long standing, surprisingly 
very little research on ruminant plasma lipoproteins has been reported. Lipoproteins are complex 
molecules of lipid and protein and allow the body to transport otherwise insoluble lipid in the 
blood to tissues for immediate use or storage as is the case in adipose tissue. Lipoproteins similar 
to those in other mammals, have been identified in ruminants but when compared with humans, 
the overall concentration is low. The distribution of particle sizes also differs. The former, 
however, does not necessarily mean that lipoproteins are insignificant in ruminants. They may 
well have a rapid turnover rate and hence be highly significant despite the low plasma 
concentrations. Alternatively the metabolism may not follow the same sequence of events as in 
humans and hence create the different lipoprotein patterns. 
This thesis is divided into five sections. Following the general introduction, Section 2 
provides an overview of the structure and metabolism of lipoproteins, based mainly on research in 
human and rats along with details of the metabolic differences between ruminants and 
monogastrics. Research on sheep lipoproteins is also reviewed. 
Two approaches were used to investigate the metabolism of lipoproteins in sheep and 
these are described in Sections 3 and 4. Each section contains an introduction, specific literature 
review as well as the experimental methods and findings. 
Section 3 describes trials designed to create carcass composition differences in sheep 
using the management strategy of early weaning and the long-term infusion of insulin. A study 
of lipoprotein lipase (LPL) activities was made in these lambs to see if differences in fat 
deposition were associated with differences in LPL activity. Lipoprotein lipase is the enzyme 
controlling the rate limiting step for the utilization of triacylglycerol from lipoproteins. In human 
2 
and rat studies, LPL activity was enhanced by insulin so a further aim of this investigation was to 
study the response of sheep LPL to insulin. 
The metabolism of sheep lipoproteins was also studied using in vivo injections of 
iodinated lipoproteins (Section 4) to assess whether the metabolism of lipoproteins in sheep was 
similar to that in humans, rats or any other animal. By comparing the removal rates of the 
lipoproteins with those found in other animals the significance oflipoprotein turnover, even 
though the plasma concentrations are low, was also assessed. A mathematical model to describe 
the metabolism of apolipoprotein B in sheep is proposed. 
The final section summarises this thesis. Its theoretical significance is discussed and 
proposals for future work are included. 
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2. OVERVIEW. 
This review is intended to give readers of a wide variety of backgrounds an overview of 
the key aspects of this thesis. To this end, the characteristics of plasma lipoproteins and 
metabolism is described based mainly on human and rat studies, lipid metabolism in the ruminant 
is presented and studies on sheep lipoproteins are reviewed. Reviews on more specific aspects 
are included with Section 3 and 4. 
2.1 PLASMA LIPOPROTEINS. 
Considering that lipoproteins are the body's means of "solubilizing" hydrophobic fats 
in the blood, the importance of lipoproteins in fat metabolism is immediately apparent 
Specifically, the role of lipoproteins is to transport dietary or endogenously synthesised lipids to 
tissues for oxidative metabolism (eg heart and red muscle), storage (adipose tissue), synthesis of 
steroid hormones (adrenal gland, gonads) or the maintenance of the integrity of membranes. 
Over the past 15 years, with the discovery of lipoprotein receptors and the application of 
molecular biological and genetic techniques to the study of apoproteins, receptors and enzymes of 
lipoprotein metabolism, there has been a marked increase in the information available on 
lipoprotein systems. The following is an overview of lipoprotein structures, synthesis and 
metabolism. Reviews covering different aspects of lipoproteins are included for further reading. 
Most lipoprotein work has been done with humans and rats, although some aspects of 
other animal lipoprotein systems have been studied (review: Chapman, 1980). The 1986 review 
of Chapman collates the numerous but disperse data on the physico-chemical characteristics of 
mammalian lipoproteins and provides tables of easily accessible information for individual 
species. The data on sheep lipoproteins is sparse. This is covered in 2.3. 
2.1.1 Description. 
Plasma lipoproteins are considered to be macrospheres (Figure 2.1) with a hydrophobic 
core containing triacylglycerol and cholesterol esters surrounded by a monolayer containing more 
hydrophilic lipids (Phospholipids and cholesterol) and apolipoproteins. The lipoproteins are 
generally divided into six classes based on their flotation density. This is a function of the ratio 
4 
of protein and lipid. As the size and the proportion of triacylglycerol decrease and the proportion 
of protein and phospholipid increases, the density of the particle increases (Table 2.1). The 
classes are: 
* 
* 
* 
* 
* 
* 
chylomicrons (chylo) triacylglycerol-rich lipoproteins of intestinal origin (d<0.95g/ml) 
very low density lipoprotein (VLDL) triacylglycerol-rich lipoproteins mostly of hepatic 
origin (0.95-1.006g/ml) 
intermediate density lipoprotein (IDL) (1.006-1.019 g/rnl) 
low density lipoprotein (LDL) (1.019-1.063g/rnl) 
high density lipoprotein fraction 2 (HDL2) (1.063-1.125g/rnl) 
high density lipoprotein fraction 3 (HDL3) (1. 125-1.21g/rnl). 
The protein constituents of lipoproteins are known as apolipoproteins or apoproteins. 
More than ten such proteins have been identified. The molecular weights, functions and 
distribution within the lipoprotein classes of human apoproteins are summarized in Table 2.2. 
The distribution of apoproteins is important in the metabolism of the particles because the 
apoproteins, not only offer stability to the particles, but direct metabolism by acting as (1) 
activators for specific enzymes in lipid metabolism and (2) recognition sites for receptors which 
facilitate the uptake and removal of lipoproteins. A similar distribution of the major apoproteins 
is found in other mammals. 
The primary structure of most apoproteins is known and various functional domains 
have been identified. Arnphipathic helical regions, believed to allow lipid binding and orientation 
of the apoproteins within the surface monolayer, have been shown in the structure of apoAI, 
apoAII, apoCI, apoCII, apoCIII and apoE. The sequences in apoAI and apoCII responsible for 
the activation of lecithin: cholesterol acyltransferase (LCAT) and lipoprotein lipase (LPL) 
respectively, are known. Similarly the receptor binding sequence in apoE has been identified. 
The structure, function and variations of the apoprotein genes and their association with abnormal 
lipid metabolism are providing further information on the apoproteins and their roles in 
lipoprotein metabolism (reviews: Mahley et at., 1984; Breslow, 1986 and 1988). 
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Figure 2.1 Model of plasma lipoproteins illustrates the general features of central hydrophobic 
lipid core and a surface monolayer of phospholipid, cholesterol and apoprotein ( Iceberg-sea 
model adapted from Brewer, 1981). 
Table 2.1: Characteristics of Human Plasma Lipoproteins 
Compositionl 
----------------------------------------------------------------------
Density Size Phospho- Free Chol2 Triacyl- Protein 
lipid chof ester glycerol 
(g/rnl) (nrn) 
Chylo <0.95 75-1200 4.0 1.0 3.0 90.0 2.0 
VLDL 0.95 -1.006 30-80 18.0 7.0 12.0 55.0 8.0 
IDL 1.006-1.019 25-35 24.2 5.8 22.7 29.5 17.8 
LDL 1.019-1.063 18-25 23.6 8.5 42.3 5.1 20.5 
HDL2 1.063-1.125 9-12 28.1 3.6 18.8 2.5 46.1 
HDL3 1.125-1.210 5-9 20.0 1.9 14.2 1.9 61.0 
1 Weight % of tbtallipoproteins 
2 cholesterol 
Adapted from P. Dolphin (1985) and A.M. Gotto et al. (1986). 
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Table 2.2: The Molecular Weight, Plasma Distribution and Functions of the Major Human 
Apoproteins. 
Apoprotein Molecular Distribution in Function 
Weight Lipoproteins 
ApoAI 28016 HDL3, nascent Activation of LCAT, receptor 
chylomicron binding 
ApoAII 17414 HDL3, nascent Activation of HL 
chylomicron 
ApoAIV 44465 HDL, nascent Activation of LCAT 
chylomicron, 
VHDL1 
ApoB48 264000 Chylomicron and Particle biosynthesis and 
chylomicron secretion 
remnants 
ApoBlOO 550000 VLDL, IDL, LDL Particle biosynthesis and 
secretion, receptor binding. 
ApoCI 6630 Chylomicron, Activation of LCAT, inhibits 
VLDL, IDL, HDL interaction with hepatic receptors 
ApoCII 8900 Chylomicron, Activation of LPL, inhibits 
VLDL, IDL, HDL interaction with hepatic receptors 
ApoCIII 8800 Chylomicron, Inhibition of LPL and premature 
VLDL, IDL, HDL remnant clearance 
ApoD 32000 HDLz,HDL3, 
VHDL ? 
ApoE 34145 Chylomicron, Activation of LCAT, receptor 
VLDL, IDL, (LDL) binding 
HDLz 
1 Very high density lipoprotein (d>1.21 g/ml) 
Adapted from P. Dolphin (1985) and A.M. Gotto et ai. (1986). 
2.1.2 Synthesis, assembly and secretion of lipoproteins. 
Triacylglycerol-rkh lipoproteins. 
Both the liver and the intestinal epithelium synthesise lipoproteins destined for the 
plasma. The pathways (Figure 2.2) for the synthesis oflipoprotein components and secretion of 
the particle are similar in both sites and resemble that for other export proteins. 
One difference between the liver and the intestinal epithelium is the source of lipids. 
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The major source of fatty acids for the enterocytes is dietary fat and for hepatocytes, plasma 
triacylglycerol-fattyacids. In both sites the triacylglycerol and phosholipid are resynthesised in 
the smooth endoplasmic reticulum. In the intestinal absOIptive cell, dietary and bilary cholesterol 
are reesterified by acylcoenzyme A: cholesterol acyltransferase (ACA T) and packaged into 
chylomicrons, whilst in the liver, cholesterol and cholesterol esters from de novo synthesis or 
hepatic uptake of other lipoproteins are incorporated into VLDL. The amount of lipid to be 
incorporated into lipoproteins determines the size and number of lipoproteins produced by the 
two tissues. 
The apoproteins are synthesised as preproteins on the membrane- bound ribosomes of 
the rough endoplasmic reticulum. The amino terminal signal peptide is cotranslationally removed 
and the protein sequestered into the lumen of the rough endoplasmic reticulum. ApoAI and 
apoAII are synthesised with additional propeptides. Post-translational modifications, which 
include phosphorylation and glycosylation of apoB, apoE, and apoCIII and terminal addition of 
sialic acid to apoB occur in the endoplasmic reticulum and golgi (review: Driscoll and Getz, 
1986). 
Perhaps one of the most interesting reports is the questioning of "the dogma that mature 
mRNA are inviolate" with the finding in the intestine of humans and rabbits that either during or 
after transcription of the gene for apoB, a U for C substitution is made to give a termination! 
sequence. This results in the smaller apoB48 (powell et at., 1987; Chen et al., 1987; Goldstein and 
Brown, 1987). 
The details of the assembly of lipoproteins are still unclear. Perhaps at least for apoB, 
cotranslational addition of lipid may be required. Lipoprotein-like particles are seen in the 
smooth endoplasmic reticulum and golgi. The lipoproteins are released in secretory vesicles and 
secreted by reverse pinocytosis (exocytosis) into the Space of Disse in the liver and into the 
intestinal lymph in the intestine. 
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Nascent VLDL and chylomicron collected by the rupture of secretory vesicles of the 
golgi differ in composition from their plasma equivalents. VLDL is synthesised containing only 
apoB and apoE, with little or no apoC and less cholesterol than the mature plasma VLDL. 
Lymphatic chylomicrons contain apoB, apoAI and apoAIV. Synthesis of apoB is essential for the 
secretion oftrlacylglycerol-rich lipoproteins as shown in abetalipoproteinemia by the 
accumulation of triacylglycerol droplets in hepatocytes and enterocytes and the lack of plasma 
VLDL and chylomicron. 
Figure 2.2 
Protein Synthesis 
RER 
BDL. 
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Nascent HDL have been described as discoidal particles composed ofbilayers of 
phosholipids with apoproteins at the disc edge. Few specific details are known about their 
synthesis or secretion. HDL-like particles have not been shown within the cells but have been 
consistently seen in hepatic perfusates and in intestinal lymph. The liver synthesises both the 
major HDL apoproteins, apoE and apoAI, although the intestine is probably the primary source of 
apoAI where its secretion is associated with chylomicrons. ApoAI may be transferred to HDL by 
passive exchange or as part of remnant formation. The liver and the intestine may secrete a 
nascent HDL particle but HDL also arises from the catabolism of chylomicrons and VLDL (Gotto 
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et al., 1986). There is still some debate as to whether the excess surface components leaving 
chylomicrons and VLDL become HDL precursors. ApoCII and apoCIII have been reported to 
become part of spherical HDLz-like particles but phospholipid and cholesterol become bilaminate 
vesicular structures which Dolphin (1985) suggested are not converted to HDL. The difficulties 
associated with extrapolating from in vitro to in vivo clouds this issue. 
Apoprotein synthesis in other tissues. 
Apoproteins have been found to be synthesised in several tissues. For example, apoE is 
synthesised in the human kidney, adrenal gland and macrophages. In birds, apoAI and apoB are 
synthesised in kidney and skeletal muscle. The significance of these alternative sources of 
apoproteins has yet to be established. 
2.1.3 Catabolism and interrelationships of lipoproteins. 
On leaving the cell, all lipoprotein components except apoB exchange with other 
lipoproteins. Cholesterol and phospholipid also exchange with cell membranes. This process 
may involve specific exchange or transfer proteins. Phospholipid exchange proteins appear to be 
more abundant across species than do cholesterol ester/triacylglycerol exchange proteins. These 
exchange or transfer proteins result in the equilibration of the fatty acid composition of lipids 
between lipoproteins. Due to this dynamic equilibrium, kinetic studies of individual lipoprotein 
components have proved difficult. 
Catabolism of chylomicrons. 
Lymphatic chylomicrons enter the plasma via the thoracic duct, immediately lose 
apoAI, apoAIV and phospholipid to HDL and acquire cholesterol esters, apoCII, apoCm and 
apoE from HDL. The rearrangement of apoproteins primes the particles for the action of 
lipoprotein lipase(LPL) and the subsequent removal of the remnant chylomicron on recognition 
by the E receptor. 
LPL is an enzyme involved in the hydrolysis of lipoprotein triacylglycerol. It is 
synthesised in the parenchymal cells and once secreted, transported to the capillary endothelium 
where it is bound by heparan sulphate to the cell surface. ApoCII on the chylomicron activates 
LPL which hydrolyses triacylglycerol and some phospholipid releasing fatty acids for cellular 
use. With the removal of core triacylglycerol from the chylomicron, excess surface components, 
such as cholesterol and phospholipid, appear to form bilaminate vesicular structures which are 
suggested to be nascent HDL. ApoA. apoCII and apoCIII are transferred back to HDL. 
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The smaller particles formed from chylomicrons are referred to as chylomicron 
remnants. They have the same density as VLDL particles but differ in composition. Lacking 
apoC, the remnants are cleared from the plasma via the hepatic apoE receptor and perhaps, in 
part, by the LDL receptor. Thus, remnants provide a source of dietary triacylglycerol and 
cholesterol for the liver. The cholesterol may then be either excreted in bile, oxidised to bile acids 
or used in the biosynthesis of other lipoproteins. This uptake by the liver appears unsaturable. 
Catabolism of VLDL. 
The initial catabolism of VLDL resembles that of chylomicrons. On entering plasma, 
nascent VLDL acquire apoCII and apoClII from HDL. Since apoCII is an obligatory cofactor for 
LPL, this addition allows VLDL-triacylgylcerol (VLDL-TG) to be hydrolysed and release non-
esterified fatty acids (NEFA) to tissues. The hydrolysis of core triacylglycerol is accompanied by 
the loss of surface components, such as apoCII and apoCIII. These changes lead to the formation 
of smaller more dense IDL particles also known as VLDL remnants. 
IDL may be further depleted of core lipids by the continuing action of LPL and perhaps 
hepatic lipase (HL) to yield LDL. Alternatively, IDL may be cleared from the plasma via the 
hepatic B,E orE receptors or via the extrahepatic B,E receptor (Chao et ai., 1981). The 
proportion of IDL catabolised by each pathway seems to be species dependant. In humans, 90% 
of the VLDL-B 100 may be converted to LDL-B although recent evidence suggests this may be 
much lower (Janus et al., 1980b; Eaton et al., 1976; Ginsberg et ai., 1981; Kesaniemi et at., 
1985). In rats, where hepatic VLDL contains 3 forms of apoB; PI, PlI, PIII, the majority of 
VLDL contains apoB PIII (apoBJ and are rapidly cleared as IDL while a proportion ofVLDL-Bh 
(PI & PH) becomes LDL (Sparks et al., 1983; Elovson et al., 1981; Eisenberg, 1983). 
LDL is recognised by the B,E receptor (LDL receptor) on the plasma membrane of a 
wide variety of tissues (including liver) and is taken up for use in cells as described below. The 
use of LDL by tissues depends on bloodflow and the number of receptors ego the adrenal gland 
actively uses LDL while adipose and muscle tissues are relatively inactive. There is some 
evidence for receptor independent uptake of LDL in Watanabe heritable hyperlipidemic (WHHL) 
rabbits (Goldstein and Brown, 1983). These rabbits lack LDL receptors. 
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Role of Receptors. 
Following the early work of Brown and Goldstein (1974), who showed the presence of 
an LDL receptor in familiar hypercholestrolemic patients and the receptors importance in 
regulating cellular cholesterol synthesis, much attention has focussed on the receptors. The LDL 
receptor and its gene is now well characterised in terms of structure, function and regulation 
(review: Gevers et al., 1986). 
Although the receptors for chylomicron remnants (E) and LDL (B,E) are distinct, the 
uptake, cellular transport and catabolism of the lipoproteins, as assessed by electron microscopy 
and radioautography, are indistinguishable (Jones et at., 1984; Chao et al., 1981). The continuous 
process of endocytosis via the clathrin coated pits, internalizes receptor-bound lipoprotein. 
Uncoated vesicles then combine to form specific endocytic vesicles known as endosomes or 
multi vesicular bodies. The acid interior of endosomes cause the lipoproteins and receptors to 
dissociate. The receptors recycle to the cell surface whilst the remaining endosome is targeted to 
the lysosome. Fusion with the lysosome results in the formation of secondary lysosomes which 
contain hydrolytic enymes that convert the proteins to amino acids and the lipids to free 
cholesterol and fatty acids. 
Catabolism of HDL. 
The metabolism of HDL particles is -intertwined with that of all the other classes of 
lipoproteins. Excess surface components from the catabolism of chylomicron and VLDL are 
possible precursors of plasma HDL, apoCs from HDL are transferred to nascent VLDL and 
chylomicron and indeed, all the components of HDL are exchanged with other lipoproteins. 
HDL has been divided into two major subclasses. HDLz and HDL3• HDL3 becomes 
HDLz after incorporating protein, phospholipid and cholesterol from VLDL or chylomicron 
catabolism and the conversion of cholesterol to cholesterol esters by LCAT. Cholesterol ester/ 
triacylgylcerol exchange proteins mediate the transfer of triacylglyerol to and cholesterol ester 
from HDLz. HDLz is converted back to HDL3 on hydrolysis of triacylgylcerol by LPL or HL. 
The major role of HDL has been postulated to be reverse cholesterol transport. In this 
hypothesis, HDL acquires cholesterol from the peripheral cells through either a surface receptor 
or direct lipid-lipid interaction. The cholesterol once on the HDL particle is converted to 
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cholesterol ester by the action of LeA T and the cholesterol ester moves to the particle core. The 
cholesterol ester may be rapidly redistributed to lipoproteins containing apoB or apoE via 
cholesterol ester transfer proteins and subsequently removed from the plasma mainly by 
endocytosis of the lipoproteins in the liver, thus completing the reverse cholesterol transport 
systems. 
If the level of cholesterol ester transfer protein is low (eg. in rats, dogs, pigs and sheep) 
the cholesterol ester remains within HDL. However, with the addition of more cholesterol and its 
conversion to cholesterol ester the HDL particle becomes a larger HDLz-type particle, and apoAI 
may be lost and apoE gained. HDL containing cholesterol ester may be removed by the liver by 
the E receptor or an apoAI receptor thus completing the reverse cholesterol transport system. 
There is however, some suggestion that the HDL particle may not be removed during delivery of 
cholesterol esters to liver, adrenal and gonad tissues and that HDL binds to sites other than the E 
or B, E receptors. Nevertheless, HDL with apoE may be specifically targeted to the liver for 
removal of cholesterol (Weisgraber, 1985 review). Thus, the details of the steps in reverse 
cholesterol transport are still sketChy. 
The negative correlation between plasma HDL-cholesterol and atherosclerosis has 
stimulated interest in HDL metabolism. Differences between animals, and in vitro and in vivo 
experiments, along with the exchange of all components of HDL with other lipoproteins and cell 
membranes have contributed to the difficulty in studying HDL. 
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2.2 THE ROLE OF LIPOPROTEIN METABOLISM IN RUMINANT LIPID 
METABOLISM. 
Until recently, the role of lipoproteins in ruminant metabolism has been overlooked, 
probably because the concentration of total lipoprotein in ruminant plasma is typically low 
relative to other animals (Chapman, 1980) and the distribution of the lipoproteins in tenus of 
density have been poorly defined. This is a particular problem with cattle lipoproteins where the 
1.006-1.063g/ml fraction is heterogenous and no standard conditions for their isolation has yet 
been established. Ruminant research has tended to focus on volatile fatty acids and plasma non-
esterified fatty acids (NEFA). Despite the longstanding interest in fat deposition in ruminants, 
few papers have investigated lipoprotein metabolism. The majority of previous lipoprotein work 
has investigated the contribution of lipoprotein triacylglycerol to milk fat synthesis and, more 
recently, the role of HDL and LDL cholesterol in ovarian steroidogenesis (review: Grummer and 
Carroll, 1988). 
This section describes the differences between ruminant and nonruminant lipid 
metabolism and the role of lipoproteins in ruminants. 
2.2.1 The gastrointestinal tract. 
Compared to a single-stomached animal, where fat metabolism begins in the small 
intestine, the ruminant is very different. Due to the structure of the digestive tract (Figure 2.3) 
with the reticulum, rumen, omasum and abomasum before the small intestine, the lipid entering 
the duodenum differs substantially from dietary lipid. 
Figure 2.3 The digestive tract of ruminants. (after Kowalczyk, 1989) 
Ileum Caecum Rectum 
Oesophagus Duodenum Colon Anus 
Reticulum Rumen 
Abomasum Omasum 
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In the rumen, a large fermentation vat containing a mixed population of bacteria and 
protozoa, there is a rapid and almost complete hydrolysis of dietary lipid; dietary unsaturated 
fatty acids, mostly linoleic and linolenic acids, are hydrogenated and isomerized; carbohydrates 
and proteins are fermented to produce short chain(C2-C5) volatile fatty acids (VFA). The major 
VFA, acetate, propionate and butyrate are important sources of energy to ruminants. Most VFA 
are absorbed from the rumen or omasum. Butyrate and propionate are metabolised in the 
endothelial cells to P-hydroxybutarate and lactate, respectively. VFA are also used by the 
ruminal bacteria and protozoa to synthesise lipids mainly fatty acids and phospholipid. A high 
proportion of microbial fatty acids are branched chain and odd carbon number straight chain fatty 
acids (C13,14,15,16,17). Microbial lipid constitutes 20% of the ruminallipid which makes it a 
significant lipid source for the animal. 
The acid environment of the abomasum, which is comparable to the stomach of 
monogastric animals, kills the bacteria and protozoa releasing their lipid. Medium and long chain 
fatty acids pass through the omasum and abomasum unchanged. Unlike monogastrics, however, 
the supply of digesta, duodenal, pancreatic secretions and bile to the duodenum is continuous. 
Pancreatic lipase hydrolyses esterified lipids and pancreatic phospholipase hydrolyses any 
phosphatidylcholine or phosphatidylethanolamine. The bile containing phosphatidylcholine, bile 
salts and cholesterol, increases the esterified and unsaturated fatty acids in the digesta, and along 
with microbial phosphatidylethanolamine plays a major role in solubilizing the intestinal lipids as 
micelles prior to uptake. 
The mechanisms for the release of fatty acids from particulate matter and the uptake of 
lipids by the epithelium remain unclear. Nevertheless, the hydrolysis of esterified fatty acids and 
the uptake of fatty acids is complete prior to the ileum. In contrast to monogastrics, digestion 
and absorption of fatty acids in sheep are consistently high, regardless of chain length. 
Intestinal synthesis of lipoproteins; 
The morphology of ruminant mucosal tissue is similar to that in nonruminants. Some 
long chain fatty acid are transported directly into the portal vein with no specificity for chain 
length. A specific microsomal desaturase however, converts some stearate to oleate. Fatty acids 
are subsequently esterified to triacylglycerol via the ClI-glycerophosphate pathway in the rough 
endoplasmic reticulum and golgi membranes. In addition, nonruminants also use the 
monoglyceride pathway. The prominent synthetic pathway for phospholipids is the reacylation of 
1-lysophosphatidylcholine. The small intestine is also the major site of cholesterol synthesis 
(Noble, 1981), but the extent of cholesterol esterification is unknown. 
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The discovery and characterization of lipoproteins in intestinal lymph (Harrison et al., 
1974; Gooden et ai., 1979) provided evidence that ruminant enterocytes assemble lipids into 
lipoproteins for transport. These lipoproteins differ, however, from those in nonruminants in size 
and composition. In sheep, 75% of the lymph lipid is carried in VLDL-sized lipoproteins 
(Harrison et al., 1974). Since the supply of fatty acids in digesta is low and continuous rather 
than fluctuating to peaks after meals, as observed in nonruminants, the enterocytes never face a 
large load of lipid to package. The synthesis of surface components is sufficient to produce the 
smaller sized VLDL. However, as demonstrated by the presence of chylo in lymph following the 
duodenal infusion of oil, the ruminant intestine is capable of producing larger particles if required 
(Harrison et al., 1974; Gooden et at., 1979). The higher ratios of phospholipid to triacylglycerol 
and cholesterol to cholesterol ester in ruminant lymph lipoproteins reflect the higher ratio of 
surface to core components of the smaller particles. Furthermore, the composition of fatty acids 
also differs. Linoleic acid is preferentially esterified to phospholipid. 
Further evidence that dietary lipid are transported as lipoproteins comes from Glascock 
and Welch (1974) who showed that labelled fatty acids introduced ruminally or postruminally are 
incorporated into blood lipoproteins. This method has been used to label lipoproteins for kinetic 
studies although it is limited by their low specific activity (Lascelles et ai., 1964; Palmquist and 
Matto. 1978). 
Although little or no work has been done on the intestinal synthesis of lipoproteins in 
ruminants, the synthesis, assembly and secretion of lipoproteins are assumed to be similar to the 
mechanisms observed in nonruminants. 
2.2.2 Liver 
Although the liver plays a central role in the synthesis and catabolism of lipoproteins in 
nonruminants, the role of the ruminant liver in lipoprotein metabolism is poorly defined. 
In contrast to other animals, very little fatty acid is synthesised in the ruminant liver 
(review: Bell, 1981). The liver is, however, the major organ responsible for removing plasma 
non-esterified fatty acids and their uptake is proportional to the plasma concentration. The 
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assembly and secretion of VLDL probably depends on the metabolic state of the animal. For 
example, Bergman et at. (1971) showed very little incorporation of plasma 14C-fatty acids into 
plasma triacylglycerol in sheep and dogs in vivo. Kleppe et at. (1988) using hepatocytes bathed 
in 14C-oleate, demonstrated goat hepatocytes were capable of synthesising lipoproteins, although 
the secretion rate was much lower than in rat hepatocytes. Goat hepatocytes esterified less fatty 
acid to triacylglycerol and also converted a lesser amount of fatty acid to CO2 and acid soluble 
precipitates (ketones) than did rat hepatocytes. Nevertheless, the higher activity of rat 
hepatocytes was insufficient to account for the high secretion of triacylglycerol. Kleppe and 
colleagues (1988) concluded that in ruminants the secretion of lipoprotein may become limiting if 
the influx of fatty acid was too high. However, since the accumulation of triacylglycerol in 
hepatocytes was not observed, the results could suggest that assembly and secretion of 
lipoproteins was not limited, but the uptake ofNEFA and esterification to triacylglycerol may be 
the limiting steps. There are, however, many papers on fatty liver in ruminants. Several have 
proposed a role for lipoproteins but very few experiments with lipoproteins have been conducted. 
Mamo et al. (1983 a,b) suggested that in sheep the low rate of hepatic triacylglycerol 
secretion and low plasma VLDL-TG concentrations were due to a limiting membrane in liver 
sinusoids. For example, in stressed sheep, either fasted or alloxan treated, they found that plasma 
and hepatic triacylglycerol increased and suggested that this was due to the effect of pressure on 
the liver basement membrane. Wright et al. (1983) showed the membrane to be an artifact. An 
alternative explanation is that the increased hepatic esterification of fatty acids outstrips the 
production of surface components for VLDL synthesis and consequently plasma and hepatic 
triacylglycerol are higher than normal. Phospholipid, cholesterol (Brumby et al., 1975) and 
protein (Heimberg et al., 1974) have been suggested to be components that might limit VLDL 
synthesis. In rat hepatocytes, NEF A increased triacylglycerol and phospholipid synthesis but not 
protein synthesis (pelech et al., 1983). Whether this is similar in ruminant hepatocytes is 
untested. 
The liver is also active in catabolising cholesterol-containing lipoproteins. For example, 
by infusing chylomicron with radioactive lipids into sheep and dogs, Bergman et al. (1971) 
demonstrated that the liver is the primary site for removal of chylomicron cholesterol and also 
removes a small amount oftriacylglycerol (10%), presumably as chylomicron remnants. 
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2.2.3 Adipose Tissue. 
Adipose tissue is the major site of triacylglycerol synthesis and storage in non-lactating 
ruminants (Vernon, 1981; Madsen, 1983; Leat, 1983). The major differences between ruminant 
and nonruminant adipose tissue metabolism stem from the presence of the rumen in the former 
(discussed above) and the resulting availability of substrates, particularly acetate, and the non-
availability of glucose. The actual metabolic pathways and their regulation within adipose tissue, 
however, are similar to those of nonruminants although the activity of the enzymes differ. 
More than 80% of adipose tissue is triacylglycerol. Fat deposition occurs when the rate 
of fatty acid esterification (regulatory component) exceeds the hydrolysis of triacylglycerol. 
Triacylglycerol is synthesised by the glycerol-3-phosphate pathway, as in nonruminants, but in 
contrast, glucose provides glycerol-3-phosphate whilst acetate provides ATP and NADPH. Fatty 
acids may be synthesised endogenously (de novo, or recycled from lipolysis) or exogenously 
(plasma NEFA or lipoprotein-triacylglycerol). Fatty acids synthesised de novo are primarily 
derived from acetate. Lactate, propionate, pyruvate and ketone bodies are alternative precursors. 
The major fatty acids produced in sheep are palmitate, stearate and oleate. Hydrolysis of adipose 
triacylglycerol by a hormone sensitive tissue lipase releases fatty acids which may be re-
esterified. 
While the composition of adipose tissue fat in ruminants is less affected by diet than in 
nonruminants, it does reflect the modified dietary and microbial lipids. In contrast to 
monogastrics, 80% of the fatty acids are CI4:0, CI6:0, C18:0 and C18:1 with little C18:2 and 
C18:3; cis and trans isomers of unsaturated fatty acids occur along with odd-length and branched 
chain fatty acids. When 'protected' fats are fed to ruminants (Scott and Cook, 1975), the fatty 
acid composition of adipose tissue reflects the dietary fatty acids as in nonruminants. It is 
therefore obvious that intestinal fatty acids are transported to adipose tissues. This occurs either 
as lipoprotein-triacylglycerol or NEF A. 
Christie (1981) suggests that "the increased availability of fatty acids in animals fed 
lipid supplements is primarily due to an increase in lipoprotein rather than free fatty acid per se." 
The incorporation of 14C_fatty acids into sheep adipose tissue triacylglycerol following the 
infusion of labelled triacylglycerol (payne and Masters, 1971) and the detection of LPL (see 
Section 3) in ovine, bovine and caprine adipose tissues suggests a role for lipoproteins. 
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Ruminant LPL show the general characteristics observed in LPL from other species 
(Vernon, 1981). However, Turne et at. (1983) observed the ~ of preparations of sheep adipose 
tissue LPL was one tenth that of similar rat preparations and suggested that sheep adipose tissue 
may thus have greater potential for removing plasma triacylglycerols and depositing fat. 
Although Vernon (1981) suggested that the triacylglycerol-rich lipoproteins may be the 
main source of exogenous fatty acids for adipose tissue, he then only discussed plasma non-
esterified fatty acids. This may be because the plasma non-esterified fatty acids may be very 
significant due to their high turnover rate, and evidence supporting the suggested role of 
lipoproteins is lacking. No consideration is given, however, to the possibility of a high turnover 
of lipoprotein triacylglycerol. 
The relative contribution of the different sources of fatty acids to the synthesis of 
adipose tissue triacylglycerol is therefore still unclear. It is obvious however, that the 
contributions vary with the metabolic state of the animal. For example, Vernon (1981) 
summarised experiments measuring the rates of synthesis and esterification of fatty acids suggest 
that de novo synthesised fatty acids contributed 3% of the esterified fatty acids in suckling lambs, 
25% in 6-12 month sheep and 10% in mature sheep. The latter two in vitro experiments however, 
used concentrations ofNEFA high enough to decrease the rate of fat synthesis. Using adipose 
tissue slices without exogenous fatty acid, Baldwin (1970) found that de novo synthesised fatty 
acids accounted for about 35% of the glyceride synthesis which indicated that fatty acids recycled 
from lipolysis were important. 
Vernon (1981) calculated that less than 35% of the esterified fatty acid were de novo 
synthesized fatty acids and the proportion varied with the metabolic state of the animal. Indeed, 
in vitro experiments have demonstrated that the contribution of de novo synthesised fatty acid to 
fat deposition decreases as the supply of exogenous fatty acids increase. 
Lipid metabolism in adipose tissue of ruminants has been comprehensively reviewed by Vernon 
(1981) and in general by Madsen (1983) and Leat (1983). 
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2.2.4 Mammary gland. 
Most studies on lipoprotein metabolism in ruminants have investigated the contribution 
of lipoproteins to the synthesis of milkfat. The mammary glands synthesise short chain fatty 
acids (C4-CI6) from acetate and IJ-hydroxybutarate which account for approximately 50% of 
milkfat. The long chain fatty acids are delivered as NEFA or by lipoproteins via hydrolysis of 
their triacylglycerol by LPL. 
In goats, Barry et al. (1963) demonstrated there were arterio-venous differences in 
triacylglycerol-fatty acids of chylomicron and LDL(1.005-1.019g/ml) across the mammary gland. 
Lascelles et al. (1964) confirmed the transfer of fatty acid from lymph LDL (1.006-1063g/ml) to 
milkfat. 
In 1973, Raphael et al. observed a decrease in plasma VLDL-TG concentration during 
lactation in cattle and suggested this indicated the role of lipoproteins in milk fat production. 
Glascock and Welch (1974) calculated that 47% of milk glyceride-fatty acid was derived from 
low density lipoproteins using arterio-venous differences. Palmquist and Mattos (1978) followed 
the transfer of radiolabelled linoleic acid from injected lipoproteins and post-ruminally infused 
fatty acid to milkfat. They concluded that 76% of absorbed lipid is taken up by the mammary 
gland and 44% of milkfat is directly of dietary origin. 
Similarly in sheep, King et al. (1983) used arterio-venous differences to show that fatty 
acids from lower density lipoprotein triacylglycerols could account for 35% milkfat production 
and that although most lipoprotein fatty acid was esterified to phospholipid and cholesterol ester, 
triacylglycerol-fatty acid was the major lipid taken up by the mammary gland. 
Arterio-venous differences ofNEFA across the mammary gland are small and variable. 
These difficulties have arisen from the contribution ofNEFA from the action ofLPL on 
lipoprotein-triacylglycerol and hence make the measurement ofNEFA contribution by this 
method impossible. Annison et al. (1967) combined the infusion of labelled fatty acids with 
arterio-venous differences to show the specific activity of the NEFA changed during passage 
through the mammary glands. 
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Changes in mammary lipoprotein lipase activity as lactation commences and arterio d 
venous differences in LPL activity across the mammary glands support the role of lipoproteins in 
milkfat production (Lascelles et al., 1964; Barry et al., 1963). 
It is clear that the proportion of milk fat fatty acids derived from the diet or other tissues 
or synthesised de novo differs with the nutritional status of the animal and the stage of lactation. 
In early lactation, fatty acids are released from the adipose tissue, taken up by the liver, 
synthesised into VLDL, secreted and subsequently removed by the mammary gland. In middle 
lactation, 10% of the exogenous fatty acids may be from adipose tissue and 85-90% from dietary 
origins. 
2.2.5 Whole body metabolism. 
There is very limited data available on the metabolism of plasma lipoproteins in ruminants and 
most often it is assumed to be the same as in nonruminants. Studies in monogastrics and to a 
lesser extent in ruminants have shown lipoprotein triacylglycerol to be a source of fatty acids for 
the tissues. In ruminants, the results of feeding 'protected' fats (Scott and Cook, 1975) and the 
presence of LPL, the enzyme for the hydrolysis of lipoprotein-triacylglycerol, in a variety of 
tissues supports a role for lipoproteins in lipid metabolism. The meagre available kinetic data 
suggests that, at least in lactating animals, catabolism of VLDL-TG and chylomicron-TG is rapid 
with Tl/z of 2-11 min. (palmquist and Mattos, 1978; Lascelles et al., 1964; Glascock and Welch, 
1974). 
Recently the role of HDL and LDL cholesterol in ovarian steroidogenisis was 
demonstrated using cattle (review: Grummer and Carroll, 1988). 
2.2.6 Conclusion 
Although lipoproteins have been shown to be important in mammary gland metabolism, 
the role oflipoproteins in fat deposition in adipose tissue and whole body lipid metabolism has 
largely been ignored. 
The ruminant lipoprotein system is potentially an interesting system to study because of 
the significant differences in the metabolism of lipids in ruminant and non-ruminants digestive 
tracts. and the effect of these differences on the metabolic processes in the animal. Furthermore, 
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differences between ruminants and non-ruminants may help clarify some of the different aspects 
seen in human and rat lipoprotein systems. 
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2.3 SHEEP PLASMA LIPOPROTEINS. 
Although there are now a large number of publications on plasma lipids in sheep, there 
are very few reports on sheep lipoproteins and even fewer on lipoprotein metabolism. This is 
despite the comments by several reveiwers (Vernon, 1981; Thornton and Tume, 1984; Byers and 
Schelling, 1988) that lipoproteins may playa significant role in lipid metabolism. 
Leat et al. (1976) used analytical ultracentrifugation to show the flotation characteristics 
of sheep lipoproteins were similar to those of human lipoproteins. They subsequently used this 
method and cellulose acetate electrophoresis to validate the use of a 1.063g1ml density cut for 
LDL and HDL on preparative ultracentrifugation. They found the lipoproteins to be well 
separated and did not substantiate the LDL-like lipoprotein found in the 1.063-1.07 glml density 
fraction by Nelson (1973). 
Leat et al. (1976) calculated the concentration of lipoproteins from the sum of lipid and 
protein constituents as shown below. 
Sheep (5) 
Man (2) 
Plasma concentrations (mg /100ml) 
Chylornicrons VLDL LDL 
4.3 10.7 67.4 
26.3 108.7 373.3 
HDL 
261.8 
300.3 
Although HDL occurs at similar concentrations in sheep and human plasma, sheep have 
lower levels of chylomicrons, VLDL and LDL. Obviously the total lipoprotein concentration is 
much lower in sheep than in man. This is supported by other reports on sheep lipoproteins 
(Nelson, 1973; Noble et at., 1977; Forte et al., 1983). 
The majority of plasma lipids in sheep are carried in HDL. Most of the remaining lipid 
is associated with LDL (Leat et ai., 1976; Nelson, 1973; Noble, 1981; Noble et al., 1977). Even 
though this distribution is distinctly different from humans, it is not unusual for non-human 
mammals (Chapman, 1986). Nevertheless, sheep plasma is characterized by very low 
concentrations of VLDL. The actual distribution of lipid between chylomicrons, VLDL, LDL 
and 'VHDL', defined as d>1.21g1rnl, varies among reports but generally VLDL contains less than 
5% of plasma lipid. Even the existance of lipoprotein less dense than 1.006g/ml has been 
questioned (Nelson, 1973). Forte et al. (1983) found no evidence of VLDL and subsequently 
collected LDL as <1.063 g/ml while King et al. (1983) were able to separate both chylomicrons 
and VLDL. The differences between reports may be due to differences in isolation procedures, 
breed, dietary treatment, age, stage of maturity or sensitivity of the analytical methods. Such 
variability has also been noted in work on rats and humans (Chapman, 1986). 
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The low concentration of VLDL has been attributed to the lack of dietary lipids (Leat et 
al., 1976), biohydrogenation of dietary lipids by ruminal microflora and the low lipogenesis due 
to the limited supply of dietary carbohydrate (Mamo, 1986). In suckling lambs, where the diet is 
rich in fat, Leat et al. (1976) found that all the lipoprotein classes were increased and VLDL 
accounted for 7-15% of plasma lipoproteins compared to 4-5% in adult sheep. When the supply 
of dietary lipids was increased experimentally, by feeding "protected fats" (Scott and Cook, 1975; 
Noble et al., 1977), the dietary fatty acids in all the lipoprotein fractions increased and were 
subsequently seen in a variety of tissues. 
It is perhaps prudent to point out that because of the low concentrations of VLDL and 
chylomicrons, these two lipoprotein classes tend to be lumped together. Indeed, the naming of 
lipoprotein classes based on traditional definitions of flotation characteristics can cause 
considerable difficulties. Chylomicrons, defmed on a flotation basis, are less dense than 
O.95g/mI, but on a metabolic basis are synthesised in the intestinal epithelium. In sheep, as 
described earlier, the intestinally synthesised lipoproteins are small and isolated in the VLDL 
density range. From the evidence available there seems no reason to suspect that either the liver 
or the small intestine are unable to synthesise lipoproteins. Therefore it seems reasonable to 
assume that lipoproteins from each origin exist. 
Nelson (1973) suggested that lipid and lipoprotein metabolism in sheep may be 
significantly different and VLDL is not essential for fat transport or metabolism. An alternative 
may be that there is a low production of VLDL and the pathway for removal is very efficient. 
2.3.2 Lipid composition of the lipoproteins. 
Most of the plasma cholesterol (52.3%), cholesterol ester (72.7%) and phospholipid 
(65.8%) are in the HDL fraction (values from Leat et ai., 1976) while triacylglycerol is found in 
the lower density lipoproteins. Leat et al.(1976) suggested 72.6% of the triacylglycerol is in 
24 
chylomicrons and VLDL while Noble et al. (1977) found only 33% triacylglycerol in VLDL and 
55.7% in LDL. 
Whilst the distribution of lipoproteins in sheep is different to man the actual chemical 
composition of the particles is similar. VLDL is rich in triacylglycerol (41 %) but contains 
significant amounts of cholesterol ester and phospholipid. The major lipids in LDL and HDL are 
cholesterol ester and phospholipid. LDL has a higher proportion of cholesterol (9%) and 
triacylg1ycerol (6%) than HDL (Leat et al., 1976; Noble et al., 1977). Nelson (1973) found 
similar compositions to these apart from finding that VLDL had less than 1 % phosholipid. 
VHDL appeared to contain mostly NEF A and phospholipid and small amounts of cholesterol 
ester and cholesterol (Leat et at., 1976; Nelson, 1973). 
Phospholipid distribution. 
Nelson (1973) found phosphatidylcholine to be the major phospholipid in sheep plasma 
HDL and VHDL while equal amounts of sphingomyelin and phosphatidylcholine made up the 
majority of LDL. 
Fatty acid distribution. 
In sheep, HDL has a higher proportion of unsaturated fatty acids than the lower density 
lipoproteins. This difference in distribution is accounted for by the cholesterol ester. Greater than 
80% of the fatty acid in HDL cholesterol ester is 18:2 and 18:3 while in VLDL and LDL the 
proportion of unsaturated fatty acid is much less (Noble et al., 1977). Fatty acids esterified to 
phospholipid and triacylglycerol show little differences between the various lipoproteins (Noble 
et al., 1977). This disproportionate distribution has also been noted in cows but contrasts with 
humans where cholesterol esters of different lipoproteins have similar fatty acid compositions. 
This may represent an efficient mechanism to conserve the polyenoic fatty acids that escape 
ruminal hydrogenation (Scott and Cook, 1975) and may be a function of the low cholesterol ester 
transfer protein found in sheep. Forte et al. (1983) suggested this may result from different 
biosynthetic origins of cholesterol esters; hepatic versus LCA T synthesis. 
Protein composition. 
The proportion of protein in lipoproteins increases with the density of the particle. Leat 
et al. (1976) suggested VLDL, LDL and HDL were 11,20 and 45% protein, respectively. Forte 
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et aI. (1983) found plasma HDL contained apoproteins of similar molecular weight to apoAI and 
apoC proteins while the lower density fraction contained a single large molecular weight 
component similar to human apoBlOO' Mamo (1986) reported the apoproteins of all the major 
classes of sheep lipoproteins. The apoproteins were, in general, similar to those found in human 
lipoproteins but some differences in distribution were noted. VLDL contained apoAI, apoAII, 
apoAIV, apoB and apoC; LDL contained apoAI apoAII apoAIV, apoB and apoE; while HDL 
contained apoAI, apoAII, apoAIII, apoAIV and apoE. The tentative identifications based on 
molecular weights and comparison to mobility of rat apoproteins on SDS-polyacylamide gel 
electrophoresis led to some uncertainty. VLDL and HDL seemed poor in apoC but the apoprotein 
identified as apoAII may be apoC of a higher molecular weight than observed in humans. 
Because of the isolation method, the isomers of apoB and their molecular weights could not be 
determined. 
2.4 SUMMARY. 
Lipoproteins are complexes of lipid and protein that allow the transport of otherwise 
insoluble lipid in the blood. The plasma lipoproteins are heterogeneous in size, density, lipid and 
protein composition, origin and function. They have, however, been divided into several classes 
with generally similar characteristics. The triacylgylcerol rich lipoproteins, chylomicrons and 
VLDL are synthesised in the intestinal epithelium and the liver to transport dietary or hepatic 
triacylglycerol to peripheral cells. LPL releases fatty acids from the lipoprotein triacylglycerol. 
Surface lipids and apoproteins are lost to HDL and the particles become smaller, more dense IDL 
or remnants. These are further delipidated to LDL or removed as whole particles by the liver. 
The metabolism of lipid in the ruminant is significantly different from that in 
monogastrics. These differences stem from the presence of the rumen and the subsequent 
differences in nutrients supplied to the animal. VF A provide a major source of energy and 
carbon; the lipid composition is altered and the availability of glucose decreased. The primary 
task of the ruminant liver is gluconeogenesis. Unlike other animals, little fatty acid is synthesised 
in the liver, and adipose tissue is the major site of synthesis of long chain fatty acids in the 
ruminant. The liver, however, takes up plasma fatty acids. Some may be esterified as 
triacylglycerol and secreted as VLDL. Adipose tissue fatty acids are stored as triacylglycerol, 
oxidized or exported as NEF A in the plasma for use in other cells including the liver. The role of 
lipoprotein in the transport of lipid in ruminants has been suggested but little research has been 
conducted. 
Lipoproteins in sheep have similar density distribution to those in man though the 
plasma concentrations and distribution between classes are different. The lipid and protein 
composition of the lipoprotein particles have been studied but there are few reports on 
metabolism. 
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The overall aim of this study was to investigate the metabolism of lipoproteins in sheep 
with particular emphasis on the triacylglycerol-rich lipoproteins and to assess whether their 
metabolism is similar in a qualitative and quantitative sense to those of other animals and whether 
this may account for the differences in lipoproteins distribution in sheep and humans. and whether 
lipoproteins may play an important role in fat deposition in sheep. Two approaches were used. In 
the following section, studies on LPL are presented and Section 4 decribes kinetic studies of 
VLDL and LDL. 
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3. LIPOPROTEIN LIPASE STUDIES. 
3.1 INTRODUCTION TO LIPOPROTEIN LIPASE STUDIES. 
Lipoprotein lipase, LPL, is the key enzyme in the catabolism oftriacylglycerol-rich 
lipoproteins. It hydrolyses the triacylglycerol core releasing fatty acids for use by the cells. The 
lipoprotein particle becomes smaller and surface components are lost or transferred to HDL. The 
resulting change in apoprotein composition makes these particles susceptible to removal from the 
plasma via receptors. Although LPL occurs in most tissues and is of interest in whole body 
metabolism of lipoproteins, LPL in adipose tissue is of particular interest since it provides fatty 
acids for fat deposition. 
One way of assessing the significance of lipoprotein metabolism in sheep is to measure 
LPL, a rate-limiting enzyme in their catabolism, in situations where the contribution of 
lipoprotein metabolism may be expected to differ. Previous studies from this, and other 
laboratories, have suggested that weaning lambs early reduces fat deposition (Chambers, 1984; 
Fennessy, 1971). Measurement ofLPL activity should therefore reveal differences between 
rearing treatments if lipoprotein metabolism is contributing significantly to the differences in 
fatness. 
There are few publications on sheep LPL. In the following section, research on LPL is 
reviewed with emphasis on its role in lipid metabolism, its regulation and findings in ruminants. 
This thesis describes the preparation of samples and the assay for LPL activity in sheep adipose 
tissue and plasma following the release of LPL from the capillary endothelium by heparin (PHP). 
The distribution of LPL activity among adipose tissue from three sites from lambs at two 
different ages is described. The effects of early weaning and of insulin infusion are also assessed. 
Three lamb trials designed to alter carcass composition by early weaning are described 
and the effects on carcass composition and adipose tissue LPL activity are presented. Two of 
these trials included treatments that studied the effects of insulin on LPL activity directly. In 
Trial 1, the effects of long term infusions of insulin on carcass composition and LPL activity were 
measured. In Trial 2, euglycemic clamps were used to study the shorter term effects of increased 
plasma insulin concentrations. Since several aspects varied from trial to trial, each trial is 
presented individually prior to a general discussion being made. 
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3.2 LITERATURE REVIEW OF LIPOPROTEIN LIPASE. 
3.2.1 The Enzyme. 
Lipoprotein Lipase (BC 1.1.34) is the extrahepatic enzyme responsible for the 
hydrolysis of plasma lipoprotein triacylglycerol and so controls the rate limiting step in the 
removal of triacylglycerol from plasma for use in cells. LPL activity has been described in a wide 
variety of species; human, rat, mouse, hamster, pig, chicken, duck, goat, cow, sheep, rainbow 
trout, ground squirrel, guinea-pig, and turkey (review: Cryer, 1987) and in many different tissues; 
skeletal muscle, cardiac muscle, lung, adipose tissue, lactating mammary gland, aorta, uterus, 
corpus luteum and granulosa cells (review: Cryer, 1987). The presence ofLPL activity 
presumably gives these tissues the ability to use lipoprotein triacylglycerol. 
The enzymes from different tissues seem similar. Antibodies against adipose tissue 
LPL inhibited LPL from other tissues within the species and some across species interaction was 
found (Bensadoun and Kompiang, 1979; Kompiang et al., 1976). LPL is a glycoprotein of 
molecular weight 48-67000 daltons. It is synthesised in the parenchymal cells and transported to 
the capillary endothelium where it is bound to an heparan Sulphate. Here it exerts its action on 
lipoprotein triacylglycerol. Lipoproteins rich in triacylglycerol bind at a lipid-binding site on 
LPL. Upon activation by apoCII, which is on the lipoprotein particle, LPL hydrolyses some of 
the triacylglycerol core. This results in the release offree fatty acids, di- and mono-acylglycerols 
and glycerol for use by cells. The removal of triacylglycerol from the lipoprotein cores, results in 
smaller particles and excess surface components are transferred to HDL. VLDL and chylomicron 
particles may go through a number of cycles consisting of binding to LPL; hydrolysis of lipid and 
detachment during their degradation to LDL or remnants. respectively. 
The synthesis of LPL by parenchymal cells, rather than endothelial cells, allows the 
tissues to regulate the synthesis of LPL to meet their particular requirements for non-esterified 
fatty acids. The synthesis, activation by glycosylation and secretion of LPL is controlled by a 
myriad of hormones (see below). The release of mature enzyme from the endoplasmic reticulum 
requires microtubular activity. The enzyme may move in the proposed membrane continuum 
which link fat cells and endothelial cells. (Blanchette-Mackie and Scow, 1981a,b). 
There are at least 3 pools of LPL in the tissue; intracellular, extracellular and that bound 
to the capillary endothelial cells. Although earlier studies reported intracellular LPL was 
cytosolic, this now seems to be an artifact. Careful homogenization revealed that LPL is located 
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in microsomal membrane fractions which is consistent with LPL being a secretory product. The 
extracellular LPL is the enzyme en route from the parenchymal cells to the endothelium. The 
third pool comprises the active enzyme bound to the endothelium through association with cell 
surface glycosaminoglycans rather than a specific receptor. A variety of evidence from in vivo 
and in vitro studies has suggested this. The enzyme is rapidly released by an in vivo intravenous 
injection of heparin; injection of LPL-specific immuno-globins inhibits triacylglycerol removal 
and in vitro studies with specific glycosaminoglycan - degrading enzymes support the suggestion 
that the enzyme is bound to endothelial cells via a glycosaminoglycan. (Shimada et at., 1981; 
Cheng et ai., 1981; Williams et ai., 1983). 
Natural lipoprotein-bound triacylglycerol is the preferred substrate for LPL, although the enzyme 
will bind and hydrolyse synthetic lipoproteins. The enzyme has a preference for the sn-l position 
of triacylglycerol (Nilsson-Ehle et ai., 1974), although mono-acylglycerols, di-acylglycerols and 
phospholipids may also act as substrates (Quinn et at., 1982; Kinnunen et ai., 1983). ApoCII is 
required to activate LPL. The C-terminal of apoCII contains the activating region and ApoCII 
may function by accepting released fatty acids and transferring them to albumin (Kinnunen et al., 
1983). In vitro studies have shown that the activation ofLPL by apoCII is inhibited by salt and 
non-esterified fatty acids. These inhibitors interfere with the apoCII-enzyme interaction. The 
reported inhibitory effects of apoCIII and apoE may be nonspecific because accessibility of the 
lipid substrate within the lipoprotein may be decreased in the presence of these lipid-binding 
proteins. Nevertheless, although inhibition has been reported in vitro, it may well not apply at 
physiological concentrations in vivo. 
3.2.2 Regulation of LPL 
LPL activities change in response to a variety of situations; nutritional, environmental, 
physiological, genetic or pathological. In general, reciprocal changes occur in adipose and muscle 
tissues. For example, in a well fed rat, when adipose tissue is actively storing triacylglycerol, 
LPL activity is high. Muscle on the other hand, does not depend on fatty acids for oxidation and 
LPL activity is low. Thus, changes in LPL activity have an important role in directing nutrients 
towards certain tissues. 
Several factors may contribute to the changes in LPL activity in different situations. Since in 
vitro studies suggest LPL is not saturated at normal plasma triacylglycerol concentrations, 
changes in lipoprotein triacylglycerol concentrations will result in changes in LPL activity. If 
plasma concentrations of triacylglycerol increase, LPL activity increases. Differences in apparent 
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Km ofLPL of different tissues may allow, for example, the cardiac LPL to preferentially use 
lipoprotein-triacylglycerol over adipose tissue LPL when nutrition and hence plasma lipoprotein 
concentrations are low (Breckenridge, 1985). Secondly, increases in LPL activity may arise from 
increased synthesis of new enzyme. Jansen et at. (1978) demonstrated increased immuno-
precipitable LPL on refeeding rats after a fast. Thirdly, the increases could arise from activation 
of preformed LPL within the parenchymal cells. 
Whether all these influences on LPL are mediated by hormonal changes is unknown. 
Adipose tissue LPL, at least, has been shown to be under hormonal control. There is now a 
considerable body of evidence that insulin is a major physiological regulator of LPL. 
In vitro studies using isolated adipose tissues or cells have shown that insulin increases 
LPL activity. In rats, there is a strong positive correlation between plasma insulin concentrations 
and adipose tissue LPL activity (Cryer et at., 1976). The activity is reduced in diabetic humans 
and alloxan-diabetic animals (review: O'Looney and Vahouny, 1987). In vivo studies in animals 
(Garflnkel et ai., 1976; Borensztajn et at., 1972; Pykalisto et at., 1975) including cows (Rao et 
al., 1973) have shown that injecting insulin increases adipose tissue LPL activity. The insulin 
effect on LPL activity may be transcriptional, translational or post-translational or combinations 
thereof (Vydelingum et at., 1983; Ong et at., 1988; Semenkovich et at., 1989). 
A variety of other hormones and factors affect the regulation ofLPL. Briefly, 
catecholamines, adrenocorticotrophin, glucagon, thyroid stimulating hormone, dibutyryl c-AMP, 
caffeine and theophylline inhibit the stimulatory action of insulin on adipose tissue lipoprotein 
lipase activity. Glucocorticoids enhance the insulin effect and stimulate adipose tissue LPL 
activities. Oestrogens depress lipoprotein lipase activities in adipose tissue (review: Cryer, 1981). 
The hormonal regulation of LPL in other tissues is less well studied. 
Most studies on the regulation of LPL activity have been made on rats or humans but all 
species may not regulate LPL in the same manner (Cryer, 1986). 
3.2.3 Role of LPL. 
LPL has two interrelated functions; lipoprotein catabolism and the supply of fatty acids 
for tissues. LPL plays a key regulatory role in the catabolism of triacylglycerol-rich lipoproteins 
(Reardon et al., 1982a). Its action in converting VLDL to LDL is described in 3.2.1. In patients 
and experimental animals deficient in LPL or apoCn, VLDL and chylomicrons accumulate 
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resulting in severe hypertriglyceridaemia. Indeed, the hydrolysis of lipid by LPL has been 
demonstrated to be the rate-limiting step in the removal of VLDL and chylomicron triacylglycerol 
from plasma (Garfinkel et ai., 1967; Kompiang et ai., 1976; Bensadoun and Kompiang, 1979). 
Clearly LPL plays an important role in transforming VLDL to LDL and in tissues utilizing fatty 
acids from plasma triacylglycerol-rich lipoproteins. 
Despite the potential importance of lipoprotein-triacylglycerol-fatty acids to energy 
metabolism, in vivo studies on the significance of this contribution are limited. This is probably 
due to the difficulty of distinguishing fatty acids released from lipoproteins by LPL and those 
NEFA bound to albumin. The work of Wolfe and Durkot (1985) suggested that in rats the fatty 
acids released by LPL did not need to enter the plasma free fatty acid pool prior to oxidation. 
This is important, ifLPL is to have a 'directive' role as suggested by reciprocal changes in 
activities in different tissues. Only a portion of fatty acids released by LPL are taken up directly 
by tissues (Scow et at., 1976). 
Fatty acids released by LPL may be either oxidized for energy, as in cardiac and 
skeletal muscles, or resynthesized into triacylglycerol for storage, as in adipose tissue, or secreted 
as milkfat in the mammary tissue, or to fulfill specific roles such as a surfactant as in the lungs. 
The role of LPL in different tissues is illustrated by the changes in LPL activities in different 
tissues during development (review: Cryer, 1985). 
Because of the interest in fat deposition in meat-producing animals, the role ofLPL in 
fat accretion is of particular interest in the present study. There are four sources of fatty acids for 
the deposition of fat; de novo synthesised fatty acids, fatty acids recycled from lipolysis, plasma 
NEFA, and fatty acids released from triacylglycerol-rich lipoproteins by LPL. The question is 
what are the relative contributions of the four sources. 
In many species, including man and rats, fatty acids released from plasma lipoprotein 
triacylglycerol are the predominant source of fatty acids stored as fat in adipose tissue 
(Hollenberg, 1966). This may not be true in all animals. In other species such as sheep (Ingle et 
ai., 1972) and cattle (Hanson and Ballard, 1967) where adipose tissue also plays an important role 
in synthesising long-chain fatty acids, the role of LPL is less clear. 
3.2.4 Measurement of LPL 
The measurement of LPL activity requires the preparation of the enzyme, the 
preparation of a suitable substrate, components for activation of the enzyme and to accept 
released fatty acids, optimal incubation conditions and procedures for extraction and 
quantification of the reaction products. 
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There are two common sources of enzyme; post heparin plasma (PHP) and extracts of 
tissues. Injection of heparin releases severallipases into the plasma, including LPL, 
monoglyceride esterase(s) and hepatic triacylglycerollipase. The amount and time-course of 
lipase activities depends on the amount of heparin employed. LPL and hepatic triacylglycerol 
lipase were distinguished from each other about 12 years ago and their differing characteristics 
allow each to be assayed. Numerous assays have been devised to measure LPL and hepatic 
triacylglycerollipase in the same PHP sample. Most assays involved measuring total lipase 
activity, hepatic triacylglycerollipase activity by inhibiting LPL with salt, protamine (Krauss et 
at., 1974) or antibodies (Huttunen et at., 1975; Greten et at., 1977) and calculating the activity of 
LPL in PHP by subtraction. Selective assays for LPL are difficult since the only reported 
inhibitor of hepatic lipase is sodium dodecyl sulphate. The difficulty with this type of assay is 
that the incubation conditions are never optimal for both individual enzymes. In 1977, Nilsson-
Ehle and Ekman published a method which allowed direct detennination of each enzyme at its 
optimal conditions for pH and salt concentrations, even in the presence of other enzymes. The 
specificity of the assay resulted from preparing specific substrates by homogenising 3H-triolein 
and phoshotidylcholine with and without albumin. 
Prior to assay, LPL activity in tissue samples is extracted either as acetone-ether 
powders, heparin eluates or in fresh homogenates. Acetone-ether powders prepared by 
homogenizing the tissue in acetone and delipidating with acetone followed by ether, are extracted 
into either ammonium buffer or tris-HCI buffer with 20% ethylene glycol with or without heparin. 
This preparation represents total lipase activity; intracellular, extracellular and endothelial-bound 
LPL. Heparin eluates are prepared by incubating tissue samples in a buffer containing heparin. 
The enzyme activity represents pre-fonned enzyme and depends on the temperature and time of 
incubation as these affect the rate of release, activation and inactivation of the enzyme (Nilsson-
Ehle, 1974). Cryer and Jones (1981) compared LPL activities in fresh homogenates and 
extractions of acetone-ether powders and recommended acetone-ether preparations because in 
these preparations enzyme activity was higher and LPL characteristics were more easily 
demonstrated than in fresh homogenates. 
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Early assays used commercially available triacylglycerol emulsions such as Intralipid 
(e.g. Borensztajn et al., 1972). Radioactive-labelled triacylglycerol included in the emulsions 
increased the sensitivity of the assay. Emulsions were prepared by sonicating the labelled 
triacylglycerol in buffer with a detergent but the emulsions had limited stability and were not 
easily reproduced. NUsson-Ehle and Schotz (1976) developed a stable radioactive emulsion of 
triacylglycerol with phospholipid in glycerol which overcame these problems. The incubation 
media for the LPL assay also contained albumin as a fatty acid acceptor and serum as a source of 
apoCII in buffer pH 8 to 8.6. The products of the reaction are generally determined as non-
esterified fatty acids. The one-step partition system of Belfrage and Vaughan (1969) stopped the 
reaction by adding an organic solvent mixture and subsequently extracting the fatty acids into an 
upper methanol-water phase by the addition of an alkaline buffer. This, along with the use of 
radioactively labelled triacylglycerols, simplified the assay. 
These and other aspects of measuring LPL activities have been recently reviewed by 
Nilsson-EWe (1987). 
3.2.5 Lipoprotein Lipase in Ruminants. 
LPL from bovine milk is a model enzyme for in vitro studies on the structure and 
kinetics ofLPL (Olivecrona and Bengtsson-Olivecrona, 1987). However, there are few studies 
on LPL in ruminant tissues or in vivo studies. Vernon (1981) summarized LPL research in 
ruminants by suggesting the known properties of adipose tissue LPL were similar to adipose 
tissue enzymes in other species. Since then, Tume et al. (1983) have compared LPL from sheep 
and rat adipose tissues. Their work indicated sheep LPL has a lower ~ and hence higher affinity 
for the substrate than rat adipose LPL. Tume and Thornton (1985) also found that the activation 
of by serum depended on the source of serum. Serum from underfed sheep activated sheep 
adipose tissue LPL more than serum from fed sheep, and ovine serum was more potent than rat 
serum. These researchers subsequently isolated two distinct proteins from sheep plasma that 
activated sheep adipose LPL similarly to human apoCll ('fume and Thornton, 1987). 
Differences in LPL activities from different adipose tissue depots have been noted in 
ruminants ('fume et ai., 1983; Haugebak et al., 1974) and different adipose depots respond 
differently during growth and dietary manipulations, (Hood, 1982). These differences in 
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ruminants probably reflect the different rates of development of the adipose tissue depots as well 
as the mechanisms of adipose tissue growth in ruminants. In very young animals, adipose tissue 
grows by hypertrophy and hyperplasia (Hood, 1982). On fattening, hypertrophy appears the 
major mechanism for adipose tissue growth although, even in mature animals, pre-adipose cells 
may proliferate. 
Some physiological effects on LPL activity have been reported in sheep adipose tissue. 
For example, adipose LPL activities were markedly reduced by fasting sheep for 4 days (Tume et 
at., 1983) or by feeding growing lambs maintenance rations rather than ad libitum (Haugebak et 
ai., 1974). Lactation also reduced LPL activity in omental tissue (Smith and Walsh, 1984) 
suggesting that fatty acids were redirected to milk fat synthesis. In experiments using post 
heparin plasma, LPL activity was also depressed in alloxan-treated sheep (Mamo, 1986). 
Tume et al. (1983) reported that the LPL activity in sheep muscle was approximately 
one tenth that in adipose tissue on an equal weight basis. Because of the contribution of skeletal 
muscle to body mass, muscle LPL activity is a major contributor to total body lipoprotein lipase 
activity. 
Conclusion. 
LPL has been demonstrated to be an important enzyme in the catabolism of 
triacylg1ycerol rich lipoproteins and in supplying fatty acids for use by tissues. 
The role of LPL and hence lipoprotein metabolism in sheep was assessed in three trials. 
All three trials examine the effect of early weaning on carcass composition and adipose tissue 
LPL activity. In addition, Trial 1 considers the distribution ofLPL between adipose tissue sites at 
two different ages and the effect of long term insulin infusion. Trial 2 also examines the effects 
of early weaning on PlIP LPL and uses the euglycemic clamp technique to examine the short 
term effects of insulin on adipose tissue LPL activity. 
35 
3.3 TRIAL 1. 
3.3.1 Trial Design. 
These experiments were performed on lambs in a trial conducted by Willis (1990). 
Only lambs used in this thesis are described. The general experimental procedures are included 
in brief. Specific details are reported by Willis (1990). A 2 x 2 x 2 factorial experiment was 
conducted with 48 Border Leicester x Dorset wether lambs. This comprised two rearing 
procedures (suckled and early weaned), two insulin treatments (no insulin, and exogenous 
insulin) and two slaughter-ages (12 and 23 weeks). At five weeks of age, half the lambs were 
weaned while the remaining lambs continued to suckle. All lambs had access to grass ad libitum. 
The weaned and suckled animals were further sub-divided and 8 lambs in each group were treated 
with exogenous insulin. The insulin dose increased from 0 to 38 IU/d at week 20 and was 
administered by either continuous infusion or a daily intravenous injection (Willis, 1990). Both 
treatments were considered equivalent 
Each week, all animals were weighed and blood samples were withdrawn after a 4 h 
fast for determination of glucose, urea and insulin (Willis, 1990). Prior to slaughter, intravenous 
glucose tolerance (OTT), insulin sensitivity (1ST), glucose turnover and incorporation of [U14C]_ 
glucose into glyceride glycerol were measured 
All lambs were killed by exsanguination. Samples of adipose tissue from omental, 
perirenal and subcutaneous (above the tail) adipose tissue depots were taken for the measurement 
ofLPL activity. 
3.3.2 Methods. 
3.3.2.1 Lipoprotein Lipase Assay for Adipose Tissue Samples. 
The assay for lipoprotein lipase activity was based on that of Nilsson-Ehle and Schotz 
(1976), Tume et ai. (1983) and Tume (pers. comm.). Acetone-ether powders were prepared from 
adipose tissue samples. These were extracted using buffer containing heparin and assayed using 
a synthetic lipoprotein prepared as an anhydrous emulsion of Tri[3H] oleylglycerol. The fatty 
acids released were extracted by phase partitioning and their radioactivity determined. 
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Preparation of Acetone-Ether Powders 
Immediately on slaughter )samples (3-5 g) of omental, perirenal and subcutaneous 
adipose tissues were taken, placed into warm NaCI (0.73% w/v 37· C) and transferred to the 
laboratory for preparation of the acetone-ether powders. Care was taken to maintain the 
temperature at 37 ±2 • C. The adipose tissue samples were blotted dry and 1 g samples were 
briefly homogenized at 37· C in 0.75 ml TRIS-HCl buffer (0.1 M, pH 7.4) and 0.25 ml heat-
treated serum (ovine serum heated to 62· C for 10 min to eliminate endogenous lipolytic activity). 
The homogenate was then extracted with ice-cold acetone (40 ml). After mixing and allowing to 
stand on ice, the acetone was decanted and filtered through a sintered glass funnel. The 
precipitate remaining in the tube was re-extracted with cold acetone (40 ml) five times, followed 
by four extractions with diethyl ether (40 ml) before collecting the acetone-ether powder on the 
sintered glass funnel. Freshly distilled acetone and diethyl ether were used for all extractions. 
The prepared acetone-ether powder was transferred to a vial, weighed and stored at -70· C in a 
desiccated container. 
Extraction of LPL from Acetone-ether Powders 
The acetone-ether powders were crushed in the vials using glass rods and subsequently 
extracted by homogenising for 45 s in 3.5 ml extraction buffer [910 ,u heparin, (500 U/ml) added 
to 98 ml NH40H-NH4Cl buffer (0.05 M, pH 8.1)] and standing on ice for 20 min. The 
suspension was then frozen in liquid nitrogen and stored at -70· C until assayed. 
Preparation of the Concentrated Substrate m Anhydrous Emulsion 
Trioleylg1ycerol (300 mg), L-ot-phosphatidylcholine (18 mg) (egg yolk, Sigma Chern. 
Co. USA) and Tri[9,1O-3H] oleylglycerol (80 &J containing 1.25 x 109 cpm) (Amersham, 
Australia) were combined in a 10 ml glass tube and dried in a stream of nitrogen. 6.25 g glycerol 
(purified by heating and drying over phosphorous oxide) was then added. The tube was packed 
in ice before homogenization with an Ultra-Turrax homogeniser for 30 s five times, with 30 s 
breaks in between each burst. The depth of probe and speed were recorded to give consistency in 
future preparations. The concentrated substrate was stored at 5 • C for up to 6 months. 
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Preparation of the Diluted Substrate 
Concentrated substrate (wanned to room temperature), Tris-HeI buffer (0.2 M, pH 8.1) 
with freshly added bovine serum albumin (BSA, 4.5%) and ovine serum were mixed in a ratio of 
1 :4: 1 (v/v/V) by vortexing for 5 min. The density of glycerol (1.26 g/ml) was used to weigh the 
required amount of substrate. BSA fraction V, and bulk serum were tested for lipase activity. 
Bulk serum was aliquoted into I and 0.75 ml aliquots and stored frozen for use in the assays. The 
amount of serum required for maximal activity was assessed for each batch. 
Incubation and Determination of Fatty Acids Released 
0.1 ml diluted substrate (fmal concentration 5.65 mM) and 0.1 ml enzyme preparation 
or buffer (for blanks) was vortexed then incubated for 30 min at 37· C in a shaking waterbath 
(Grant 200 strokes.min·I ). Each enzyme preparation was assayed in triplicate. The reaction was 
stopped and the fatty acids extracted by adding 3.25 ml methanol: chloroform: heptane (1.45 : 
1.25: 1 v/V/v). After mixing, 1.05 ml K2C03-borate buffer (0.1 M, pH 10.5) was added and the 
tubes were vortexed for 15 s. The mixture was centrifuged (3000 g x 5 min) to separate the 
phases and the radioactivity in the fatty acids was determined by counting 1 ml of the MeOH-H20 
phase in Triton X:Toluene scintillant (1:2 v/v; 2,3-diphenyloxazole (PPO) 0.4% w/v) using a 
Phillips PW 4700 Liquid Scintillation Counter, preset for 3H in Triton X:Toluene Scintillant 
The counting efficiency of substrates and samples was the same. Cpm was used in the calculation 
of LPL activity. 
Calculation of Enzyme Activity. 
The radioactivity in an aliquot (25 Ill) of the dilute substrate was counted in 1 ml K 2C03 
buffer to determine the specific activity of the substrate as cpmx4 
1140 x 3 
The LPL activity in each sample was calculated from the equation:-
Activity = 
Activity units 
Sample cpm 
S.SA 
v 
Samplecpm 
t 
_1 
x S.SA 
V 
x Eff 
E.Vol 
x 
wt 
U defined as nmole fatty acid released.min-I.g-! wet weight tissue. 
Sample - blank cpm. 
Substrate Specific Activity. 
Volume of the MeOH-H20 phase = 2.45 rnl 
Eff 
Wt 
Efficiency of extraction of released fatty acids into MeOH-H20 phase 63.7% (see 
3.3.3.1) 
Wet weight of tissue used (g). 
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E.Vol Dilution factor to account for 100 /Jl sample taken from 3.5 ml enzyme suspension 
= 35. 
Quality Control. 
A bulk sample of post heparin plasma (PHP) was obtained by injecting 100 U . kg-! 
heparin into a sheep and withdmwing blood 15 min later. The plasma was centrifuged (1000 g, 5 
min), aliquoted and frozen (-70· C). Triplicate samples (50 J,Ll) of PHP were assayed with each 
assay along with repeats oftwo tissue extracts to assess assay variability and substrate integrity. 
3.3.2.2 Carcass and Non-carcass Composition. 
On slaughter, carcass and non-carcass components were separated, weighed and frozen. 
GR, the depth of fat over the 12th rib, was measured as an indicator of carcass fatness. The 
frozen tissue was coarsely cut up and minced three times. The minced tissue was thoroughly 
mixed and samples taken for freeze drying and chemical analysis. Water, fat (Soxhlet 
extraction), protein (Kjeldahl nitrogen x 6.25)and ash (500· C for 9 h) were determined. 
3.3.2.3 Statistics. 
Statistical analysis were performed using the F-test of the Genstat statistical package. 
This trial was considered a 2 x 2 factorial design, rearing and insulin for each individual tissue at 
each slaughter age. Data is presented as mean ± standard error of the mean for each cell in the 2 x 
2 factorial. The effects of slaughter age was assessed by considering the trial as a 2 x 2 x 2 
factorial design with slaughter age as the third level. Similarly the effect of tissue site was 
assessed by considering the trial as a 3 x 2 x 2 factorial design with tissue site, rearing and insulin 
being the factors at each slaughter age. 
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3.3.3 Results. 
3.3.3.1 The Lipoprotein Lipase assay. 
Preparation of samples 
The preparation of acetone-ether powders from sheep adipose tissue required exhaustive 
defatting. Extraction of acetone-ether powders in a variety of buffers without heparin (0.05 M 
TRIS-HCl, pH 8.0 with 1 M ethylene glycol; 0.05 M NH40H-NH4Cl, pH 8.1 and pH 8.6) 
resulted in enzyme preparations with very low activity. The inclusion of heparin (4.6U/ml) in 
the NH40H-NH4Cl extraction buffer (0.05M, pH 8.1) resulted in enzyme preparations with lipase 
activity (Figure 3.1). Doubling the concentration of heparin had little effect on the lipase activity 
in the preparation. An extraction time of 20 min on ice gave maximal activity for LPL (Figure 
3.1). Freezing the samples in liquid nitrogen, storing at -70· C and thawing immediately prior to 
assay resulted in less than 1 % difference in activity. Since centrifugation of extracts to remove 
particulate matter resulted in the loss of greater than 50% of the activity, samples were vortexed 
and 100 ,.u. aliquots of the suspension were used in the assay. 
Post heparin plasma, for use as quality control samples, was prepared by injecting 100 
U heparin. kg-! into a sheep and sampling blood 15 min later. The release oflipoprotein lipase 
was dependent on the dose of heparin used. Injection of 10 U heparin per kg body weight as used 
in some human studies (Krauss et ai., 1974) resulted in PHP with low lipase activity which was 
inhibited by the presence of normal serum in the substrate preparation. The time course of the 
release ofPHP LPL was determined by injecting heparin (100 U/kg body weight) into two lambs 
and collecting plasma samples between 0 and 20 min (Figure 3.2). Prior to the injection of 
heparin the activity ofLPL in the plasma was low. Maximal LPL activity occurred 15 min post 
injection. 
The Assay for LPL 
Enzyme activity increased linearly with the amount of enzyme in either PHP or adipose 
tissue extracts (Figure 3.3) and with time for at least 30 min (Figure 3.4). Inclusion of 1 M NaCl 
in the reaction mixture resulted in the loss of more than 95 % of the lipase activity measured in 
samples without NaCl for both PHP and extracts of acetone-ether powders of adipose tissue. 
When the substrate was prepared without serum, the lipase activity was decreased by more than 
80%. Figure 3.5 shows the activation of LPL activity by serum and the effect of increasing 
Figure 3,1: The effect of time and heparin concentration on the extraction of LPL activity 
acetone-ether powders prepared from sheep adipose tissue, 
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Figure 3,2: The activity of LPL in plasma as a function of time following the injection of heparin 
(100 U/kg bodyweight) into two lambs, 
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Figure 3.3: The effect of enzyme concentration on the release of 3H-fatty acids 
using two sources of enzyme - PHP and extraction of acetone-ether powders of adipose tissue. 
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Figure 3.4: The effect of incubation time on the release of 3H-fatty acid in the LPL assay using 
acetone-ether powder extracts of adipose tissue. 
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Figure 3.5: The activation of LPL activity by serum. The effect of serum concentration (% 
:reaction mixture) on the assay of LPL activity from acetone-ether powder extracts of adipose 
tissue. 
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concentrations of serum in the reaction mixture. The optimal ratio of serum to dilute substrate 
was 1:5. 
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The efficiency of extraction of released fatty acids from the reaction mixture was 
assessed by preparing substrate with [3H]-0Ieic acid instead of triacylglycerol, preparing reaction 
mixtures at 37· C and then extracting with methanol: chloroform: heptane (1.45: 1.25: 1, v Iv Iv). 
The efficiency was consistently 63.7:1:0.45% (mean ::!:sd). There was no difference in extraction 
effiCiency if borate was omitted from the buffer. The extraction efficiency was determined for 
each new solvent preparation. 
Intra-assay variation, as assessed by PHP and extracts of acetone-ether powders of 
adipose tissue, was less than 1.5% while the inter-assay variation was 20% (n=20) over all assays. 
3.3.3.2 LPL Activities in Adipose Tissue. 
The mean LPL activities in adipose tissue of lambs slaughtered at 12 weeks are shown 
in Table 3.1. The three adipose sites were subcutaneous, omental and perirenal fats. Suckled 
lambs had lower LPL activities in all adipose tissue sites than the weaned animals. The animals 
infused with insulin showed lower LPL activities in all tissues compared to non-insulin treated 
lambs. The differences were not significant. Perirenal and omental tissue showed similar LPL 
activity while the activity in subcutaneous adipose tissue was lower. 
The treatment means of LPL activities in adipose tissue of lambs slaughtered at 23 
weeks are shown in Table 3.2. LPL activity was greater in weaned than suckled lambs in all 
adipose tissues tested. This difference was statistically significant in subcutaneous and omental 
tissues. Infusing insulin increased LPL activity in the weaned animals but tended to decrease the 
LPL activity in suckled lambs. 
The distribution of LPL in the three adipose tissue sites differed from that in lambs 
slaughtered at 12 weeks. LPL activity was similar in all tissue sites at the 23 week slaughter. 
There was no difference in the LPL activity of subcutaneous adipose tissue between 12 and 23 
weeks but the LPL activity in omental and perirenal tissues were lower at 23 weeks (p <0.001). 
The data for omental tissue where one cell has only 2 animals should, however, be treated with 
caution. 
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The results of the LPL assays for individual lambs for the three tissue sites at the 12 and 
23 week slaughter are in Appendix 3. 
Table 3.1: Mean LPL Activity in Adipose Tissues of Lambs Slaughtered in 12 Weeks 
Adipose Tissue Site 
Subcutaneous Omental 
Weaned (8) 205 :1:43 313 :1:47 
Weaned + Insulin (4) 122 :1:36 225 ±52 
Suckled (8) 191 :1:90 226 :1:54 
Suckled + Insulin (4) 53 :1:16 142 :1:18 
Statistics 
Rearing ns ns 
Insulin ns ns 
Rearing x insulin ns ns 
LPL activity in nmol fatty acid produced.min-I.g-I wet weight tissue 
Mean:l: SEM. 
(n) number of lambs in treatment 
Statistics from two way analysis of variance for individual tissues. 
ns p>O.10 
Perirenal 
316 ±40 
276 :1:55 
279 :1:70 
193 :1:47 
ns 
ns 
ns 
Table 3.2: Mean LPL Activity in Adipose Tissue of Lambs Slaughtered at 23 Weeks 
Weaned (7) 
Weaned + Insulin (3) 
Suckled (6) 
Suckled + Insulin (3) 
Statistics 
Rearing 
Insulin 
Rearing x Insulin 
Adipose Tissue Deposit 
Subcutaneous Omental 
144 :1:44 
235 :1:90 
88 :1:18 
77 :1:27 
p = 0.04 
ns 
ns 
102 :1:28 
240 :1:101 
p = 0.003 
P = 0.019 
P = 0.008 
Perirenal 
134 :1:42 
145 :1:71 
101 :1:31 
85 :1:32 
ns 
ns 
ns 
LPL Activity in U.g-l wet weight tissue = nmole fatty acid produced.min-l.g-l wet weight tissue. 
Mean :l:SEM 
(n) := number of lambs 
1 n=2 
2n=8 
3 n=4 
Statistics from two way analysis of variance for individual tissues. 
ns p>O.lO 
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3.3.3.3 Total Lipoprotein Lipase Activity from each Tissue Deposit. 
Since the LPL activity was expressed per gram weight of wet tissue and the amount of 
tissue in each site varied between treatments, the total LPL activity was calculated as LPL activity 
per g tissue multiplied by the weight of tissue. Individual tissue weights were used for perirenal 
and omental tissues while the subcutaneous fat was estimated as carcass fat. The mean total LPL 
activities are presented in Table 3.3. Experimental treatments caused no significant differences 
between total tissue lipase activity at each adipose site. 
Table 3.3: Total LPL Activity (U xlO-3 per organ) in Subcutaneous, Omental and Perirenal 
Adipose Tissue in the 23 week Slaughter Group. 
Adipose tissue 
Weaned (8) 
Weaned + Insulin (4) 
Suckled (8) 
Suckled + Insulin (4) 
Statistics 
Rearing 
Insulin 
Rearing x Insulin 
Subcutaneous 
797 
1044 
802 
718 
ns 
ns 
ns 
LPL Activity U ::::: nmole fatty acid released.min- I . 
Omental 
77 
122 
82 
65 
ns 
ns 
ns 
Statistics from two way analysis of variance for individual tissues. 
ns p>O.10 
3.3.3.4 Plasma Insulin Concentrations. 
Perirenal 
48 
21 
66 
43 
ns 
ns 
ns 
These measurements, along with measurements of insulin status, form the 
basis of the thesis of Willis (1990) and are reported here in summary only. 
Plasma insulin concentrations (Table 3.4) measured in pre-slaughter blood 
samples revealed a significant effect of rearing at both slaughter ages. Suckled lambs 
had higher plasma insulin levels than weaned lambs. The infusion of exogenous insulin 
increased the plasma insulin concentrations. This effect was significant at 23 weeks 
when the rate of insulin infusion was greatest. 
Table 3.4: Plasma Insulin Concentrations ("D/ml) in Blood Samples Taken During the Week 
Prior to Slaughter from Lambs Slaughtered at 12 and 23 Weeks. Data from Willis (1990). 
Weaned (8) 
Weaned + Insulin (4) 
Suckled (8) 
Suckled + Insulin (4) 
Statistics 
Rearing 
Insulin 
Rearing x insulin 
Mean ± SEM. 
3.3.3.5 Body Composition. 
Slaughter Age 
12 weeks 23 weeks 
17.8 ±3.61 
11.7 ±4.49 
25.9 ±3.09 
31.1 ±8.84 
p = 0.05 
ns 
ns 
13.4 ± 1.46 
37.1 ±11.70 
17.4±1.71 
55.6 ± 3.88 
p= 0.01 
P = 0.001 
ns 
The different rearing treatments produced animals with different carcass composition 
(Table 3.5, Appendix 3.3). At both slaughter ages the suckled lambs had increased body 
weights, increased fat in the total body, carcass and non-carcass components and increased OR 
but decreased body protein compared to early weaned lambs. 
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The effect of exogenous insulin was different at the two slaughter ages. At 12 weeks, 
exogenous insulin decreased non-carcass fat in both rearing treatments. A significant interaction 
between insulin treatment and rearing was observed in measurements of OR, body and carcass 
compositions. In weaned lambs, exogenous insulin reduced fatness arid increased protein while 
in suckled lambs, exogenous insulin increased fatness and decreased protein. At 23 weeks, 
exogenous insulin increased protein and decreased fatness, as shown by total body, carcass and 
non-carcass composition in both weaned and suckled lambs. 
Table 3.5 Pre-slaughter liveweights (kg), OR measurements (mm) and fat 
composition of carcass, noncarcass components and total body (%) of 
lambs slaughtered at 12 weeks and 23 weeks. 
Fat Composition $ 
----------------------------------------------------
Liveweight OR Carcass Noncarcass Total 
12 week slaughter 
Weaned (8) 28.42 4.4 18.60 9.73 14.95 
Weaned +Insulin (4) 30.85 4.0 14.62 7.82 11.79 
Suckled (8) 33.85 11.0 22.14 12.28 18.24 
Suckled +Insulin (4) 32.39 14.0 24.09 11.74 19.24 
Statistics 
Rearing <0.01 <0.0001 0.001 0.001 0.001 
Insulin ns <0.05 ns 0.05 ns 
Interaction ns <0.07 0.001 ns 0.005 
----------------------------------------------------------------------------------------------------------------
23 week slaughter 
Weaned (8) 44.42 14.5 27.50 17.98 23.72 
Weaned +Insulin (4) 44.30 12.5 25.47 16.92 22.15 
Suckled (8) 51.00 21.5 34.72 18.74 28.81 
Suckled +Insulin (4) 53.03 23.7 33.71 15.08 26.80 
Statistics 
Rearing p<.OOl p<0.0005 0.001 ns <0.001 
Insulin ns ns 0.07 p<.OI <0.01 
Interaction ns ns ns ns ns 
Mean value for animals in each group. 
* Adjusted for the covariate empty body weight. 
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3.3.4 Discussion. 
3.3.4.1 The assay ofLPL Activity. 
An assay for the measurement of lipoprotein lipase activity in sheep adipose tissue and 
PHP using anhydrous emulsions of [3H]-triacylglycerol stabilized with lecithin (Nilsson-Ehle and 
Schotz, 1976) is described. 
To prepare PHP from sheep, heparin doses of 100 U/kg body weight were required. 
Heparin doses of 10 U/kg, as used in some human studies, appeared to preferentially release 
hepatic lipase rather than lipoprotein lipase (Tume pers. comm.). The activity of LPL in PHP 
represents a balance between the release of LPL from the endothelium, activation of LPL by 
heparin, further release ofLPL presumably from the extracellular pool, and the rapid degradation 
by the liver. Prior to the injection of heparin the activity of LPL in the plasma is low. Maximal 
LPL activity occurred 15 min post injection. The time to reach maximal activity was 
subsequently confirmed in 10 lambs by Armstrong (1987) and was similar to that observed by 
Mamo (1986) in lambs. Nilsson-Ehle (1987) recommends the same time for humans using a 
similar heparin dose. PHP was collected without anticoagulant. Although Nilsson-Ehle (1987) 
recommends using EDT A as anticoagulant to avoid the delay of allowing the blood to clot, in the 
present study, there was sufficient heparin in the plasma to prevent clotting. 
Acetone-ether powders were prepared using the method described for sheep adipose 
tissue by Tume et ale (1983) by maintaining the tissue samples at 37· C prior to homogenizing in 
buffer containing carrier serum and exhaustive defatting. The present work confirmed that the 
extraction of lipoprotein lipase from acetone-ether powders required heparin as indicated by 
Tume et al. (1983). This is in contrast to the work of Mamo (1986). 
In addition to lipoprotein lipase, acetone-ether powders of adipose tissue contained 
hormone-sensitive lipases and PHP contained a number of other lipases such as hepatic 
endothelial lipase. It is therefore important to have a specific assay for lipoprotein lipase. This 
was achieved by preparing a specific substrate for lipoprotein lipase, ensuring the triacylglycerol 
was free of monoglycerides, including serum as a source of activator and using the optimal pH for 
lipoprotein lipase. The inclusion of 1 M N aCl, a known inhibitor of lipoprotein lipase, in the 
reaction mixture inhibited the lipase activity by at least 95%. Omission of serum from the 
reaction mixture reduced the lipase activity by 80%. Similar results were obtained by Nilsson-
Ehle and Schotz (1976) with rat adipose tissue. The remaining activity may be attributed to 
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activation of lipoprotein lipase by apoCII in the plasma added during the preparation of acetone~ 
ether powders or in the PHP itself, since inhibition by 1 M NaCl was more complete than serum 
omission. The inhibitory effect of NaCl and the stimulatory effect of serum strongly indicate that 
the assay is specific for lipoprotein lipase. 
The precision of the assay was assessed by re~assaying the same source of enzyme in 
the same assay and on different days. The intra-assay variation « 1.5 %) was excellent but the 
inter-assay variation was high (20%). This reflects heterogeneity of both the concentrated 
emulsion and diluted substrate. The linear relationships between fatty acids released and amount 
of enzyme and incubation time demonstrated that the assay was acceptable and that the enzyme 
activity was stable throughout the assay period. The concentrations of BSA (fatty acid acceptor) 
and serum (source of activator) were appropriate and the substrate concentration was not rate 
limiting. Unfortunately, the accuracy of the assay could not be assessed as no reference samples 
or reference method were available. 
3.3.4.2 Lipoprotein Lipase in Sheep Adipose Tissue. 
This work reports the activity of LPL in sheep adipose tissues from three depot sites and 
the effects of early weaning and infusion of exogenous insulin on LPL activity. 
LPL activities were slightly higher than those reported in fed growing sheep by Tume et 
al. (1983) and considerably higher than the activities measured by Cryer and Jones (1979) on 
sheep slaughtered at abattoirs. In sheep (Tume et al., 1983), as in other animals (Cryer and 
Jones, 1979), fasting decreased LPL activity in adipose tissue. Haugebak et al. (1974) found 
lambs fed maintenance diets had much lower adipose tissue LPL activities than lambs fed ad 
libitum. The differences between this work and earlier reports in sheep may reflect nutritional 
differences in the animals. 
LPL activities in adipose tissue were considerable higher in sheep than those reported 
for human adipose tissue (13.5 nmol.min'l.g,l tissue, Nilsson-Ehle et al., 1972) but lower than 
those reported for adipose tissue from rats (500 nmol.min'l.g-l, Cryer and Jones, 1981). However, 
since no reference method or samples were available, the differences between the current work 
and the other reports for sheep and other animals may reflect differences in the analytical 
techniques. The difficulty of comparing results across species was addressed by Cryer and Jones 
(1979). They measured LPL activity in various tissues from ten animal species (mouse, hamster, 
rat, pigeon, guinea-pig, ferret, rabbit, sheep, pig, cow) and found that sheep adipose tissue had the 
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lowest LPL activity. It was also apparent a wide variation in LPL activities exists between the 
various species. Tume and Thornton (1985) suggested that the source of activator for LPL may 
be important. The comparison across species may, therefore, also depend on the source of serum 
used. Cryer (1987) further discussed the problems of comparability ofLPL activity data and 
concluded comparisons of the functional significance of tissue LPL activity and its responses to 
stressors in various species are useful. 
The distribution of LPL activity between the three adipose sites altered with the age of 
the lambs. At 12 weeks, LPL activities in omental and perirenal adipose tissue were similar but 
higher than in subcutaneous adipose tissue. At 23 weeks of age, the differences between the 
tissue sites were not as marked. There was no difference in LPL activity in subcutaneous adipose 
tissue between 12 and 23 weeks. However, the activity in omental and perirenal tissues were 
lower in the 23 than 12 week old lambs. The differences in LPL distribution between the various 
adipose depots and the effect of age presumably reflects the different growth patterns of adipose 
tissue at the different sites. During development, perirenal then omental fat depots develop prior 
to subcutaneous fat (Butler-Hogg, 1984). Several researchers have reported LPL in sheep 
adipose tissue from different depots. In fed growing sheep (30 - 40 kg), Tume et al. (1983) found 
similar activities in subcutaneous and omental tissues but lower activity in perirenal depots. 
Similarly Haugebak et at. (1974) found greater LPL activities in subcutaneous tissues than 
perirenal tissue from growing lambs. Interestingly, these workers also found no differences in 
LPL activities in subcutaneous adipose tissue taken from the hinds addle or foresaddle. Cryer and 
Jones (1979) reported that LPL activities in subcutaneous and perirenal adipose tissues from 
sheep slaughtered at the abattoirs were similar but oflow activity. 
3.3.4.3 Effects of Rearing. 
LPL activities were measured in samples of subcutaneous, perirenal and omental tissues 
from weaned and suckled lambs at 12 and 23 weeks of age. 
At 12 weeks, there was no significant differences in LPL activities between the weaned 
and suckled lambs in any of the three tissue sites (Table 3.1). LPL activities tended to be higher 
in the weaned than suckled lambs but the large variations between lambs meant the differences 
were not significant. The lack of differences in LPL activity occurred despite the weaned lambs 
having significantly less carcass (p<O.OOl) and non-carcass(p<0.OO1) fat than the suckled lambs 
(Table 3.5). The effects of suckling on LPL activity may be expected to be greater at 12 than at 
23 weeks since at 12 weeks the lambs are still suckling. 
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At 23 weeks, LPL activities in subcutaneous and omental tissues were significantly 
higher in weaned than suckled lambs. Although the differences were not always significant, 
higher LPL activities were observed in the weaned than suckled lambs, at both slaughter ages, and 
in all the tissues. This greater activity in the weaned than suckled lambs may seem surprising, in 
view of the higher fat content of the suckled lambs. This seeming anomaly probably arises from 
the expression ofLPL activities on wet weight of tissue. Nilsson-Ehle (1987) commented that 
some of the discrepancies in the literature may be due to how activity is expressed. Indeed, 
Haugebak et at. (1974) observed opposing changes in LPL activities in two groups oflambs 
depending on whether the activities were expressed per number of cells or on a tissue weight 
basis. LPL activity has been expressed with reference to a number of different variables; wet 
tissue weight, lipid, protein, DNA or cell number. The various methods convey different 
information about the system. Differences in enzyme activity may be due to actual changes in the 
enzyme activity or changes in the reference variable. 
When expressed as total tissue activity, LPL activities were higher in suckled than 
weaned lambs although not significant. This suggests that the suckled lambs tend to have a 
higher capacity to utilize triacylglycerol from lipoproteins than the weaned lambs. This is 
associated with the increased fatness in the suckled lambs. There are two points to consider in 
this suggestion. Firstly, the results in this trial were not statistically significant and as such 
require further investigation. Secondly, the measurement of LPL activities measures the capacity 
of the system for LPL activity. This activity may not truly represent the in vivo activity of the 
enzyme. That is, assay of LPL in acetone-ether extracts of adipose tissue measures total LPL 
activity which includes intracellular and extracellular LPL, whereas only endothelial-bound LPL 
is considered to be active in metabolising lipoprotein triacylglycerols. Furthermore, in vivo LPL 
activity also depends on the concentration of the substrate as under normal circumstances the 
plasma concentrations of substrate is below that required for maximal activity. 
The in vivo rates of fat synthesis were determined in these lambs by Willis (1990) using 
the incorporation of 14C from [U 14C]_glucose into glyceride glycerol by the method of Davey 
(1986). The mean rate of incorporation oflabel into glyceride glycerol (expressed as rate of 
change of specific activity of glycerol carbon) was higher in the weaned than suckled lambs but 
these differences were only significant in perirenal tissues at 12 and 23 weeks. When the data 
were expressed as total gylceride glycerol synthesis rates for each tissue, the rates were 
significantly higher in the suckled lambs. The observed differences in LPL activities follow the 
same trend as the in vivo rate of fat synthesis. When based on a per g tissue basis, LPL activities 
and incorporation of glucose carbon into glyceride glycerol were higher in the weaned than 
suckled lambs. However, when the amount of fat tissue was taken into account, the suckled 
lambs showed higher LPL activities and in vivo fat synthesis than the weaned lambs. 
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There is no doubt that early weaning changes the carcass composition. Suckled lambs 
were larger and fatter, both in carcass and non-carcass components, than the early weaned 
animals. There is now considerable evidence from this laboratory (Chambers, 1984) and others 
(Fennessy, 1971; McConnell, 1972) that early weaning reduces fatness in lambs. 
Body composition is, ultimately, dependent on the partitioning of available energy and 
nutrients between fat and protein synthesis. At least in the earlier stages, nutrient intake differed 
between the early weaned and suckled lambs. The suckled lambs had more glucose and lipid 
arriving at the small intestines, because of retention of the oesphageal groove during suckling, 
than the weaned lambs. Consequently, plasma glucose and insulin concentrations were higher in 
the suckled than weaned lambs, until 23 weeks of age, at which time the suckling effect was lost 
and the plasma concentrations of glucose and insulin were equivalent (Willis, 1990). The 
differences in nutrient intake and consequent differences in hormonal balance are presumably 
factors that account for the differences in carcass composition. 
The lack of significant differences in LPL activities between treatments, despite the 
differences in carcass composition and fat synthesis rates, may indicate that LPL activity and 
hence VLDL metabolism may not be important in regulating fat deposition in sheep. However, 
extrapolation of enzyme activity to lipoprotein turnover and the rate of fat accretion requires care. 
Since the LPL assay had a relatively high coefficient of variation and the number of lambs per 
treatment was small, additional data were collected in Trial 2 to validate the above findings. 
3.3.4.4 The Effects ofInsulin. 
The effects of plasma insulin were assessed by comparing animals infused with 
exogenous insulin to untreated animals. The infusion of exogenous insulin tended to increase 
plasma insulin concentrations in both weaned and suckled lambs although plasma insulin 
concentrations were only significantly different from non-infused lambs at the end of the trial. 
Infusion of insulin had no significant effect on LPL activities in subcutaneous, omental 
and perirenal tissues at 12 or 23 weeks. There was no significant correlations between the 
measured LPL activities (as indicated by the subcutaneous adipose tissue measurements) and 
plasma insulin concentrations, or parameters, such as OTT and 1ST, used to measure insulin 
status of the animals (Willis, 1990). 
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Sheep have often been reported to be insensitive to insulin. Although ruminants 
respond to insulin, some pathways are less sensitive to insulin in ruminants than in monogastrics. 
The insulin effects on plasma glucose (Brockman and Laarveld, 1986); the stimulation of fatty 
acid synthesis in adipose tissue (Vernon, 1978; Broad et al., 1983) and the esterification of fatty 
acids to glycerol-3-phosphate (Vernon, 1977; Payne and Masters, 1971) are all examples of a 
reduced response to insulin in ruminants. LPL may well be an example of another enzyme that is 
less sensitive to insulin in ruminants compared to non-ruminants. 
3.3.4.5 Summary 
In summary, early weaning of lambs had no significant effect on total tissue lipoprotein 
lipase activity in subcutaneous, perirenal and omental tissues compared to lambs who remained 
suckling. Infusing exogenous insulin also had no significant effect on LPL activities in the same 
tissues. 
The lambs had significantly different body compositions; early weaning reduced carcass 
fatness. Infusing exogenous insulin also decreased fatness except in suckled lambs slaughtered at 
12 weeks where insulin infusion increased fatness. 
The changes in body composition occurred despite there being no differences in LPL 
activity in subcutaneous, perirenal and omental adipose tissues. The results suggest that adipose 
tissue LPL activity and, by implication, hydrolysis oftriacylglycerol from triacylglycerol-rich 
lipoproteins may not play an important role in fat accretion in sheep. Furthermore the 
stimulatory effect of insulin on LPL activity that is observed in other species, was not apparent in 
this work. with sheep. 
To determine whether the lack of a LPL activity response in this trial is repeatable, a 
second trial was conducted. 
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3.4 TRIAL 2 
In order to validate the fmdings of the first trial that increases in fatness in the suckled 
lambs were not associated with increases in adipose tissue LPL activity and the implied 
suggestion that lipoprotein metabolism does not contribute to the increased fat deposition in these 
animals, lambs in a second trial were used. This trial also investigated the effects of early 
weaning and the infusion of insulin on LPL activity. 
Because of the apparent contradiction of decreased LPL with increased fatness when 
LPL activities were expressed on a tissue weight basis, LPL activities were expressed on a protein 
basis. Furthermore, since qifferences in plasma lipid and lipoprotein concentrations could 
contribute to changes in fat deposition without changes in LPL activity, plasma lipoprotein and 
lipid concentrations were also assessed. 
The other objectives of Trial 2 were to assess the effects of the rearing treatments on 
total body lipoprotein metabolism by measuring PHP LPL. The changes in PHP LPL and adipose 
tissue LPL were compared to indicate the partitioning of lipoprotein triacylglycerol between 
adipose and other tissues. The possibility of using PHP LPL as a tool for selecting lambs prone 
to fatness was investigated. In addition, the effects of insulin on LPL were assessed by (1) 
measuring PHP LPL activity in control lambs and those infused with insulin and (2) measuring 
adipose tissue LPL activity at two insulin infusion levels during a euglycaemic clamp. 
3.4.1 Design of Trial 2. 
The trial was conducted in conjunction with Charles at the Templeton Agricultural 
Research Station. Details relevant to lipoprotein lipase are reported here, other details are given 
by Charles (1986). 24 Coopworth x Suffolk wether lambs were assigned to each of three 
treatments. The treatments were:-
'Suckled' 
'Weaned' 
'Weaned + Insulin' 
suckling lambs were maintained with their ewes on pasture. By 
18 weeks of age the lambs had weaned themselves and the ewes 
were separated for easier management. 
lambs were weaned at 6 weeks of age. 
lambs were weaned at 6 weeks of age and infused continuously 
with insulin as in Trial 1. This treatment group was aborted at 
15 weeks due to the difficulty in maintaining patent catheters and 
ill health of the lambs. 
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Each week, body weights were measured and blood samples taken for analysis of 
plasma and lipoprotein lipids, glucose and insulin. At 14 weeks, post-heparin plasma was taken 
for LPL activity determinations. The studies of Charles (1986) involved glucose and protein 
turnover determinations, and measurement of arterio-venous differences of glucose across the 
hind limb during euglycaemic clamp experiments on 4 weaned and 4 suckled lambs. In each 
lamb, subcutaneous fat was biopsied for LPL determinations under general anaesthetic 
(Halothane or Nembutal, Abbott laboratories (NZ)Ltd, Naenae, NZ» following catheterization for 
arterio-venous difference studies. During the euglycaemic clamp experiments (De Fronzo et al., 
1979), insulin was infused at 0.629 mD. kg-o.7s • min-l for 3h then increased to 6.29 mD. kg-O.75• 
min'l for a further 6h. Subcutaneous adipose tissue was biopsied at the end of each insulin 
infusion period using local anaesthetic (Nopaine: 2% lignocaine hydrochloride Astra 
Pharmaceuticals Pty, NSW, Australia) as described by Davey (1986). A further fat sample was 
removed immediately after slaughter. 
The remaining lambs in each treatment were slaughtered for carcass and non-carcass 
composition (as in Trial 1) and, again subcutaneous fat samples were taken immediately after 
slaughter. All lambs were slaughte~d at 40 kg liveweight at about 26 weeks of age. 
3.4.2 Methods 
Although the methods were similar to those used in Trial 1, several changes were made. 
These differences are reported in full and discussed in 3.4.2.6. 
3.4.2.1 Analysis of plasma and lipoprotein lipid concentrations in weekly plasma samples. 
Chylomicrons (p<0.95 glml), VLDL (0.95-1.006 glml), LDL (1.006-1.063 glml), and 
HDL (1.063-1.21 glmI) were isolated by ultra centrifugation (described in detail 4.3) from a 
number of weekly plasma samples. Plasma and isolated lipoproteins fractions were assayed for 
total cholesterol using the Boehringer Monotest Cholesterol CHOD-P AP method while 
triacylglycerol was assayed in plasma, chylomicron and VLDL fractions using the Boehringer 
Triacylglycerol GPO-PAP method. 
3.4.2.2 Post heparin plasma lipoprotein lipase activity. 
PHP was prepared by the intravenous injection of heparin at 100 D/kg body weight. 
After 15 min, a blood sample (to ml) was drawn into a venoject tube containing no anticoagulant. 
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After centrifugation (600 g x 20 min), PHP was transferred to Wasserman tubes, frozen in liquid Nz 
and stored at -70· C until assayed. LPL activity was determined on 50 ",I PHP as described 3.3.2. 
3.4.2.3 Adipose Tissue LPL Activities 
The samples 
Adipose tissue samples were taken from weaned and suckled lambs only and fell into 
three categories: 
(1) Biopsied samples taken from 4 suckled and 4 weaned animals under halothane or 
nembutal anaesthesia following catherization for the arterio-venous studies. 
(2) Samples taken from the remaining 4 suckled and 3 weaned animals immediately on 
slaughter. 
(3) Samples taken from each animal during and after the euglycaemic clamps. The first 
biopsy sample was taken after infusing insulin at 0.629 mU. kg-o.75 • minot for three 
hours; the second biopsy after infusing insulin at 6.29 mU. kg-o.7s• minot for a further six 
hours and an additional sample was taken at slaughter. 
All adipose tissue samples were removed from the subcutaneous fat site above the tail. 
No heparin was used during preparation or experimentation on the lambs. Care was also taken to 
obtain samples that traversed the depth of the fat deposit to ensure the sample was representative 
of the adipose tissue particularly since adipocyte size has been shown to differ according to the 
distance from skin and fat cell metabolism varies depending on their size (Hood and Thornton, 
1980). Samples were immediately frozen in liquid Nz and stored at -70· C until assayed. 
Preparation of acetone-ether powders from subcutaneous adipose tissue 
(categories 1 and 2 samples). 
Triplicate samples (1 g) of frozen fat were homogenized in 0.75 m1 Tris-HCl (0.1 M, 
pH 7.4) and 0.25 ml heat-treated serum. 20 m1 ice cold acetone was added, the mixture 
rehomogenized and a further 20 m1 of acetone was used to wash the probe. The acetone 
homogenate and acetone wash were combined and centrifuged at 2500g for 10 min. Acetone 
was decanted into a pre-weighed round bottom flask for lipid determination. The precipitate was 
re-extracted 5 times with ice-cold acetone and at least 4 times with diethyl ether (stirred instead 
of homogenized). The acetone-ether powder was dried with Nz, transferred to a labelled vial for 
storage at -70· C. 
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Extraction and LPL assay of acetone-ether powders. 
Acetone-ether powders were extracted by homogenizing in 5 ml of NH40H.NH40 
buffer (0.05 M, pH 8.1) containing 23 U heparin and incubating on ice for 20 min. The samples 
were frozen in liquid Nz and stored at -70· C until assayed as in Trial 1. 
Preparation of aqueous homogenates of subcutaneous adipose tissues (Category 3 
samples.) 
This new method was used for adipose samples obtained during the euglycaemic clamp 
experiments. 
Up to 1 g offat samples, in triplicate, were homogenized in 5 ml NH40H-NH4Cl buffer 
(0.05 M, pH 8.1) containing 23 U heparin using the Ultra-turrax homogenizer. The homogenates 
were defatted by centrifuging at 600 g for 10 min and withdrawing the suspension from below the 
fat layer. All steps were performed on ice and homogenates were frozen at -70· C until assayed 
for LPL activity as described in Trial 1. 
Lipid and protein Estimations 
The amount of lipid extracted from the adipose samples in acetone-ether preparations 
was determined by weighing the lipid remaining after removing the acetone and ether from 
extracts. 
The concentrations of protein in the acetone-ether powder extracts and aqueous 
homogenates were determined using the Commassie-blue dye binding method of Bradford 
(1976). In the former. adjustment for the carrier serum was made by subtracting the protein 
content of extracts prepared from acetone-ether powders of the serum. 
3.4.2.4 Body composition. 
All animals (7 weaned and 8 suckled) were slaughtered at 40 kg liveweight. Analyses 
of body composition were performed as described in Trial 1. 
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3.4.2.5 Statistics. 
Treatment means were, in general, compared using the student t-test using MINITAB 
release 4.1. Comparison of body composition data used analysis of variance in the GENST AT 
package. The effect of insulin on LPL in the euglycemic clamps was assessed using paired t-test 
inMINITAB. 
3.4.2.6 Validity of Methods 
Preparation of acetone-ether powders differed from Trial 1 in that during defatting, 
centrifugation was used to separate the solvent from the precipitate prior to decanting. This 
method and that of Trial 1 gave more efficient delipidation than the suction defatting procedure 
described by Mamo (1986). In addition, acetone-ether powders were prepared from frozen tissue. 
Although Tume et al. (1983) reported the necessity to maintain tissues at 37· C, this was not 
found in this work as the frozen samples yielded similar LPL activity to fresh samples maintained 
at 37 0 C. Mamo (1986) also found it unnecessary to maintain tissues at 37°C. 
The preparation of aqueous homogenates from the biopsy samples allowed rapid 
deli pi dation compared to the preparation of acetone-ether powders. In order to compare the 
preparation procedures, three samples of adipose tissue were prepared in triplicate by each 
method. The variation in LPL activity for the same tissue was considerably lower with the 
aqueous homogenate method than with acetone-ether powder preparations. Cryer and Jones 
(1981) compared the acetone-ether powder and aqueous homogenate methods using rat adipose 
tissue, and recommended the acetone-ether powder method because the activity was lower and 
the characteristics of LPL were harder to demonstrate in aqueous homogenates. Tume et al. 
(1983) found lower LPL activities in aqueous homogenates than acetone-ether powders with 
sheep adipose tissue. This was not observed in this work. The aqueous homogenate method 
described in this thesis gave LPL activities slightly higher than the acetone-ether powder method. 
The described aqueous extraction method incorporated a centrifugion step to defat the 
preparation. This offered the significant advantage of efficently removing triacylglycerol from 
the enzyme preparation. If extra triacylglycerol is added to the reaction mixture with the enzyme 
preparation, then the specific activity of the triacylgylcerol substrate is decreased and the 
observed LPL activity is reduced. The triacylgylcerol concentrations in the preparations were not 
determined but little triacylglycerol must have been added to the reaction as LPL activity was not . 
decreased. Aqueous homogenates demonstrated the general characteristics of LPL. That is, 
activation by serum (300%), inhibition by NaCI (100% with incubation, 86% in reaction mix), 
and a linear release of fatty acids with time and enzyme concentration. 
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Heparin was required in the preparations but no incubation time was required. Indeed, 
if allowed to stand for greater than 10 min the LPL activity slowly decreased. A requirement for 
heparin was also observed by Tume et al. (1983) but they found an incubation period of 30 to 60 
mins was necessary for maximal LPL activity. This difference may be due to the samples being 
maintained at 37 • C rather than frozen. 
Although the same assay method was used for the determination of LPL activity as in 
Trial 1, stringent controls on the preparation of diluted substrate in particular, the temperature, 
time and speed of vortexing and time window in which the diluted preparation was used lead to a 
reduction in the inter-assay coefficient of variation. 
3.4.3 RESULTS 
3.4.3.1 Plasma Lipids and Lipoproteins. 
Plasma cholesterol and triacylglycerol concentrations were measured in lambs prior to 
weaning- and following weaning in untreated and insulin-infused lambs. The results are shown in 
Tables 3.6 and 3.7 and Figures 3.6 and 3.7. 
Plasma concentrations of cholesterol (Table 3.6; Figure 3.6) declined during the first 7 
weeks then remained around 1.1 mmol. I-I for the remainder of the Trial. Infusion of insulin had 
no effect on plasma cholesterol concentrations. Plasma triacylglycerol concentrations (Table 3.7; 
Figure 3.7) also decreased during the first 7 weeks but after weaning were more variable than 
cholesterol concentrations. The same fluctuations were observed in the control and insulin-
infused lambs. Concentrations oftriacylglycerol were very low (0.23 - 0.76 mmo1.1 -1). The 
variability is unexplained but could reflect differing treatment of the flock, sampling technique or 
assay procedures. 
Concentrations of triacylglycerol in chylomicrons and VLDL and cholesterol in all the 
lipoprotein fractions were examined (Table 3.8). There were no differences between the weaned 
and insulin-infused weaned lambs. As with total plasma lipid, the lipid content of all the 
lipoprotein fractions decreased with the age of the lambs. By week 8, there was virtually no 
measurable lipid in the chylomicron fraction (d < 0.95 g/ml). 
Table 3.6 Plasma total cholesterol concentration (mmoU-1) in weekly blood samples 
from selected lambs. 
Week 
Suckled 
1. 
2. 
3. 
4. 
5. 
6. 
3.07 ±0,42 
3.50 +0.21 
3.36 ±0.52 
2.77 +0.15 
2.03 ±0.15 
1.89 ±0.17 
Treatment 
Weaned 
+ Insulin 
Weaned 
*Weaning-------------------------------------------------------------------------------------------------
7. 1.46 ±0.08 1.37 + 0.15(3) 
8. 1.19 ±0.04 1.15 ± 0.08 
9. 1.37 ±0.12 1.34 ± 0.16 
10. 1.06 ±0.17 1.35 ± 0.12 
11. 1.34 ±0.08 1.32 + 0.12 
12. 1.05 ±0.05 0.96 ±0.06 
13. 1.15 ±0.07 1.00 ± 0.08 
14. 1.19 ±0.08 1.26 ± 0.10 
15. 1.33 ±0.08 1.24 ± 0.07 
16. 1.44 ±0.17 1.07 :1:0.14 
MEAN ± SEM n:: 4 except where indicated (n). 
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Table 3.7: Plasma triacylglycerol concentrations (mmol.l-1) in weekly blood samples 
from selected lambs. 
Week 
Suckled 
1 
2 
3 
4 
5 
6 
0.92±0.04 
1.41+0.12 
0.92±0.08 
0.86±O.01 
0.79±O.11 
0.66±0.07 
Treatment 
Weaned 
+ Insulin 
Weaned 
*Weaning-------------------------------------------------------------------------------------------------
7 0.60±O.04 0.53+0.08 (3) 
8 0.61±0.03 0.51±0.05 
9 0.71±0.11 0.75±0.11 
10 0.71±0.1O 0.76±0.04 
11 0.56±O.09 0.59+0.06 
12 0.23±O.04 0.28±.O.07 
13 0.4O±.Q.07 0.33±O.03 
14 0.73±O.09 0.76±O.15 
15 0.Sl±O.05 0.49+0.08 
16 0.310±0.OlS 0.36±0.09 
MEAN + SEM n = 4 except where indicated (n). 
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Figure 3.6: Mean plasma cholesterol concentration in suckled, weaned and insulin-infuSed 
weaned lambs during first 14 weeks. 
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Figure 3.7: Mean plasma triacylglycerol concentration in suckled, weaned and insulin-infused 
weaned lambs during the first 14 weeks. 
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Table 3.8: Lipoprotein - triacylglycerol and cholesterol concentrations (mmol.r 1) in plasma from lambs described in Trial 2. 
Week Treatment Chylomicrons VLDL LDL HDL 
Triacyglycerol Cholesterol Triacylglycerol Cholesterol Cholesterol Cholesterol 
1 S 0.149 ± 0.077 0.571 ± 0.0304 0.216 ± 0.037 0.0143± 0.0113 0.947:1: 0.337 1.327 ± 0.722 
6 S 0.0438 :I: 0.0264 0.119 :I: 0.062 0.0812 ± 0.0383 0.0150 :I: 0.0053 0.489 ± 0.193 0.956 ± 0.298 
9 W 0.000 0.0600 ± 0.0216 0.128 ± 0.082 0.0025 ± 0.0050 0.360 ± 0.091 0.540 :I: 0.099 
W+I 0.000 0.0175 ± 0.0126* 0.130 ± 0.091 0.005 :I: 0.0058 0.0363 :I: 0.148 0.522 ± 0.103 
12 W 0.000 0.105 ± 0.048 0.0100 ± 0.0141 0.0325 ± 0.0206 0.227 ± 0.069 0.483 ± 0.063 
W+I 0.000 0.032 :I: 0.034 0.0275 :I: 0.0340 0.0125 :I: 0.0189 0.165:1: 0.034 0.468 ± 0.086 
14 W 0.1100 ± 0.0294 0.0725 ± 0.0685 0.195 :I: 0.079 0.0075 ± 0.0095 0.310 ± 0.96 0.515:1: 0.068 
W+I 0.0950 ± 0.0238 0.0575 ± 0.0299 0.133 :I: 0.046 0.005 ± 0.010 0.312:1: 0.116 0.555 ± 0.115 
S - Suckling (n=8). W - Weaned (n=4). W + I - Weaned infused with insulin (n=4). 
Mean ± SD 
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3.4.3.2 LPL activity in postheparin plasma 
LPL activity in PHP was greater in the suckled (183 ± 15 V/m!) than weaned lambs 
(103 ± 7 V/m!) (P < 0.001). Weaned lambs infused with insulin had PHP lipoprotein lipase 
activities (129 ± 12 Vim I) intermediate between those in suckled and weaned animals but were 
not significantly different from either group. The activities ofPHP LPL for individual lambs are 
in Appendix 3.5 
3.4.3.3 Effects of rearing. 
LPL activity in biopsied adipose tissue (Category 1) 
The activities of LPL in biopsied adipose tissue taken under general anaesthetic are in 
Figure 3.8 (data in Appendix 3). LPL activities are expressed as units of enzyme activity/g wet 
weight tissue, units of activity/mg protein in extract and units of activity/g lipid. Tissue weights 
for two of the suckled lambs were not recorded so activities on a weight basis could not be 
calculated for these lambs. LPL activity tended to be higher in the suckled than weaned lambs 
whether the LPL activity was expressed per g tissue, per mg protein or per g lipid. The 
differences were not statistically significant. 
Composition of biopsied adipose tissue. 
Figure 3.9 illustrates the composition of biopsied subcutaneous fat. Suckled animals 
had less lipid per gram of adipose tissue than weaned lambs. The adipose tissue was 70 - 85% 
lipid by weight. The proportion of tissue comprising protein was similar in both weaned (1.2%) 
and suckled (1.0%) lambs. 
LPL activity in adipose tissue at Slaughter (Category 2) 
Samples of subcutaneous fat taken from 4 suckled and 3 weaned animals used only for 
analysis of body composition should be devoid of interferences from other treatments such as 
anaesthetics. There were no differences in the LPL activities between the suckled and weaned 
lambs (Table 3.9). 
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Figure 3.8: LPL activity in biopsy samples of adipose tissue from suckled and weaned lambs. 
LPL activity is expressed as U/g tisue weight, U/mg protein and U/g lipid. 
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Table 3.9. LPL activities in subcutaneous adipose tissue removed immediately after 
slaughter of suckled and weaned lambs. (Category 2). 
U/g tissue 
Suckled (4) 153 ± 36 
Weaned (3) 237 ± 22 
significance ns 
U =nmol fatty acid released. min-l 
ns p>O.l 
IvlEAN ± SEM 
3.4.3.4 Body composition. 
LPL Activities 
U/mg protein U/g lipid 
27 ± 6 198 ± 46 
28 ± 2 277 ± 31 
ns ns 
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Because lambs were slaughtered at the same liveweights there was no treatment effect 
on empty body weights (34.5 kg). Weaned lambs were however slightly fatter and had less 
protein than the suckled lambs as illustrated by the carcass and non carcass components. In 
respect to total body composition, the differences in protein composition were significant (Table 
3.10). 
Table 3.10. 
Total body: 
Carcass: 
Non-carcass: 
GR(mm) 
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Chemical composition (%) of total body, carcass and non-carcass 
components of suckled and weaned lambs slaughtered at 40 kg liveweight in 
Trial 2. 
Fat 
Protein* 
Water 
Ash 
Fat 
Protein 
Water 
Ash 
Fat 
Protein 
Water 
Ash 
Suckled 
(n=8) 
23.13 
15.44 
57.22 
3.77 
28.62 
15.48 
51.26 
4.45 
15.36 
15.39 
65.64 
2.83 
14.38 
Weaned 
(n=7) 
24.50 
14.93 
56.93 
3.77 
30.79 
14.96 
49.42 
4.45 
15.98 
14.91 
65.47 
2.85 
15.14 
* Means differ significantly; p < 0.05 
3.4.3.5 Effects of insulin. 
The effect of insulin on adipose tissue LPL was assessed by biopsing subcutaneous 
adipose tissue during euglycemic clamps at two insulin infusion rates. The euglycaemic clamps 
fell into two classes. In 3 weaned and 1 suckled lamb, the lower insulin infusion rate of 0.629 
mU.kg-O.75• min-1 did not decrease the plasma glucose concentration to the desired clamp level (65 
mg%). Only after infusing insulin at 6.29 mU.kg-O·75• min-1 were plasma glucose concentrations 
maintained at 65 mg% by the infusion of 20% dextrose. In the other four lambs, euglycaemia (65 
mg%) was maintained in both infusion periods. 
69 
The mean LPL activities in subcutaneous adipose tissue biopsied at the end of the first 
and second insulin infusion periods and at slaughter are given in Table 3.11. There was no 
interaction between rearing and insulin level when the weaned and suckled animals were analysed 
individually. The large standard deviations represented between animal variations rather than the 
assay procedure since the assay coefficients of variation, which included preparation of the 
aqueous homogenates, were 6.8 and 5.9% per wet weight tissue and per mg protein respectfully. 
When between lamb variation was eliminated using the paired t-test, the LPL activity was 
significantly higher in adipose tissue biopsied at the end of the second infusion period than after 
the first. Significantly higher (p<0.03) LPL activities were also observed in adipose tissue 
removed at slaughter compared to the biopsied tissues. 
Table 3.11 Mean LPL activity in adipose tissue samples taken during and after a euglycaemic 
clamp at two insulin levels. 
Insulin Level 
1 
2 
slaughter 
LPL activity 
U/g tissue 
21.5 :1:1.6 (6) 
45.1 :1:5.7 (8) 
65.9 :1:7.4 (8) 
U = nmol fatty acid released. min -I 
Insulin levell = 0.629 mU.kg-O•75 • min-I, 
Insulin level 2 = 6.29 mU.kg-O.7S• min-I, 
Data is mean value :I: sem (number of animals) 
NB weaned and suckled animals were combined 
U /mg protein 
1.98 :1:0.28 (6) 
4.70 :1:0.74 (8) 
7.930 :1:0.66 (8) 
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3.4.4 DISCUSSION 
3.4.4.1 Lipid levels and lipoproteins in plasma. 
Plasma concentrations of cholesterol and triacylglycerol declined during the first 6 
weeks of life to the low levels observed in adult sheep (Section 4; Terpstra et al. 1982). The 
decline was not reliant on weaning and the decreased intake of dietary fat since the reduction 
occurred in all lambs prior to weaning. The decline in plasma lipid concentrations from week 1 
contrasts to the fmdings of Leat et al. (1976) who observed 'postabsorptive hyperlipidemia' with 
maximal plasma lipid concentrations occuring at 3-4 weeks of age. The reasons for the difference 
between the current fmdings and those of Leat et ai. (1976) are uncertain. As well as breed and 
feed differences, the animals used by Leat et ai. (1976) were fasted for 16 hours compared to four 
hours in the present study. In an adult ruminant a prolonged period of fasting is required to empty 
the rumen, but in a very young lamb, a 16 hour fast constitutes a major fast. Mamo et ai. (1983) 
found plasma triacylglycerol concentrations increased in adult sheep on fasting. It is possible that 
the increased plasma lipid levels reported by Leat et al. (1976) may be due to this effect, with the 
magnitude decreasing as the lamb grows. However, since the changes in plasma lipid 
concentrations, on fasting, were not substantiated in Tume and Thornton's laboratory (1985) this 
explanation is tentative. Since the lipoprotein concentrations are expected to increase with 
suckling due to the increase in dietary fat available, it may be that Leat et ai. (1976) measured the 
lipoprotein concentrations postprandially and not after the fast recorded. The four hour fast used 
in the current study may have been sufficient time to clear any additional lipoproteins derived 
from suckling from the plasma. 
The distribution of lipid in lipoprotein fractions was found to be similar to that observed 
in other ovine studies (Leat et at., 1976; Terpstra et al. 1982) with HDL carrying most of the 
cholesterol. 
The infusion of insulin into weaned lambs had no effect on plasma lipid concentrations. 
In contrast, in man, untreated diabetes may show marked hypertriglyceridemia, which when 
treated with insulin is reduced. The effects of insulin on enhancing LPL activities in adipose 
tissue and removing lipoprotein triacylglycerol are also documented in human and experimental 
animals. The lack of such differences in plasma triacylglycerol concentrations in sheep during the 
long-term infusion of insulin suggests that either sheep are insensitive to insulin or the 
mechanisms by which insulin influences plasma lipids differ from those in humans or other 
experimental animals. 
3.4.4.2 Post heparin plasma LPL activities. 
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The activity of LPL in normal plasma was very low which is probably due to the 
effective removal and metabolism of LPL by the liver. Injection of heparin releases LPL from its 
capillary endothelial binding site and consequently PHP lipoprotein lipase activity is the 
combined activity from all tissues with the enzyme. Heparin also releases other lipases but the 
LPL assay is designed to specifically measure lipoprotein lipase (see 3.3). 
PHP LPL activities (150 nmol/min/ml) were slightly higher than those measured by 
Mamo (1986) in sheep which probably reflects the different assay methods, nutritional status, age 
or breed of the sheep. Typical LPL activities in human PHP are 200 nmol/min/ml (Nilsson-Ehle, 
1987). The wide variability ofPHP LPL in lambs in the present study is similar to the variability 
noted in humans (Nilsson-Ehle, 1987). 
LPL activity in PHP from 14 weeks old lambs was greater in the suckled (183 VIm!) 
than weaned lambs (103 Vlml p<O.OOl). At this age, although all the lambs consumed grass, the 
suckled lambs were still suckling and with milk as a dietary source of lipids and gluconeogenic 
precursors, the suckling lambs should synthesise more triacylglycerol- rich lipoproteins and 
require higher LPL activity than their weaned counterparts to release fatty acids from the 
triacylg1ycerol-rich lipoproteins for the cells. At 16 weeks, however, there was no difference in 
the plasma triacylglycerol concentration between the weaned and suckled lambs. Since plasma 
concentrations merely reflect the balance between the synthesis and catabolism, they do not 
necessarily indicate the actual rate of these two processes. Thus, the higher PHP LPL activity in 
the suckled lambs may still reflect the increased production and metabolism of triacylglycerol-
rich lipoproteins. The supplementation of the suckled lambs' diet with milk may offer the lambs 
a nutritional advantage, hence the increased PHP LPL activity in suckled lambs reflects the higher 
plane of nutrition. In other animals, PHP LPL is considered to increase with the plane of 
nutrition (Cryer and Jones, 1981) and indeed Mamo (1986) found that fasting decreased PHP LPL 
in wethers. 
Although in Trial 1, the different rearing treatments led to differences in body fat, this 
was not observed in Trial 2. Consequently the increased PHP LPL activity in the suckled animals 
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was not associated with increased fatness in lambs slaughtered at 40 kg. These results indicate 
that PHP LPL cannot be used as an indicator of fatness to genetically select lambs. This may not 
be surprising, since PHP LPL activity represents the total LPL activity in the body. It reflects the 
potential of the whole body to utilize lipoproteins and thus depends on the balance of the changes 
in all tissues. In the current trial, there were no correlations between PHP LPL and adipose tissue 
LPL or PHP LPL and measurements of carcass fatness. The increased PHP LPL may be due to 
an increase in contribution from tissues other than adipose tissue. The increased PHP LPL in the 
suckled lambs was associated with increased protein rather than fat. 
Infusion of insulin into weaned lambs failed to affect PHP LPL activity although a 
number of reports in other animals suggest that insulin is a major regulator ofLPL activities. 
Armstrong (1987) also found no difference in PHP LPL activity in two groups of lambs differing 
in plasma insulin concentrations. In contrast, in sheep treated with alloxan to induce diabetes, 
PHP showed a considerable decrease in LPL activities (Mamo, 1986). The role of insulin in 
regulating LPL is, therefore, still unclear in sheep. 
3.4.4.3 Effects of rearing on Subcutaneous adipose tissue LPL. 
Subcutaneous adipose tissue LPL activity was not significantly affected by the rearing 
treatments when measured in samples either biopsied under general anaesthetic (Nembutal or 
Halothane) or removed immediately after slaughter. Despite their differences in nutrient intake in 
early life and the influence of this on regulators of LPL presumably such as insulin, differences 
due to suckling may no longer be apparent at this slaughter age. Haugebak et al. (1974) 
demonstrated that changes in LPL activity depended on the previous diet, but they also indicated 
that as the length of time on the new diet increased, the response of adipose tissue LPL decreased. 
Eckel (1987) also commented that the changes in LPL activity depended on the length of time on 
a new diet. There was a considerable delay while lambs grew to 40kg. At slaughter, there was no 
difference in the fat content of the weaned and suckled lambs. Hence, differences in adipose 
tissue LPL activity should not be expected and were not observed. The trial design, in catering 
for other student proposals, limited the number of similar samples available and the more ideal 
timing of sampling. 
LPL activity differences in biopsied and slaughter samples may arise from the 
combined effects of anaesthesia and stress, since LPL activities are sensitive to a wide variety of 
hormonal changes including catecholamines. 
3.4.4.6 Effects of insulin on LPL activity. 
The euglycaemic clamp procedure was used to assess the effect of insulin on adipose 
tissue LPL activity under conditions where plasma glucose concentrations were maintained 
constant, at physiological levels, to avoid the complications of a hormonal response to falling 
plasma glucose concentrations. Measurements were made at two insulin infusion rates to 
examine the effect of increased plasma insulin concentrations on the LPL activities of 
subcutaneous adipose tissue. 
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By comparing adipose tissue LPL between the two insulin levels, this study showed that 
insulin independently stimulated adipose tissue LPL activity in sheep. With an 8-10 fold increase 
in plasma insulin concentrations, the adipose tissue LPL increased two fold after six hours. The 
euglycemic clamp technique has been previously used in humans to demonstrate insulin's role in 
regulating adipose tissue LPL activity, although with variable results depending on the length of 
infusion, rate of infusion and plasma glucose concentration. Sadur and Eckel (1982) failed to 
show a significant increase in adipose tissue LPL after infusing insulin for 3 hours and achieving 
plasma insulin concentrations 7 times higher than normal. After a further 3 hours, they observed 
a two fold increase in LPL activity. With plasma insulin concentrations 10 times higher than 
normal for 5 hours, Yld-Jarvinen et al. (1984) did not observe any increase in LPL activity but 
when plasma insulin concentrations were 50 times higher than normal, a 50% increase in LPL 
activity occurred. It appears that the. regulation of LPL by insulin which occurs in other animals, 
is also occuring in sheep. However, the sensitivity of the system to insulin is difficult to assess 
because of the variablity of results and the number of factors affecting them. 
In almost identical euglycemic clamp experiments, Davey (1986) found that the 
increased plasma insulin concentrations increased adipose tissue fat synthesis as measured in vivo 
by incorporation of labelled glucose into glyceride glycerol. Providing lipoprotein substrate is 
available, the increased LPL activity observed in the present trial could provide fatty acids for this 
increased fat synthesis. 
The higher LPL activities in samples taken at slaughter may reflect continued increase 
in LPL activity. Previous slaughter samples were also greater than biopsied samples suggesting 
the anaesthetic used may be decreasing the activity observed in the biopsied samples. 
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3.4.4.7 Conclusion. 
In Trial 2, no differences in adipose tissue LPL activity were observed between rearing 
treatments. Since the decrease in fatness of early weaned lambs in comparison to suckled lambs 
was not apparent in this trial, these results neither support or contradict the proposed role of LPL 
in adipose tissue fat accretion. At 14 weeks, the suckled lambs had higher PHP LPL activity than 
weaned lambs illustrating a difference in total body metabolism of lipoproteins between the 
rearing treatments. PHP LPL activity was not correlated with adipose tissue LPL or with carcass 
fatness suggesting PHP LPL is not a suitable screening enzyme to predict fatness of individual 
lambs. The long term infusion of insulin tended to increase PHP LPL activity although the 
difference was not statistically significant. The stimulatory effect of insulin on adipose tissue 
LPL activity was clearly demonstrated using the euglycaemic clamp technique. 
Although several of the hypothesis of this trial were successfully tested, the initial aim 
of confirming the role or lack of a role of LPL activity in fat deposition in suckling lambs remains 
unanswered. Further samples were analysed from a third trial. 
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3.5 TRIAL 3. 
3.5.1. Design of Trial 3. 
This trial was designed to assess the effects of rearing on body composition, PHP and 
adipose tissue LPL activity and insulin receptor activity (Willis, 1990). 16 Border Leicester x 
Dorset wether lambs were allocated to one of two treatment groups; suckled or early weaned (5 
weeks), At 12 weeks, PHP was prepared as described in Trial 2. The lambs were slaughtered two 
days later by exsanguination and samples of subcutaneous adipose tissue for the assay of LPL 
activity were taken, immediately frozen in liquid Nz and stored at -70 0 C. Aqueous homogenates 
were prepared as described in 3.4.2.3 and LPL activity in the tissue homogenates and PHP were 
determined as in 3.3.2.1. The carcass and non-carcass compositions were analysed as previously 
described in 3.3.2.2 
3.5.2. Results. 
LPL activities in PHP collected at 12 weeks are given in Table 3.13. PHP-LPL activity 
was higher in the suckled (131 :1:44 Vlml) than weaned lambs (85 :1:34 V/ml, p<0.05). LPL activity 
in subcutaneous fat was determined at 12 weeks (Table 3.14). There was no difference in the 
LPL activities between weaned and suckled lambs when activity was expressed per g tissue. 
When was expressed as V/mg protein, LPL activities were higher in the suckled than weaned 
lambs (p=.08). 
Body composition of the lambs is presented in Table 3.15. The weaned lambs had 
significantly higher protein in total body, non-carcass and carcass components. Non-carcass fat 
was significantly higher in the suckled than weaned lambs. Although fat in the carcass and total 
body were higher in the suckled lambs, these differences were not significant. Differences in OR 
showed that the suckled lambs (8.0 mm) had significantly more subcutaneous fat than the weaned 
lambs (S.4mm), 
Table 3.13 LPL activity in PHP prepared by injecting weaned and suckled lambs with heparin 
(lOOU.kg"!) and sampling blood 15 min later. 
Treatment Lamb number PHP-LPL 
(U/ml) 
Weaned 
107 137.32 
131 77.06 
135 57.95 
140 39.39 
148 89.49 
152 72.57 
161 129.23 
164 75.36 
76 
84.8±33.5 
Suckled 
113 71.54 
114 79.15 
121 118.05 
137 132.00 
141 193.05 
142 143.74 
185 187.17 
186 125.27 
131.2±44.1 
p=0.034 
Table 3.14 Mean LPL activities in aqueous homogenates of subcutaneous adipose tissue in 
weaned and suckled lambs at 12 weeks .. 
LPL activity 
U/g tissue U/mg protein 
Weaned (8) 295±45 76.0± 9.7 
Suckled (8) 386:1:40 107 ± 13 
p=0.15 p=0.083 
MEAN:l:SEM 
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Table 3.15 Chemical compositionl (%) of total body; carcass and non-carcass components, empty 
body weight and GR of suckled and weaned lambs slaughtered at 12 weeks of age in 
Trial 3. 
Suckled Weaned 
(n=8) (n=8) 
Total body: 
Fat 16.21 14.45 
Protein* 19.67 20.43 
Water 59.34 60.51 
Ash 4.45 4.59 
Carcass: 
Fat 18.74 17.09 
Protein* 17.00 17.49 
Water 59.34 60.51 
Ash 4.82 4.94 
Non-carcass: 
Fat* 12.95 11.13 
Protein* 23.08 24.13 
Water 59.34 60.51 
Ash 3.98 4.15 
Empty bodyweight (kg) 26.86 25.47 
GR(mm)** 8.0 5.4 
* significantly different p<0.1O 
** significantly different p<0.05 
1 adjusted for Empty body weight 
3.5.3. Discussion. 
As with Trial 1, early weaning led to differences in body composition of the lambs. The 
protein content of the carcass and non carcass components, as well as total body, were 
significantly higher in the weaned lambs. This was associated with decreased fat in these lambs 
although the differences in fat were only significant in the non-carcass component. GR, which 
measures the depth of subcutaneous fat over the 12th rib, was however significantly greater in the 
suckled than weaned lambs. 
LPL activity in PHP at 12 weeks was greater in the suckled than weaned lambs. 
Similarly LPL activity in subcutaneous adipose tissue taken at slaughter was greater in the 
suckled than weaned lambs. When expressed on a protein basis this difference was significant. 
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In this Trial, the increased subcutaneous fat in the suckled lambs, as demonstrated by 
GR measurements, was associated with increased LPL activity in the subcutaneous fat. These 
results suggest that LPL and the supply of fatty acids from lipoproteins may, indeed, contribute to 
the deposition of fat in sheep. The suggestion from Trial 1 that lipoprotein triacylglycerol-fatty 
acids may be spared by adipose tissue for use in other tissues, while the adipose tissue synthesised 
fatty acids for deposition, is contradicted. 
3.6 GENERAL DISCUSSION. 
Introduction 
Release of fatty acids from triacylglycerol-rich lipoproteins requires the hydrolysis by 
LPL. This enzyme plays a key role in the metabolism of plasma lipoproteins and the supply of 
fatty acids to tissues. Very little work has been reported on the metabolism of lipoproteins in 
sheep and the role and contribution of lipoprotein metabolism to normal metabolism is unknown. 
Although in man and rats, lipoprotein triacylglycerol supply the majority of fatty acids for fat 
accretion, the role of lipoproteins in sheep cannot be assumed to be the same. Indeed, in contrast 
to humans and birds, where liver is the major site of fatty acid synthesis, and rats and mice where 
both the liver and adipose tissue synthesise fatty acids, in sheep, adipose tissue is the primary site 
of fatty acid synthesis. It is therefore possible that LPL in sheep directs lipoprotein-
triacylglycerol-fatty acids to tissues other than adipose tissues as an energy source in preference 
to providing fatty acids for fat deposition. 
In this study, the effects of early weaning lambs on adipose tissue LPL activity and 
body composition were investigated to demonstrate the role of adipose tissue LPL in fat 
accretion. Since PHP LPL is an indicator of total body lipoprotein utilization, the effects of early 
weaning on PHP LPL were determined and the usefulness of PHP LPL activity as an indicator of 
body fatness was assessed. Since insulin is believed to be a major regulator of LPL in man and 
other animals, a further aim of this study was to determine the effects of insulin on LPL activity 
using long and short term infusions of insulin. 
Effect of rearing on LPL activity in adipose tissue. 
Two rearing strategies were used in all three trials; lambs were weaned early (5 or 6 
weeks) or allowed to suckle until naturally weaned at around 14 weeks. The effects of rearing on 
adipose tissue LPL was variable and depended on how LPL activities were expressed, age of the 
lambs at sampling, presumably breed differences and seasonal differences in pasture qUality. 
Such variations have been noted in other LPL studies. 
When LPL was expressed per g tissue, there were no significant differences in LPL 
activity between suckled and weaned lambs except at 23 weeks in Trial 1 when subcutaneous and 
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omental adipose tissue LPL activities were greater in the weaned than suckled lambs. The 
seeming contradiction of increased LPL activity being associated with reduced fat deposition has 
been discussed previously and may be due to differences in fat cell size. When LPL activities 
were expressed as total activity in the fat depot, there was no significant difference between the 
two treatments. 
When LPL activity was expressed per mg protein, there was significantly more LPL 
activity in subcutaneous adipose tissue in the suckled than weaned lambs slaughtered at 12 weeks 
(Trial 3). However, when measured at 26 weeks (Trial 2), there were no differences in LPL 
activity between treatments. 
LPL activity is affected by the plane of nutrition in a wide variety of animals with 
fasting markedly decreasing the activity of adipose tissue LPL (Cryer, 1981; Cryer and Jones, 
1979; Tume et ai., 1983). In the current study, the suckling lambs may have an nutritional 
advantage over the weaned lambs by the supplementation of their diet with milk. There were, 
however, no differences in lipoprotein concentrations between the weaned and suckled lambs 
when measured at 16 weeks (Trial 2). 
In Trial 3, samples were taken when lambs were still suckling but in Trial 2 thelambs 
had not suckled for 8 or more weeks. It is, therefore, not surprising that in Trial 2 no treatment 
differences were observed in LPL activity at 26 weeks since any direct effect of suckling had 
probably been lost. In addition, the lower nutritional status of lambs at the end of Trial 2 was 
reflected in the slower growth and the lower LPL activities measured in adipose tissues of these 
lambs. The different nutritional status may affect the partitioning of nutrients. 
Although differences in LPL have been observed in fed, fasted and refed animals, there 
are few studies that have examined the longer term effects of diet on LPL activity. Studies on 
LPL activities in tissues during development in the rat (review: Cryer, 1981) showed that during 
suckling, muscle LPL activity was predominant whilst adipose tissue LPL activity was cyclic. 
After weaning, adipose tissue LPL activity was related to fat cell filling (Hietanan and 
Greenwood, 1977). Haugebak et al. (1974) found that growing lambs fed maintenance rations 
had no adipose tissue LPL activity while lambs fed ad libitum showed considerable activity. 
When fed finishing diets, LPL increased in all lambs but depended on their previous diet. The 
protein level in the finishing diet had no effect on LPL activities. 
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The effects of feeding are probably due to insulin since injecting insulin into fasted rats 
mimics the postprandial increases in LPL activity. In addition, refeeding carbohydrate stimulated 
LPL activity more than refeeding fat. This effect is believed to be due to the higher plasma 
insulin concentrations associated with carbohydrate feeding. The results from the present study in 
sheep are consistent with these observations in that the higher LPL activities in the suckled lambs 
were associated with higher plasma insulin levels. 
Effect of rearing on body composition. 
In Trial 1, weaning at 5 weeks produced smaller leaner lambs compared to lambs that 
continued to suckle. Differences in body composition were observed both at 12 and 23 weeks. 
The increase in fatness in the suckled lambs was associated with a decrease in protein and, since 
muscle has more water than adipose tissue, a decrease in water. Similar results were observed in 
Trial 3, although the differences in carcass and total body fat were not statistically significant. 
The effects of early weaning on body composition were similar to those reported in 
previous studies (Chambers, 1982; Searle and Griffith, 1983; Fennessy et al., 1972). On weaning, 
the early weaned lambs experience a growth check, presumably due to a reduction in nutrient 
intake, until the rumen fully develops. During this time fat is mobilized from the adipose stores. 
This initial response is followed by a period when the weaned lambs do not deposit fat but the 
suckling animals continue to deposit fat. The initial loss of fat from the deposits along with the 
following fat stasus cause the reduced fatness in the early weaned lambs. Subsequently, as body 
weight increases, the weaned lambs again deposit fat and consequently, at higher body weights, 
the effects of early weaning may no longer be observed. The final body composition depends on 
the partitioning of nutrients between fat and protein synthesis. In these trials, if protein increased 
there was a compensatory decrease in fat. The different diets of the weaned and suckled lambs 
gave different patterns of nutrients which were directed differently into protein and fat synthesis. 
The differences in body composition seen in Trials 1 and 3 were not observed in Trial 2. 
There are several factors that might contribute to the lack of a weaning effect in Trial 2. Lambs in 
Trial 2 were weaned at 6 rather than 5 weeks of age and were slaughtered at 40 kg liveweight. 
The lambs were also of different breeds and seasonal differences in pasture quality may also 
contribute to the variations in lamb growth rates. 
Weaning at 6 rather than 5 weeks undoubtedly contributes to the lack of carcass 
differences. The growth check experienced on weaning was less severe in these lambs than in 
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similar previous trials (Charles, 1986). At the 6 week weaning age, the lambs may have been 
more accustomed to eating solid food and hence experienced less delay in growth, less initial fat 
mobilization and subsequently adapted to the diet quicker. Fennessy et ai. (1972) compared 
lambs weaned at 3.5,5.5,7.5, and 9.5 weeks and noted that the later weaning ages were less 
effective at decreasing carcass fatness. In Trial 2, by 16 weeks of age the weaned and suckled 
lambs had similar growth rates and at 40 kg (some 10 weeks later), any differences in body 
composition resulting from early weaning had been eliminated. In previous publications, the 
effects of early weaning were measured in 20-25 kg lambs but the lack of a weaning effect in 
Trial 2 can not be attributed solely to higher body weight since 40 kg liveweight was intermediate 
between the 12 (31kg) and 23 (48kg) week slaughter groups in Trial!. The lack of difference 
between the weaned and suckled lambs in Trial 2 may simply be due to the lower plane of 
nutrition of these lambs as demonstrated by the slower growth. 
Relationships between adipose tissue LPL activity and fat deposition. 
As meat producing animals, the deposition of fat in ruminants is important. Fat is 
deposited when the intake of energy exceeds that required for development, growth and 
maintenance and is a balance between anabolic and catabolic processes in the fat cell. The four 
sources of fatty acids for the synthesis and deposition of triacylglycerol are de novo synthesis, 
fatty acids recycled from lipolysis, plasma NEFA and lipoprotein triacylglycerol- fatty acid. In 
man and rats, fatty acids derived from hydrolysis of triacylglycerol by LPL are considered the 
primary source of fatty acids for fat deposition. Lipid metabolism in ruminants, however, is 
significantly different from that in monogastrics in that adipose tissue is the major site of fatty 
acid synthesis in ruminants. This raises the question as to the importance of lipoprotein-
triacylglycerol in providing fatty acids for fat deposition in ruminants or whether lipoprotein 
triacylglycerol-fatty acids may be diverted to other tissues as a source of energy during fat 
deposition. 
In Trial 3, LPL activity per mg protein was significantly higher in subcutaneous tissue 
from the suckled than weaned lambs. This increased LPL activity was associated with increased 
subcutaneous fat as measured by OR and indicates that LPL activity and the metabolism of 
lipoprotein- triacylgylcerols do playa role in providing fatty acids for fat deposition. In Trial 2, 
no differences in adipose tissue LPL activity were apparent and no differences in carcass fatness 
were observed. 
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Considering the ergonomics of fat deposition, depositing fat from preformed longchain 
fatty acids requires about half the energy to synthesise them from acetate. It would thus be more 
economical, from an energy perspective, if the animal has excess energy, to use pre-formed fatty 
acids for fat deposition and at the same time 'spare' other metabolites for use by other tissues. By 
this mechanism, fatty acids are not being synthesised de novo at the same time that other tissues 
are oxidising available fatty acids for energy. 
Experiments (Scott and Cook, 1974) using fat protected from metabolism in the rumen 
showed that dietary lipid, either NEFA or lipoprotein -triacylglycerol was incorporated into 
adipose tissue fat. Thornton and Tume (1984) suggest long chain fatty acids are important in fat 
deposition in sheep. The changes in LPL indicate lipoprotein -triacylglycerol playa significant 
role in this process. 
Effect of rearing on LPL activity in PHP. 
PHP was prepared in lambs in Trial 2 (14 weeks old) and Trial 3 (12 weeks old). In 
both trials, PHP-LPL was significantly higher in the suckled than weaned lambs. Since injecting 
heparin releases LPL from all tissues PHP-LPL represents the total body's potential to use 
lipoprotein triacylglycerol. Clearly the suckling lambs have greater potential to use more 
lipoprotein triacylglycerol than the weaned lambs. PHP, however, gives no indication of the 
contribution of different tissues to LPL activity and the tissue contributions undoubtedly vary 
with the nutritional state of the animal. In suckling rats, muscle was the major source of LPL 
while Tan et al. (1977) calculated that muscle LPL was equivalent to two thirds of adipose LPL in 
fed adult rats but may contribute twice the LPL of adipose tissue in fasted rats. In growing lambs, 
Tume et al., (1983) reported that LPL activity in muscle was approximately one tenth that of 
adipose tissue on a tissue weight basis. Muscle LPL is therefore a major component in PHP LPL 
activity. In Trial 2, the increase in PHP-LPL was not associated with increased adipose tissue 
LPL activity (in samples taken somewhat later) while in Trial 3 increased PHP-LPL was 
associated with increased adipose tissue LPL activity. In Trial 2, the suckled lambs contained 
higher body protein than weaned lambs while in Trial 3, the suckled lambs were fatter than the 
weaned lambs. It seems LPL may be directing available lipoproteins to muscle rather than adipose 
tissue in Trial 2. This would be in keeping with the slower growth and lower plane of nutrition of 
lambs in Trial 2. Since the PHP LPL activity was determined in Trial 2 much earlier than the 
adipose tissue LPL activities, it is possible that in both trials the higher PHP LPL activity in the 
suckled lambs reflects higher adipose tissue LPL activity in these animals at this time. By the 
time adipose tissue samples were taken at slaughter in Trial 2, adipose tissue LPL was no longer 
higher in these animals. 
In sheep, Mamo (1986) has reported that fasting decreased PHP-LPL activity but in 
rats, Cryer (1981) found that PHP-LPL activity was similar in fed and fasted animals due to 
reciprocal changes in adipose and heart tissues. The contribution of different adipose depots to 
PHP -LPL may also vary depending on the development rate of the tissue as suggested in Trial 1 
where omental and perirenal tissues showed greater LPL activity than subcutaneous. This is 
supported by the differences in LPL activities measured in different adipose sites by Tume et al. 
(1983) and Cryer and Jones (1979). 
PHP LPL and fat deposition. 
Because increased PHP-LPL was associated with increased subcutaneous fat in Trial 3, 
but with no difference in fat content in Trial 2, PHP-LPL would not be a useful marker for 
assessing the potential fatness of individual lambs. The LPL activity depends on when PHP and 
fat measurements are taken. PHP LPL reflects use of lipoprotein triacylglycerol by all tissues not 
just adipose tissue and it represents the state of the animal at the time of PHP collection rather 
than the potential of the system. 
Effects of insulin on LPL in adipose tissue and PHP. 
The effects of insulin on sheep adipose tissue and PHP LPL were investigated using the 
continuous infusion of insulin from weaning age until slaughter and by using the euglycemic 
clamp technique. 
In Trial 1, long term infusions of insulin resulted in no change in LPL activity in 
adipose tissue when expressed per g tissue or per fat depot. In several in vivo studies in rats 
(Borensztajn et al., 1972; Garfinkel et at., 1976; Pykalisto et al., 1975) the injection of insulin 
increased adipose tissue LPL activity. In a similar experiment in dairy cows, Rao et al. (1973) 
found increased LPL activity in adipose tissue biopsied 15 minutes after injecting insulin. The 
difference between the current trial and the other reported in vivo studies is the duration of insulin 
treatment. Single injections of insulin result in acute increases in plasma insulin concentrations 
and decreases in plasma glucose concentrations. In this study, insulin was infused over 7 or 18 
weeks and only resulted in plasma insulin levels being significantly higher than in non-infused 
animals at 18 weeks. This gradual increase in plasma insulin concentrations may reduce the 
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effects of insulin by the development of insulin resistance. Indeed, Willis (1990) found that the 
insulin infused lambs in this trial were less sensitive to insulin than non-infused lambs. Thus the 
lack of difference in adipose tissue LPL activity may be attributed to this. 
At 12 weeks there was no difference in plasma insulin concentration or LPL activity 
between treatments. However, the effect of insulin infusion on body composition depended on 
rearing. Insulin infusion increased fatness in suckled lambs while in weaned lambs the reverse 
was true. The differences in fatness between the rearing treatments and the lack of effect of LPL 
activity may depend on the availability of substrates. At 23 weeks, insulin infusion decreased 
total body fatness in favour of protein synthesis. Insulin infused animals had higher insulin 
concentrations but adipose tissue LPL activity were unchanged and the carcasses were leaner. 
In Trial 2, PHP LPL in lambs infused with insulin were not significantly different from 
control lambs. The lack of an insulin effect may be because of the duration of the insulin infusion 
and the contribution to PHP of LPL from different tissue types. 
When plasma insulin concentrations were raised eight to ten times higher than normal 
using the euglycemic clamp technique, adipose tissue LPL activity was increased two fold. This 
result was similar to the findings in humans using this technique. Davey (1986) also noted 
difference in insulin effects on fat synthesis in sheep depending on whether the insulin was 
administered long term or short term as in euglycemic clamps. With the long term infusion of 
insulin, Davey (1986) suggests the insulin effects may be reduced by the development of insulin 
resistance, production of anti -insulin antibodies or compensatory increases in glucagon. 
Summary. 
These results indicate that in suckling lamb, the increased fat deposition was associated 
with increased activity of LPL in adipose tissue. Thus lipoproteins may supply fatty acids for 
deposition of fat in adipose tissue. Adipose tissue LPL activity was also demonstrated to be 
stimulated by insulin. The role and regulation of adipose tissue LPL in the lamb is therefore 
similar to the findings in other animals. 
Although these results indicate a role for lipoproteins in fat deposition in sheep, the 
actual contribution oflipoproteins is unknown. For lipoproteins to make a truly significant 
contribution, the turnover of lipoprotein triacylglycerol would have to be high as the plasma 
concentration of lipoprotein triacylglycerol is low. The turnover rates of triacylglycerol-rich 
lipoproteins are investigated in the following section. 
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4. KINETIC STUDIES OF LIPOPROTEINS. 
4.1 INTRODUCTION. 
The profIle of lipoproteins in sheep and humans is distinctly different (2.2). Measuring the 
plasma concentrations of each class of lipoprotein shows you little about the systems of 
metabolism or why or how they differ. The system needs to be described and the pathways 
quantitated. Kinetic studies are a means of obtaining this additional information. The plasma 
concentration of a metabolite is a balance between synthesis and catabolism. Lower plasma 
concentrations could, therefore, arise from decreased synthesis or from rapid metabolism. 
Comparing the kinetics of lipoproteins in hyperlipidemic and normal humans has helped to 
characterize these disease states and reveal differences in metabolism which explain the abnormal 
lipoprotein profIles in hyperlipidemias. A study of the kinetics of sheep lipoproteins and a 
comparison of these with studies in humans should shed some light on the system of lipoprotein 
metabolism in sheep and may explain why their plasma concentrations differ from those in 
human and other animals. 
The overall systems for lipoprotein metabolism in the limited number of animals (rat, 
rabbit, swine, non-human primates) studied to date have been similar to the system described for 
humans, although the rates and proportions oflipoproteins catabolised by anyone pathway vary. 
VLDL, synthesised by the liver to carry triacylglycerol to cells, is catabolised to smaller IDL. IDL 
may be removed from circulation or catabolised to LDL. LDL is removed from the plasma by 
internalization of the whole particle following binding to the LDL (B,E)receptor. The de novo 
synthesis of lipoproteins, other than VLDL, in this cascade, has been reported from kinetic studies 
in some human hyperlipidemias and some animals. 
Lipoproteins are composite particles, and not all the components are metabolised at the 
same rate. ApoB, the major apoprotein in VLDL, IDL and LDL, plays a central role in their 
metabolism. Since apoB has been found to remain with the particle during catabolism, apoB has 
been used as a marker in kinetic studies of these lipoproteins. Most commonly, the kinetic 
studies of apoB involve the injection of iodinated lipoproteins and following the label into 
different lipoprotein classes. The relationships between the particles and turnover rates are 
determined either using mathematical formula or multi compartmental analysis. 
The work described here was undertaken to study the kinetics of lipoprotein metabolism in 
sheep using the injection of iodinated VLDL and LDL. The objectives were to characterize the 
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system of lipoprotein metabolism in sheep by describing the relationships between the apoB-
containing lipoproteins; to measure the VLDL-B and LDL-B turnover rates and to compare sheep 
apoB kinetics with those reported for other animals. 
This study does not consider the metabolism of other lipoproteins or of any other 
lipoprotein components other than apoB. It is recognised that the metabolism of apoB and 
triacylglycerol. although related, are independent. 
The following chapters of this section present a literature review of kinetic studies, the 
methods. results and discussion of the injection of iodinated VLDL and LDL into sheep. The 
fmal chapter describes the formulation of a mathematical model to describe the metabolism of 
apoB in sheep. 
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4.2 LITERATURE REVIEW OF APOB KINETIC STUDIES. 
4.2.1 Introduction 
The first kinetic studies with lipoproteins were published over 30 years ago. Gitlin et al. 
(1958) separated lipoproteins from human plasma into three density classes, iodinated each 
fraction, then reinjected them. They observed that label injected with VLDL appeared in LDL 
and the metabolism of peptides of 04 lipoproteins was independent of {J lipoproteins. After these 
courageous beginnings, there was a slump in the use of kinetics for studying lipoprotein 
metabolism until the lipoproteins, particularly the apoproteins, were characterized. When it was 
realised that lipoprotein particles were not catabolised as a whole but that each component may 
follow a different path; experiments separating the lipid and protein moieties followed. These 
experiments revealed the metabolism of the protein is heterogeneous and led to studies on the 
individual apoproteins. 
A major breakthrough came in 1975 when Sigurdsson and colleagues observed that VLDL-
B was converted to LDL-B. Since the absolute mass of apoB per particle remained constant, it 
was concluded the metabolism of apoB could be used to investigate the metabolism of and 
interrelationsWps between VLDL and LDL, and later, IDL. Furthermore, apoB plays a 
controlling role in directing the synthesis and catabolism of apoB-containing lipoproteins since 
the rate of apoB synthesis may be a rate limiting step in lipoprotein synthesis, and LDL uptake 
and catabolism is via an apoB receptor (Brown and Goldstein 1983). The discovery offorms of 
apoB (Kane et al., 1980; Krishnaiah et al., 1980) and the heterogeneity of their metabolism 
emphasised the role of apoB in directing metabolism. 
Kinetic studies of different forms of apoB revealed particles containing Wgh molecular 
weight apoB were catabolised more slowly and are more likely to be converted to LDL-B than 
those with lower molecular weight apoB (in rats; Elovson et al., 1981, Elovson, 1982; Sparks and 
Marsh, 1981; Sparks et al., 1983; in humans; Nestel et al., 1983). In the recent kinetic studies of 
Houlston et al. (1988) and Demnant et al. (1988), a variation in the apoB gene influenced the 
fractional catabolic rate of LDL and plasma total cholesterol and LDL-cholesterol concentrations. 
This review is restricted to the metabolism of apoB in vivo. Kinetic studies of other 
lipoprotein components (apoproteins, triacylglycerol and cholesterol) in various lipoprotein 
classes, individually or in combination, as well as in vitro studies are important in gaining an 
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understanding of the overall metabolism of lipoproteins but are beyond the scope of this review. 
Their findings are incorporated into the initial review of this dissertation. 
Turnover studies involve labelling the apoprotein, reinjecting (if exogenously labelled) and 
following the label in plasma over a period of time. Different classes of lipoprotein need to be 
separated; the specific activity of apoB determined; and finally the results analysed. As 
illustrated below a wide variety of methods have been used and this has lead to some 
inconsistencies in the results from different laboratories. Kinetic studies in humans, both in 
health and disease (hyperiipidemias), rats and other mammals are reviewed. 
4.2.2 Labelling Apoproteins. 
For in vivo kinetic studies, either exogenously or endogenously-labelled tracer is used. The 
choice of tracer depends on the facilities available, cost, ease of use and experimental design. 
Whatever the labelling method, the tracer must fulfill the role of being a true tracer for the tracee 
if the data analysis is to be meaningful. The tracer must be chemically, physically and 
biologically the same as the tracee. It must be measurable but negligible in quantity when 
compared to the tracee so as not to perturb normal metabolism. In the majority of papers, 
apoproteins have been exogenously labelled with radioactive iodine using the iodine 
monochloride method of McFarlane (1958) adapted for lipoproteins by Bilheimer et ai. (1972). 
This method labels all the components of the lipoprotein but this potential problem is overcome 
by analysing the apoprotein of interest. 
The advantages of exogenously labelling are 
1. a specific lipoprotein can be labelled 
2. only low doses of radiation are required (50 ",Ci "I in humans) 
3. the tracer may be introduced as a bolus so standard methods of data analysis can be used 
4. direct study of the catabolic process is obtained while information about anabolism may 
be inferred under steady state conditions. 
The disadvantages of exogenous labelling, especially in regards to iodination, are related to 
the ability of the tracer to act as a true tracer. Ultracentrifugation, labelling, purification and 
reinjection may modify the lipoprotein. Manganese-heparin precipitation, as an alternative 
method of isolating lipoprotein for labelling, results in denatured particles. Adding any label to 
the lipoprotein can potentially change the biological activity so the number of I atoms 
incorporated/protein must be restricted. Eisenberg et ai. (1973), Langer et ai. (1972) and others 
demonstrated iodination did not alter the properties of the lipoproteins on cellulose acetate, 
immuno-electrophoresis, gel chromotography or heparin affinity chromotography. A further 
disadvantage with iodination is the potential for radiation damage. More recently, apoproteins 
have been methylated using 3H or 14C. Provided methylation is restricted, this appears to be a 
suitable alternative. 
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Different procedures to purify the tracer, by removing both unbound iodine and denatured 
tracer have been employed, resulting in differences in tracer between laboratories. Berman et ai. 
(1978) suggested a consequence of injecting denatured tracer may be very rapid catabolism. This 
is very difficult to distinguish from a genuine rapidly turning over pool. Biological screening 
(Langer et ai. 1972), by pre-injecting labelled lipoproteins into an intermediate animal, has been 
used to remove denatured particles or to check for such denaturation. Although this procedure 
may be suitable for lipoprotein with long turnover times like LDL, damage may still occur on re-
isolation. 
On reinjection, the next potential problem, in view of the relationship of the tracer and the 
tracee, may occur. VLDL isolated for the preparation of tracer is a spectrum of particles with 
respect to size and composition. Since the preparation of the tracer may take up to three days, the 
lipoprotein spectrum in the animal at the time of reinjection may differ from that isolated. This 
becomes particularly important when there are small but rapidly turning over pools, as the pool 
may not be labelled at all. 
Endogenously labelled lipoproteins may play an important role in evaluating this problem 
as all lipoproteins are labelled and will be measurable providing sufficient label is introduced. 
Endogenously labelled apoproteins have been prepared using eSSe] selenomethionine (Eaton et 
ai., 1976, 1982) and [3H] leucine (illingworth, 1975; Fisher et ai., 1980). The radioactive amino 
acid is incorporated during biosynthesis so the potential problems of equivalence of tracer and 
tracee are overcome. This method also provides a direct measure of synthesis of apoproteins and 
is particularly useful in labelling tyrosine deficient apoproteins. The major disadvantage of 
endogenous labelling is the large dose of tracer required to sufficiently label the required protein. 
Also because label continues to be incorporated following protein catabolism, more sophisticated 
data analysis is required. 
The use of dual label experiments using exogenously and endogenously labelled tracers 
may help clarify some of the difficulties associated with heterogeneity, rapid turnover pools and 
precursor-product relationships. 
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4.2.3 Isolation of Lipoprotein Fractions. 
The defInition and isolation of lipoprotein fractions have traditionally been based on 
flotation in density solutions with the limiting densities defmed from Schlerin patterns. This 
results in fractions that are not necessarily compositonally or metabolically similar. Reardon and 
Steiner (1982) and Reardon et ai. (1982b) suggested the redefinition of the limiting densities so 
fractions would fulfill their kinetic criteria of VLDL, VLDL remnants and LDL but this is as yet 
not widely accepted. Methods of isolating lipoproteins on a metabolic basis, such as collecting 
lymphatic lipoproteins or the use of heparin-sepharose columns to separate particles with different 
apoE contents (Shelburne, 1977) are also not widely used in kinetic studies. 
4.2.4 Isolating apoprotein B and Determining Specific Activity. 
The first attempts to separate apoB from the other apoproteins appear in the early seventies 
when Bilheimer et al. (1972) and Eisenberg et al. (1973) used PAGE in 8M urea and sephadex 
gel filtration to isolate apoB. Kane (1973) selectively precipitated apoB using tetra methylurea 
(TMU) and this became the standard method. Some small apolipoproteins may adhere to the 
TMU precipitate and need to be removed (Le et al., 1978). Cheaper, more accessible alternatives 
based on the insolubility of apoB in isopropanol (Egusa et al., 1983) and low ionic strength buffer 
(5mM NH4HC03, Reardon et al., 1978) were developed. 
Specific activity is calculated as counts in the apoB pellet divided by the amount of protein. 
Protein is measured using the Lowry procedure either directly by resolubilizing the pellet in 
NaOH or indirectly as the difference in protein between the total lipoprotein fraction and 
TMU/isopropanol/buffer soluble material. Traditionally, turbidity caused by lipid in the assay 
was cleared by solvent extraction but Markwell et al. (1978, 1981) described a simple one step 
assay by including 1 % SDS in the Lowry alkaline reagent. Whether TMU and isopropanol affect 
the Lowry assay is debatable(Kane et at., 1975) and early reports of differences in 
chromogenicity of apoB and Bovine Serum Albumin (BSA) lead some workers (Janus et al., 
1980 a,b and Sigurdsson et al., 1975, 1976) to include a factor (0.77) to account for this. Kane et 
al. (1975) and Reardon et al. (1979) confirmed that the chromogenicity of apoB and BSA are 
equal and suggested the earlier reported differences may be accounted for by water of 
crystallization in the BSA standard. More recently Chait et at. (1980) have introduced a radio-
immuno assay for apoB. The concentration of apoB is determined then the radioactivity 
determined as the difference before and after TMU treatment. 
Since most of the protein in LDL is apoB, determination of specific activity using total 
LDL protein has remained popular because of its simplicity. This method, however, leads to an 
overestimation of turnover. Kesaniemi et al. (1982) also demonstrated that seemingly small 
differences in the method of protein determination may significantly affect the results. If total 
LDL protein is considered to be 100%; apoB measured by the difference of total and TMU 
soluble proteins and in the resolubilized pellet were 90-95% and 85%, respectively. 
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In studies of the individual forms of apoB, SDS-PAGE and SDS-Sepharose gel filtration 
have been employed to separate the individual forms (Elovson, 1982; Nestel et al., 1983; Sparks 
and Marsh, 1981) 
4.2.5 Treatment of Results. 
Very Low Density Lipoproteins. 
VLDL decay curves following the injection oflabelled VLDL-B usually show two 
components. There are three basic procedures used to analyse the kinetic data. The simplest is 
to fit a single exponential (Figure 4.1a) to the initial decay data and calculate the fractional 
catabolic rate (FCR). The initial slope usually 'fits' the data for three to four half-lives so this 
line accounts for greater than 85% of the decay (Janus et al., 1980a,b; Sigurdsson et al., 1975; 
Chait, 1980, Brunzell et al., 1977; Packard et al., 1980). To account for the 'tail' on the decay 
curve, a two pool model was required. The general model (Figure 4.1b), described by Gurpide et 
al. (1964) allows independent entry and exit from both pools. As applied to apoB kinetics by 
Reardon et al. (1978), the label is introduced to pool A and sampling is also from this pool, so 
pool A includes the plasma but is not confined to it. These workers suggest the two pool model 
may reflect the input of several populations of particles or the heterogeneity in the catabolic 
processes. 
The third approach is to use multi compartmental analysis. Physiological studies had 
shown that VLDL is sequentially metabolised to smaller and smaller particles. Phair et al. (1975) 
incorporated this idea into a model by proposing a delipidation chain with limited entry and exit 
(Figure 4.1c). This development catered for the initial plateau that is often seen. The 
multicompartmental model introduced by Berman et al. (1978) combines a four step delipidation 
chain for the rapid-turnover component and a separate compartment for slow-turnover VLDL. 
The number of pools in the delipidation chain has been varied to fit the data (Beltz et al., 1985). 
The FCR for a given turnover depends on the number of pools with FCR decreasing as pool 
Figure 4.1 
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Three proposed models for VLDL-B metabolism. (a) a single plasma 
compartment. (b) a general two pool (A and B) model as described by Gurpide 
et ai. (1964) which allows independant entry and exit from both pools. (c) a 
four compartment delipidation chain with limited entry and exit. 
(a) 
(b) 
(c) 
numbers increase. For simplicity the mass ofVLDL-B in the delipidation chain is distributed 
equally among the pools and the rate constants are the same for all pools. 
Intermediate Density Lipoproteins. 
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Very few workers have isolated IDL for labelling and reinjection (Musliner et at., 1987; 
Ghiselli, 1982). In earlier studies, the LDL fraction collected contained the IDL (Sirgurdsson et 
at., 1975, 1976; Packard et at., 1980). The appearance and disappearance oflabelled apoB in IDL 
following the injection oflabelled VLDL-B gives some information on IDL kinetics. IDL curves 
often differ in the time it takes to reach maximum specific activity and the rate of decay 
afterwards. Most commonly a single pool is used to represent IDL (Berman et ai. 1978). Beltz et 
al. (1985) found most IDL decay curves to be biphasic but since the transport of apoB through the 
second pool was very small, they concluded that this pool could be excluded without affecting 
the transport rates. 
Low Density Lipoproteins. 
The plasma decay curve for LDL is typically biphasic. The most common model used 
(Eaton et ai., 1982; Packard et ai., 1980; Langer et ai., 1972) is a two compartment mammillary 
model described by Matthews (1957) (Figure 4.2a). The pools (Sigurdsson, 1976) were 
interpreted as an intravascular pool in equilibrium with an extravascular pool. Input and output 
were allowed from the intravascular pool. So the biphasic plasma decay curve represents the 
disappearance of homogeneous LDL and the shape is determined by the exchange with the 
extravascular pool. Nosslin (1965) showed that Matthews formula is independent of the site of 
degradation and always gives the degradation as a fraction of the intravascular mass. Goebal et 
ai. (1976) used an alternative two pool model incorporating two independent compartments with 
different turnover rates (Figure 4.2b). To explain 'polydisperse' LDL (mostly found in 
hypertriglyceridemic patients) Fisher et al. (1980) included an extra pool (Figure 4.2c) to cater for 
the small shoulder on the decay curve. 
Alternatively the FCR ofLDL-B has been determined from the ratio of radioactivity in 
urine to plasma (Langer et al., 1972). This assumes all the radioactivity is in apoB and that 
thyroid uptake is blocked. 
Relationships Between Lipoprotein Classes. 
Although many workers injecting VLDL-B followed the label into the IDL and/or LDL 
fractions, they used mathematical functions rather than the power of modeling to quantify the 
96 
Figure 4.2 Three proposed models for LDL-B metabolism. (a) a two compartment 
mammillary model decribed by Matthews (1957). (b) a three compartment model incorporating 
two independent vascular compartments with different turnover rates (Goebal et ai., 1976). (c) a 
three compartment model allowing a small shoulder on the decay curve as used by Fisher et al. 
(1980) to model polydisperse LDL in hypertrigylceridemia. 
(a) 
(b) 
(c) 
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relationships between the fractions. The proportion of VLDL being catabolised to IDL or LDL 
was calculated from the recovery of tracer in these fractions. In dual-labelling experiments, 
deconvolution analysis was used to determine this fraction (Sigurdsson et al., 1975; Janus et al., 
1980a,b; Sigurdsson, 1982). The proportion of IDL or LDL turnover derived from VLDL or IDL 
respectively was determined using the description of precursor-product relationships described by 
Zilversmit (1960) and applied to lipoproteins by Reardon et al. (1978). Comparison of the 
turnover rates of VLDL-B and LDL-B along with an estimate of one of these proportions allowed 
the other to be determined (Huff and Telford, 1985; Sigurdsson et at., 1975). Each of these 
methods requires different assumptions. 
As it became clear that the metabolism oflipoproteins is far from simple, more 
sophisticated methods were required to analyse the data and compartmental modeling was 
applied. Berman et al. (1978) proposed an integrated model for the metabolism of apoB. It 
incorporated (a) a delipidation chain and (b) a separate pool for direct metabolism ofVLDL-B, 
one pool for IDL and two pools for LDL. 
After injecting labelled VLDL and collecting data for VLDL and LDL (containing IDL), 
Packard et al. (1980) used a model with one pool for VLDL combined with a mamillary model 
for LDL. To accommodate data from hypertriglyceridemic patients, irreversible loss of apoB 
from the VLDL pool as well as the intravascular LDL pool was allowed and a variable delay 
segment between VLDL and LDL pools was introduced. Beltz et al. (1985) not only integrated 
subsystems for VLDL-B, IDL-B and LDL-B but also included VLDL-TG. For a complete 
understanding of lipoprotein metabolism, not only apoB but each lipoprotein component needs to 
be considered. 
The differences in laboratory techniques and the methods used to analyse the data, along 
with differing pre-study and during study treatment of subjects, account for some of the variation 
observed in results especially those quantitating flow and turnover rates. 
4.2.6 Kinetic Studies in Humans. 
Kinetic studies have often been used to further characterize lipoprotein metabolism in 
healthy and diseased humans. With the development of experimental methods, a substantial 
number of papers on lipoprotein kinetics comparing hyperlipidemic and normal patients were 
published in the seventies. The two cases are considered separately below. The review by 
Kesaniemi et al. (1982) also provides a useful summary of such work. 
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Normal Humans 
Bilheimer et al. (1972) showed radioactivity from VLDL first appeared in IDL then in 
LDL. The simplest scheme for lipoprotein metabolism in normal humans is the secretion of 
VLDL, lipolysis of VLDL to IDL, conversion of IDL to LDL and the removal of LDL. Many of 
the earlier reports combined IDL and LDL into one LDL fraction (1.006-1.063g/ml) (packard et 
al., 1980). Using the intersection of specific activity curves, Sigurdsson et al. (1975) suggested 
all the LDL-B (incorporating IDL) was derived from VLDL. Their dual label experiments using 
deconvolution suggested 90% VLDL-B was catabolised to LDL-B. This was supported by 
Packard et al. (1980). Due to similar synthetic rates for VLDL-B and LDL-B, it was generally 
agreed that VLDL was quantitatively catabolised to LDL and this catabolism accounted for most, 
if not all, LDL-B production (Berman, 1979; Reardon et al., 1978). 
In more recent dual label experiments, Janus et al. (1980b) showed that LDL-B produced 
from VLDL-B was approximately equal to the total synthetic rate ofLDL-B supporting the idea 
that most, if not all, LDL-B came from VLDL. Using deconvolution they found, however; that 
only 44% of the VLDL-B was catabolised to LDL-B. Other workers (Berman, Eaton et al., 1976; 
Ginsberg et ai., 1981; Kesaniemi et al., 1985) using different techniques and analysis also 
suggested a significant portion of VLDL B was not metabolized to LDL B. The LDL turnover 
rates reported by Janus et al. (1980b) are low (due mostly to lower plasma LDL concentrations) 
compared to other reports and not similar to VLDL synthetic rates as reported previously. 
When interest in IDL (1.006-1.019 g/ml) as a separate class developed, Janus et ai. (1980b) 
demonstrated all IDL may be derived from VLDL. The contribution of IDL to LDL production 
was studied by Eaton et al. (1982) using eSSe] selenomethionine and they found that 86% of 
LDL- production was accounted for by IDL conversion. An alternative pathway of synthesising 
LDL must, therefore, exist. 
In normal humans, VLDL is catabolised either to IDL and then LDL or removed from the 
plasma directly. All of the LDL-B may not be derived from VLDL via the 'cascade'. The 
general concepts are agreed upon but the intricacies still require further research. 
Plasma concentrations, fractional catabolic rates and turnover rates for VLDL-B and LDL-
B in normal humans are summarised in Table 4.1. As stated above, there is a large amount of 
variation between laboratories due to patient selection, pre-study and study conditions, and the 
analytical methods used. Thus the mean values do not represent a true mean. Nevertheless, 
Table 4.1 does provide useful guidance values. 
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Table 4.1: Plasma concentrations, fractional catabolic rate (FCR) and turnover rate for VLDL-
B and LDL-B in normal humans. 
VLDL-B 
LDL-B 
2 
Parameter 
Concentration 
(mg/d!) 
FCR 
(hoi) 
Turnover rate 
(mg/kg/d) 
Concentration 
(mg/d!) 
FCR 
(hoi) 
Turnover rate 
(mg/kg/d) 
2.2-8.0 
0.179-0.579 
9.1-15.3 
37.4-107.9 
0.012-0.019 
7.6-14.4 
Summarized from Kesaniemi et al. (1982). 
Summarized from Fisher (1982). 
Hyperlipidemic Patients. 
5.3 
0.321 0.292 
12.6 1292 mg/d 
0.015 
11.4 
Early studies on hyperlipidemic patients gave varying results depending on the individual 
patients. The genetic classification of hyper lip idemi as by Goldstein et al. (1973) was used to 
rationalize studies in the 1980s. In the hyperlipidemias, the basic model for lipoprotein 
metabolism is the same but proportions of pathways differ. These are described below. 
Familial hypercholesterolemia 
Many heterozygous patients with familial hypercholesterolemia (PH) are characterized by 
elevated levels ofLDL-B while VLDL-B concentrations are normal. Studies using iodinated 
lipoproteins (Soutar et ai., 1977; Janus et al., 1980a,b) and lipoproteins labelled with eSSe] 
selenomethionine (Eaton et al., 1982) suggested direct synthesis of LDL in PH accounts for 20-
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72% ofLDL-B and its overproduction. The FCR ofLDL in PH was markedly lower than in 
normal humans (Janus et al., 1980a; Sigurdsson et al., 1976; Langer et at., 1972; Packard et at., 
1976) and resulted from a well characterized genetic deficiency of hepatic lipoprotein receptors 
(Goldstein and Brown, 1977; Shepard, 1979). In homozygous patients the same defects are more 
pronounced (Soutar et al., 1977). 
Familial hypertriglyceridemia 
Familial hypertriglyceridemia is characterized by high plasma and VLDL concentrations 
oftriacylglycerol. The rate ofVLDL-B synthesis is normal but the FCR ofVLDL-B is decreased 
(Janus et at., 1980a,b). Chait et at. (1980) and Chait and Brunzell (1982) showed that increased 
triacylg1ycerol synthesis and the kinetics ofVLDL-B and plasma triacylglycerol were dissociated. 
Familial combined hyperlipidemia 
In familial combined hyperlipidemia, family members have increased plasma 
concentrations oftriacylg1ycerol, cholesterol or both. Janus et at. (1980b) and Chait and Brunzell 
(1982) reported increased synthesis of VLDL-B. The proportion of VLDL catabolised to LDL 
and the direct synthesis of LDL were normal. Direct degradation of VLDL and IDL may vary 
giving rise to the different expressions of the disease profile. 
Broad beta disease 
Broad beta disease or type 111 hyperlipoproteinemia is characterized by increased 
concentrations of IDL associated with a deficiency of apoE3' Reardon et al.(1982b) demonstrated 
the direct synthesis of IDL-B(Sf 12-60). Berman et al. (1978); Chait et al. (1978) and Janus et al. 
(1980b) reported decreased clearance ofVLDL-B. 
4.2.7 ApoB kinetics in other mammals. 
Kinetic studies on VLDL-B and LDL-B in animals are summarized in Table 4.2 a&b 
respectively. The table emphasises (i) the limited number of studies on animals, (ii) the 
differences in the methods used and (iii) the differences in lipoprotein metabolism between the 
various species. 
Rats 
In rats, most VLDL-B is rapidly cleared from the plasma without being converted to LDL-
B (Fidge and Poulis, 1975; Eisenberg and Rachmilewitz, 1973; Faergeman et at., 1975). 
Faergeman et al. (1975) suggested this hepatic uptake may explain the low levels ofLDL in rat 
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By injecting 14C-methylated or 1251 iodinated VLDL into rats and describing the specific activity 
curves of VLDL and LDL-B, Fidge and Poulis (1978) demonstrated that not all the LDL-B was 
derived from VLDL-B. By further subfractionation ofLDL, they demonstrated most LDL-B 
(65%) was in the Sf 0-5 fraction and only 6-15% of this was derived from VLDL. ApoB in the 
SfS_12 and Sf12_20 (IDL) fractions was derived from VLDL. Their results suggested 'direct' 
synthesis of LDL-B and the heterogeneous nature of LDL. 
In 1980, Krishnaiah et ai. published fmdings of a second form of apoB in rats although 
they noted the larger molecular weight band on SDS-PAGE was often a doublet. Three forms of 
apoB; PI, P1l, PIll were identified by Elovson et at. (1981) in rat VLDL. On SDS-PAGE, PI 
comigrates with human apoBb (apoB lOO) and PIll comigrates with apoBl (apoB48). Pl1 migrates 
slightly faster than PIll and corresponds to apoB9S on the centile scale. As in humans, the low 
molecular weight apoB is synthesised in the rat intestines. In contrast to humans, the rat liver 
synthesises high and low molecular weight apoB (Krishnaiah et ai., 1980; Elovson et ai., 1981; 
Sparks et at., 1981). VLDL-Bl was cleared from the plasma faster than apoBb (pl+Pll) and 
apoBb was preferentially catabolised to LDL-B (Elovson et at., 1981; Sparks et at., 1981; Sparks 
and Marsh, 1981; Elovson et at., 1982; Sparks et ai., 1983) 
Because rat lipoproteins and their metabolism varied markedly from humans, the search for 
alternative animal models to simulate the metabolism of lipoproteins in healthly and diseased 
humans continued. Unlike the rat, other mammals so far studied (rabbit, dog, swine and some 
primates) have little or no apoB48 in hepatic VLDL (Chapman, 1986). The lipoprotein system in 
other mammalian species was similar to humans but variations between species occurred in the 
proportion of VLDL converted to LDL and the proportion of LDL from VLDL. 
Swine 
Because the lipoprotein distribution pattern and the composition of individual lipoproteins 
is similar in swine and humans, swine have been considered a viable model. Indeed studies 
showed that LDL turnover rates in swine were similar to humans although the synthetic rates 
depend on the model (Marcel et al., 1978). Huff and Telford (1985) found, however, that the 
FCR ofLDL was faster in swine than humans. Using 1251 VLDL and 1311 LDL they also showed 
that most VLDL-B (84%) was cleared from plasma without being converted to LDL-B and 
secondly a significant portion (80%) ofLDL entered the plasma independently ofVLDL 
catabolism. This supported the earlier report that apoB was released from perfused pig liver as 
particles in the LDL density range (Nakaya et al., 1977). 
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Squirrel monkeys 
Illingworth (1975) used a different approach to assess direct synthesis ofIDL-B and LDL-
B. He injected 3H-VLDL and 14C-Ieucine into squirrel monkeys treated with Triton-WRl339 to 
block VLDL catabolism. Most, but not all apoB, entered the circulation as VLDL and the low 
plasma concentration of VLDL is probably due to its rapid turnover. 
Rabbits 
The rabbit has been used as a model for diet-induced atherosclerosis. In normal rabbit, 
VLDL-B is the major precursor for IDL-B (Kushwaha and Hazzard, 1978; Ghiselli, 1982). 
Ghiselli (1982) found LDL could be divided into two metabolically distinct classes. LDL1-B ( 
d=1.019-1.040 g/ml) was the main catabolic product ofIDL-B while little or no VLDL-B or IDL-
B entered LDLz-B (1.040-1.063g/ml). It was concluded that LDL2 may be synthesised 
independently. This fraction is only 20% ofLDL in rabbits. Ghiselli (1982) suggested most of 
the VLDL is cleared from the plasma as IDL. Kushwaha and Hazzard (1978) found that 95% of 
VLDL-B was catabolised in the first phase and the label appeared immediately in IDL and LDL 
but they suggested that the first phase consisted of both lipolytic conversion of VLDL to IDL and 
direct removal of remnant VLDL fractions by the liver. 
4.2.8 Conclusion. 
Because of the central role apoB plays in the metabolism of lower density lipoproteins 
(VLDL, IDL and LDL) and its ability to serve as a marker for these lipoprotein classes, apoB 
kinetic studies allow the metabolism and interrelationships between VLDL, IDL and LDL to be 
investigated. As described above, kinetic studies conducted in normal humans, patients with lipid 
disorders, rats and several other mammallian species has revealed an overall similarity in 
lipoprotein metabolism systems across the species. The metabolic rates and intricacies of the 
relationships between the lipoprotein fractions differ, however, between the species. 
Studies on the metabolism of lipoproteins in ruminants are lacking. Because of the 
differences in diet and digestive physiology, ruminant animals may be an interesting species to 
study. Also, since there is interest in the deposition of fat in ruminants as meat-producing 
animals, the potential usefulness of lipoproteins in whole body and adipose tissue metabolism 
warrants investigation. 
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This section goes some way in addressing this need. Although, as demonstrated above, there is 
considerable variation in methods, the basic procedure of labelling apoB, injecting the labelled 
apoprotein into the animal and following the tracer in plasma was used to study apoB in the 
sheep. The study of apoB metabolism in sheep also offers the opportunity to compare lipoprotein 
metabolism in sheep with that in other species and to explore such questions as to why plasma 
lipoprotein concentrations in sheep are low and how significant are lipoproteins in ruminant 
metabolism. 
Table 4.2(a): Experimental design and kinetics of VLDL ApoB metabolism in non-human mammals 
Results for VLDL B 
Density" Density" Method [VLDL-B] Tl/2 FeR T/O 
Animal PIP n Treatment Isotope injected measured ApoB Data analysis (h) h-i mg/d/kg Reference 
mg/ill 
Rabbit .J 4 12 hr fast I VLDL& VLDL TMU no kinetic 1.08 dh G.Ghselli 
(2.8 - IDL IDL & NaOH (1982) 
3.2 kg) LDL12 resolulr VLDL clearly 2 pools 
LDLz 2nd after 4 h 
Mini- .J 5 16 h fast 1251 VLDL VLDL TMU 2 pool Gmpide 0.79 (1.22) .69 18.48 Huff and I 
ature prior IDL model 2nd pool after I hr Telford (1985) • 
Pig 12 hrfast LDL 
fed l/day 
Rabbit .J 4 Control & 1251 VLDL VLDL TMU Biphasic (300) 0.55- to <4 hr Kushwaka& 
hyperchol- IDLI by iliff Fitted lines «95%) Hazzard (1978) 
estrolemic LDL didn't peel 24.1 0.37 21.6 
non-fasted (Mathews FCR) (after 8 h) mg/d/l00 ml 
Squirrel Overnight 3Hleu Illingworth 
Monkey fast (1975) 
+/- triton 3H-VLDL 
WR1339 
Rat .J non-fasting 3Hlysine <1.006 TMU (.03mg/ml) Faergeman et 
3HVLDL 1.006-1.063 B by diff. ai. (1975) 
Rat .J 1251 2 pools 10 & 35min Fidge & Poulis 
75,90 & 145min (1978) 
b VLDL <1.006 g.m1-1 IDL 1.006-1.019 g.ml-1 LDL 1.019-1.063 g.ml-1 
.J Precursor /product relationships investigated. 
1 IDL 1.006-025 g.ml-1 LDL 1.025-1.063 g.ml-1 
2 LDLl 1.019-40 g.ml-1 LDLz 1.040-1.063 g.ml"l Table 4.2(b): Experimental design and kinetics of LDL ApoB metabolism in non-human mammals 
Table 4.2(b): Experimental design and kinetics of LDL ApoB metabolism in non-human mammals 
DensityD DensityD ApoB [LDL-BJ TI/2 FeR T/O 
Animal n Treatment Isotope injected measured method Data analysis (h) h-1 Reference 
Mini- 4 15h fast 1311 LDL TMU 2 pool Gurpide 19.27 0.055 17.5 Huff & Telford 
ature prior (1985) 
Pig 12 brfast 
feed l/day 
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Mini-
ature 
Pig 
4 Fasted 1251 LDL Plasma'" 
1.006-1.080 
3 pools 3.1 
18.5 
99 
0.015 
mean 
(5.6:1:4.1) 
(mg/hr) 
Marceletal 
(1978) 
---------------------------------------------------------------~------------------------------------------------------------------------------------------------------------------------------------------:---« 
Swine 13 O/Nfast 1251 LDL Plasma'" 
(95% inLDL) 
Dog 3 1251 LDL Plasma* 
1.020-1.050 
hi-exponential 
Matthews 
hi-exponential 
0.83 
22.5 
0.6-3.3 
26.2-28.7 
0.041 
irrev 
removal 
0.030 
Sniderman 
etal. 
(1975) 
Sniderman 
etal. 
(1975) 
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4.3 INVESTIGATIVE PROCEDURES. 
This chapter presents the design and detailed methods for the study of apolipoprotein B 
metabolism in sheep using iodinated lipoproteins. An overview of the experiment is followed by 
laboratory methods and description of how the data was analysed. Evidence of the validity of the 
procedures from pretrial tests is described and discussed. 
The metabolism of apoB in sheep was studied in four lambs. VLDL and LDL were 
isolated from the lamb's plasma, labelled with 1251 and 1311 respectively and reinjected into the 
sheep's blood. Blood samples were taken over a period of up to two weeks. VLDL, IDL, LDL 
were separated by sequential ultracentrifugation and the specific activity of apoB was determined 
after selective precipitation with isopropanol. Graphs of specific activity versus time allowed the 
description of the relationships between these lipoprotein classes and the calculation of fractional 
catabolic rates (FCR) and turnover rates. The data was further explored by the development of a 
model of apoB metabolism using the SAAM computer program (Chapter 4.6). 
4.3.1 Animals. 
Four Suffolk-cross wethers (average weight 27 kg) were obtained from the Lincoln 
University Research Farm, housed in metabolism crates at the Johnson Memorial Laboratory and 
fed lucerne chaff and water ad lib. A minimum of four days was allowed for the animals to 
acclimatize. Potassium iodide (100mg/l) was added to drinking water to block the thyroid uptake 
of radioactive iodide. 
One day prior to injection, one jugular vein of each ram was catheterized for blood 
collection with a 16 gauge intravenous catheter (Deseret). The catheter was flushed with sterile 
citrate/saline solution (NaCl9g 1"1, trisodium citrate 35g 1"1) following each blood sample and 
daily when sampling became less frequent. 
4.3.2 Collection of donor VLDL and LDL. 
A pooled 400ml blood sample was collected from the experimental lambs using a blood 
donor bag (TUTA Citrate Phosphate Dextrose). Plasma was collected after centrifugation (600g 
x 30 min, 5 • C) and VLDL and LDL were isolated by sequential flotation ultracentrifugation 
(Mills et at., 1984; Lindgren, 1975) using thick walled polycarbonate tubes in a Ti70 rotor in a 
Beckman model L8-70 ultracentrifuge. For VLDL, 15m1 plasma was overlaid with 2ml density 
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solution 1 (d=1.006g1ml)1 and centrifuged at lOOOOOg for 16h at 20· C. After centrifugation, the 
top 3ml from each tube was pooled to yield the VLDL fraction which was washed by centrifuging 
through density solution 1 and concentrated by centrifuging in the smaller Ty65 rotor (lOOOOOg x 
16h 20· C). 
LDL was isolated between densities 1.02 and 1.063 g/ml by combining the subnatants 
from the VLDL spins and adjusting the density to 1.02g1ml with density solution 2 (d=1.088g/ml, 
lml density solution per 5mllipoproteins). Two ml of density solution 3 (d=1.02 glml) was 
overlaid and IDL removed by discarding the upper 2ml after centrifugation (100000 g x 16h 
20°C). The residue at the bottom of the tubes was adjusted to a density of 1.063g1ml with density 
solution 4 (d=1.278g1mll:5) and overlaid with 2ml density solution 5 (d=1.063g1ml) then 
centrifuged (100000 g x 20h 20°C). LDL was collected in the top 2ml. The pooled LDL 
preparations were purified and concentrated by recentrifuging under the same conditions. 
Samples of each lipoprotein preparation were assayed for protein using the assay of 
Lowry et ai. (1951) adapted by Markwell et ai. (1978) (Section 4.3.6.C). 
4.3.3 Iodination of lipoproteins. 
VLDL and LDL were labelled with 1251 and 1311 respectively using the iodine 
monochloride method of McFarlane (1958) with modifications described previously (Langer et 
aI., 1972; Fidge and Poulis, 1974; Janus and Grant pers comm.) and incorporated as outlined 
below. 
a. Preparation of iodine monochloride (lCI). 
Iodine mono chloride (lCl) (0.033M in 1M HCl) was prepared by dissolving lSOmg NaI 
in 8ml of 6M HCl and 108mg NaI03.HzO in 2m! water. To avoid precipitation of iodide on 
mixing, the iodate solution was forcibly injected into the iodide solution and then diluted to 4Om! 
with water. Free iodine was removed from the preparation by shaking in a separating funnel with 
Sm! volumes of CCl4 until the organic solvent had no trace of red colour. Any remaining CC4 
was removed by bubbling moist air through the solution for 1 h. The final volume was made to 
4Sml and stored at 4 • C. 
Immediately prior to use, ICl was diluted 1 in 15 with 2M NaCl. 
******************** 
1./ preparation of density solutions appendix 4.1 
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b. Preparation of 1251 VLDL. 
Two ml of VLDL (OAmg/m! protein) was adjusted to pH 10 with OAm! glycine buffer 
(PH 10, 1M). Langer et al. (1972) and Shepard et at. (1976) demonstrated that pH 10 minimised 
lipid labelling. In a separate vial, 400 ttCi Nal25J (Amersham, Aust.) was added to 200ttl ICI. 
The VLDL solution was transferred to the iodinating mixture and immediately vortexed. 
Duplicate S ttl samples were used to determine the efficiency of incorporation of 1251 (see d.l». 
Unbound iodine was removed using a sephadex GSO column (7.Scm x 2.3cm2) equilibrated with 
the reaction buffer. The lipoprotein-containing fractions were dialysed against 500 volumes of 
glycine buffer (PH 10, OAM) followed by 1000 volumes of 0.15M NaCl (PH 7.5) with 0.001 % 
EDT A to remove the last traces of free iodine and to equilibrate the solution to normal saline. 
The 1251 VLDL preparation was ultracentrifuged (100000g x16h 20°C) through density solution 1 
(d=1.oo6g/ml) to remove denatured material. 
c. Preparation of 1311 LDL. 
LDL was iodinated using the same protocol except 800ttCi Na1311 (Amersham, 
Aust.)was used in place of 1251 and dialysis was overnight against the EDT Nsaline solution in 
place of overnight centrifugation. 
Both iodinated lipoproteins were slowly stirred for 20min to dissociate aggregates. The 
distribution of label within the lipoprotein solutions was determined on two 100 ttl aliquots. (d.2). 
d. Analysis of lipoprotein preparations. 
1. The efficiency of labelling was determined using trichloroacetic acid (TCA) 
precipitation (Mills et al., 1984). 
The radioactivity in duplicate 5 ttl aliquots of reaction mixture was measured (see 6.b). 
The mixture was diluted with Iml water and 100ttl BSA carrier solution (5g/100ml) added before 
precipitation with 700ttl TeA (20% w/v). The samples were vortexed for 30s, allowed to stand 
for 2h and centrifuged for 3min at 5OOg. The supernatant was discarded, the protein pellet 
washed with TCA (6% w/v) and recentrifuged. Radioactivity in the protein pellet was determined 
and the incorporation of radioactivity in the lipoproteins was calculated as the percentage of the 
total counts in the reaction mixture precipitated by TCA. 
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2. The distribution of radioactive label in the lipoprotein preparation after purification 
was determined as the percentages of total label which was free in solution, bound to lipid, total 
apoprotein or apoB. 
An aliquot of iodinated lipoprotein was precipitated with TCA as described above. The 
radioactivity in the combined supernatants is a measure of unbound or free iodine in the 
preparation and the radioactivity in the TCA precipitate represents the protein and lipid bound 
radioactivity. 
To determine the amount of label bound to lipid, the TCA precipitate was air dried and 
extracted by vortexing with 1 m1 of freshly distilled petroleum ether:diethyl ether (1:1). The 
protein was repelleted by centrifugation (2000g x 5min). The solvent was immediately removed 
and the radioactivity in both the pellet and supernatant determined. 
The amount of label bound to apoB was determined using selective precipitation with 
isopropanol (Egusa et al., 1983). An aliquot (50-100 "u) of iodinated VLDL or LDL was 
augmented with 1 ml unlabelled VLDL or LDL respectively. 1 ml isopropanol (redistilled over 
KOH) was added, vortexed and incubated overnight at 4 0 C. The apoB precipitate was collected 
by centrifugation (lOOOg x 3Omin), washed with 2ml isopropanol(50% v/v), resuspended in 2m! 
isopropanol, allowed to stand 2h at room temperature and recentrifuged. Radioactivity in the 
apoB pellet was determined. 
4.3.4 Injection and blood sampling. 
1251 VLDL and 1311 LDL solutions were combined and sterilized by the addition of 
gentamycin sulphate (loo",g/ml). The dose (approximately 5 ",Ci of each label, with average 
specific activity of 1.6 x lQ4 cpm 1251 per ",g apoB) was injected at zero time through a 'butterfly 
catheter' in the uncatheterized jugular vein. Blood samples (15ml) were withdrawn via the 
indwelling catheter and transferred to tubes containing EDTA (lmg/ml blood). After 
determination of the packed cell volume, the plasma was collected by centrifuging at 1500g for 
30min at 4 • C. Plasma was stored at 4 • C until lipoproteins could be isolated. When a delay of 
more than two days became apparent with the latter samples of lambs B and D, the plasma was 
stored at q20·C and thawed immediately prior to lipoprotein isolation. 
Blood samples were taken at -0.08,0.17, 1,3,6,9, 12,20,24,30,48,96, 144,240 and 
336 hours. With lambs Band D, additional samples were taken at 0.5, 1.67, 2.33h. 
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4.3.5 Isolation of lipoproteins. 
Plasma samples (4m1) were serially centrifuged using a TFI' 45.6 rotor in a Kontron 
TGA-65 ultracentrifuge to obtain VLDL, IDL, LDL and the remaining lipoproteins 
(d>1.063g/ml). VLDL and IDL were collected by centrifuging at l.oo6g/ml and 1.02g/ml 
respectively. The integrated field-time was 92500g.min at rav8.25cm. LDL and 'HDL' were then 
separated by centrifuging for an integrated field-time of 925OOg. min at r.vlO.OOcm. at 1.063g/ml. 
All centrifugation was at 4 • C and the lipoproteins were collected by tube slicing. 
4.3.6 Determination of the specific activity of apoB. 
a. Selective precipitation of apoB. 
ApoB in the collected lipoproteins (2m!) was precipitated with 2ml isopropanol as 
described above (see 3d.2). After washing, the pellets were air dried and redissolved in NaOH 
(1M) in a 37· C shaking water bath. This took at least 24h. Aliquots were counted and assayed for 
protein. 
b. Assay of radioactivity. 
Radioactivity in samples was determined using dual label counting in an LKB 1282 
CompuGamma gamma counter. Corrections were made for background, overlap of the channels 
and for decay from day of injection. 
c. Protein assay. 
To enable the same 1501.11 aliquot of NaOH-solubilized apoB to be used for the 
determination of radioactivity and protein, a scaled down version of the method developed by 
Lowry et al.(1951) and adapted by Markwell et al.(1978) was used. A standard curve of 0-100 
ILg protein in a total volume of 1001.11 was prepared using Img/ml bovine serum albumin (Sigma 
Chemical Co., crystalline fraction V). 150 1.11 NaOH (0. 1M) was included in the standards and 
replication standards. Sample volumes were adjusted to 2501.11 with water. 7501.11 of alkali-
copper reagent (solution A 2.0% N~C03' 0.4% NaOH, 0.16% sodium tartrate, 1.0% SDS; 
solution B 4% CuS04.5H20; A:B; 100:1) was added and the additional NaOH titrated with 501.11 
HCl (3.0M). Tubes were mixed and incubated for l0r0in before 75 1.11 Folin-Ciocalteu Phenol 
reagent (1N) was added. After 45min, the absorbance at 750nm was determined using a 1ml 
cuvette. 
4.3.7 Determining the intravascular pool sizes. 
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The intravascular pool sizes of VLDL-apoB, IDL-apoB and LDL-apoB were 
determined as the product of plasma volume and plasma concentration of apoB in that 
lipoprotein. The plasma volume was calculated as 4.5% body weight (Gregersen et ai., 1959), 
The plasma concentrations of VLDL apoB. IDL apoB and LDL apoB were determined from the 
difference between total and isopropanol-soluble protein concentrations in each fraction. 
4.3.8 Irreversible loss in urine. 
Daily urine collections were made and the excretion of 1251 and 1311 radioactivity 
calculated from the urine volume and activity in a 2m1 aliquot. 
4.3.9 Analysis of data. 
a. Investigation of the precursor product relationships. 
Graphs of the specific activity of apoB in each lipoprotein fraction versus time after the 
injection of 1251 VLDL were examined using two different methods, to investigate the precursor-
product relationship between VLDL, IDL and LDL. 
The first method examined when the specific activity curves intersect (Figure 4.3) using 
the criteria of Zilversmit (1960). If a substance is the immediate and sole precursor of a second 
substance, the label from the precursor will appear in the product and the specific activity curve of 
the precursor will intersect the specific activity curve of the product at the maximum of the 
product specific activity. If the specific activity-time curves do not intersect or intersect after the 
maximum for the product, and the assumptions concerning the product pool are valid, it must be 
concluded that an alternative pathway for the synthesis of the product exists. The relative 
contribution of the measured precursor to the synthesis of the product was estimated from the 
ratio of the maximum specific activity of the product to the precursor specific activity at the same 
time. 
Figure 4.3 
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Specific activity time curves for VLDL-B and IDL-B following injection of *1-
VLDL to illustrate the Zilversmit criteria for precursor-product relationships. 
Panel (a) illustrates an input of IDL particles independent of catabolism of 
VLDL, as indicated by the product curve (0 IDL) reaching it maximum well 
before cross sing the precursor curve (e). Panel (b) illustrates sole precursor-
product relationship as indicated by the product curve (0 1DL) reaching its 
maximum activity where it intersects the precursor curve (Ii). (Figures adapted 
from Reardon and Steiner, 1982) 
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The second method, based on the work of Goldberg et al. (1983) and Le et al. (1986), 
estimates the extent to which the product CUlve is diluted by direct synthesis using the ratio of the 
area under the product specific activity curve to the area under the precursor specific activity 
curve. This method requires no knowledge of the exact maximum of the product specific activity 
but assumes all VLDL is converted LDL and requires samples to be collected until all the label 
from VLDL has appeared in LDL. Areas under the curves were measured using a leaf area meter. 
b. Kinetics. 
Kinetic parameters were calculated from the log specific activity curves for VLDL and 
LDL following the injection oflabelled VLDL and LDL respectively. The data was plotted by 
hand and a line fitted. If the line was straight then a one pool model was used. If the line was 
curvilinear, the curve was peeled to give its component straight lines using SAAM (see 10). 
In most cases the data was sufficiently explained by a monoexponential equation. In 
these cases, the line of best fit was calculated by the least squares method of regression using base 
ten logs. The half life, T 1/2' is the time taken for the specific activity to decrease by a half and was 
calculated as 0.301 divided by slope. 
Fractional catabolic rate (FCR), the fraction of a compartment that turned over or 
renewed per unit time, was calculated as 2.303 x slope or 0.693!I\/2' The turnover rate (steady 
state synthesis rate or absolute catabolic rate) was determined as the product ofFCR and 
intravascular VLDL apoB pool or intravascular LDL apoB pool as appropriate. This rate was 
normalized for body weight and expressed as mg/kg/day. It should be noted that the estimate of 
turnover rate is dependant on a good estimate of plasma apoB concentrations in the lipoprotein 
classes. 
Where the data displayed a biexponential decay, estimates of the 2 component lines 
were made graphically by hand (Matthews, 1957) and used as initial estimates when improving 
the fit using SAAM. An example of the input files used is in appendix 4.C. The curve 
parameters were used to estimate the flux through pool A, the irreversible fractional catabolic rate 
and mass of pool A using the 2 pool system described by Gurpide et ai. (1963). (See Figure 4.1). 
Where RA is the dose of radioactivity in apoB that goes into pool A. 
Ct and C2 are the intercepts of the 2 components 
ot and {3 are their respective slopes. 
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In brief, this model allows independent entry and exit from both pools. It is assumed 
that the tracer is administered to pool A and subsequently sampling, for determination of specific 
activities, is also from pool A. 
4.3.10 Application of SAAM. 
The Simulation Analysis And Modelling programme, SAAM, (Berman and Weiss, 
1978) version 30.1 was run on a Digital Corporation Ltd (DEC) VAX lIn80 under VMS 
operating system. The interactive version, CONSAM (Berman et at., 1983; Boston et at., 1982) 
was used for its ease in manipulating the model, evaluating and comparing solutions especially 
when developing an integrated model. 
The formatted input me for SAAM contained the model structure, the experimental data 
under H DAT, initial estimates and limits for the parameters under H PAR, and commands. A 
summary of the more commonly used operational units is presented in Table 4.4. and a sample of 
each type of programme in Appendix 4. 
4.3.11 Determination of plasma and lipoprotein lipid concentrations. 
Samples of plasma, VLDL, IDL, LDL and HDL were analysed for cholesterol and 
triacylglycerol using Boehringer Monotest Cholesterol CHOD-P AP method and Boehringer 
triacylglycerol GPO-PAP method on a centrifugal analyser. 
V ALIDITY OF METHODS 
This section describes evidence for the validity of the investigative procedures. 
4.3.12 Trial iodination and injection of 1251 VLDL into a sheep. 
All aspects of the proposed experiments were assessed by iodinating and injecting 
VLDL into a 25kg wether. This preliminary experiment (Table 4.5) confirmed that many aspects 
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such as blood sampling times were satisfactory but improvements in iodination and purification 
of the tracer and analysis of the sample were needed. Numerous improvements were tested and 
implemented (see 2). They included concentrating the donor lipoprotein, decreasing free label in 
the final preparation by using a larger G50 sephadex column and adding EDT A to the dialysis 
medium, and resolubilizing and assaying apoB with a scaled down Lowry procedure. The 
specific activity of tracer and it's TIll on reinjection were similar to those found in humans. 
Table 4.4. 
SAAM 
Operational 
Unit 
C(i) 
M(i) 
L(iJ) 
R(ij) 
F(i,t) 
U(i) 
T 
QO(i,t) 
QC(i,t) 
IC(i) 
K(i) 
G(i) 
A summary of the more commonly used operational units in SAAM. 
Explanation 
Compartment i of the model 
Steady state mass 
for compartment i 
Fraction of material in 
compartment j that will move to 
compartment i in a unit time 
Steady state flux of material 
from compartment j to 
compartment i 
Model solution value for 
compartment i at the time t 
Rate of entry of new material into 
compartment i from outside 
Independent time variable 
Observed values of qi at 
time t 
Calculated values of qi at time t 
Initial conditions 
Proportionality constant for 
compartment i 
General function defined by an 
equation i 
Related Tracer 
Terminology 
Qi 
Kw· 
~J 
qi(t) 
t 
qi(t) 
qi(O) 
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Table 4 .5: Details and results of Iodination of VLDL for trial injection into a 25kg wether. 
Composition of iodination reaction mixture. 
VLDL protein 
ICi 
1251 
Distribution of label in the final preparation. 
Freel 
TCAppt 
355"g 
22Onmole 
1.213 x 10' cpm 
14.2% 
85.8% 
isopropano!ppt 49% 
Specific activity apoB 1.5449 x 1<r cpmj "g 
Figure 4.4 Specific activity of 125I_apoB in VLDL. IDL and LDL following the injection of 
125I-VLDL (1.68 x1(J6cpm in apoB). 
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4.3.15 Iodination of Sheep Lipoproteins. 
The aim was to produce a tracer to follow the metabolism of lipoproteins in sheep. The 
amount of tracer to be injected should be small so as not to perturb normal lipoprotein 
metabolism, and yet still be measurable in plasma. A tracer with high specific activity is 
therefore required. Inclusion of I must not effect the biological activity or disrupt the nature of 
the particle. 
The studies of Shepard et al. (1976) and Fidge and Poulis (1974) using a variety of 
species, compared different procedures for iodinating lipoproteins and recommended the iodine 
mono chloride method because of its simplicity, low lipid labelling and minimal disruption to the 
lipoprotein particle. Since lipoproteins from different species iodinate differently especially in 
regards to the amount of lipid labelling (Fidge and Poulis, 1974) it is important to assess the 
usefulness of the method when its being applied to new species. 
The present work compared: 
1. iodine mono chloride (lCI) and Iodo-gen methods of radio-iodinating sheep lipoproteins; 
2. iodination of VLDL from two species, sheep and human; and 
3. different aspects of the iodine monochloride method to optimize the conditions for 
iodination. 
a. Comparison of Iodine Monochloride and Iodo-gen methods of Radio-iodinating 
sheep lipoproteins. 
Although ICl is thought to cause less oxidative damage than other methods, the addition 
of carrier iodine means it is difficult to obtain a product of high specific activity. In contrast, 
Iodo-gen; 1,3,4,6-tetrachloro-301-601-diphenylglycoluril (Pierce Chern. Co.) is likely to give 
higher incorporation of radio-iodine but may damage the lipoprotein particles. 
To compare the methods, aliquots of sheep VLDL were iodinated using either leI (see 
3b) or lodo-gen. In the Iodo-gen method, VLDL (0.5 mI) with HC03-buffered saline, pH 7.0 (0.4 
ml) and Na 1251 (200 IlCi) were transferred to vials precoated with 100 Ilg lodo-gen. The reaction 
mixture was occasionally swirled throughout the reaction time. After 15 or 30 min, the reaction 
was stopped by removing the lipoprotein solution. Both ICL- and lodo-gen- iodinated 
lipoproteins were purified using dialysis and ultracentrifugation as described in 4.3.3.b. 
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The results are presented in Table 4.6. The efficiency oflabelling, as determined by the 
TeA precipitable counts in the reaction mixture, was greater for the Iodo-gen method than the leI 
method. However after ultracentrifugation, the TeA precipitable radioactivity decreased in the 
Iodo-gen treated samples, suggesting Iodo-gen had a detrimental effect on the lipoproteins. Not 
only was there a smaller proportion of the label now bound in the VLDL fraction but the 
radioactivity in the infranatant was much higher when Iodo-gen (15%) rather than leI (1.8%) was 
used. Furthermore 68% of the counts in the Iodo-gen infranatant were precipitable by TeA 
suggesting Iodo-gen leads to denaturation of VLDL to smaller, more dense particles. The lodo-
gen treated samples also have a higher proportion of label in the lipid. 
Increasing the Iodo-gen reaction time from 15 to 30 min made little difference to the 
incorporation. It may be that the 15 min incubation time was also too long. 
Although the use of Iodo-gen was not extensively studied by using different 
concentrations, times, pHs etc; the method used showed that Iodo-gen increased the efficiency of 
incorporating label into VLDL but damaged the lipoproteins. Immobilised iodinating systems 
such as Iodo-gen have not been extensively used for lipoproteins although they may be useful 
given the right conditions. As with Chloramine T, the method probably requires stringent 
conditions for successful iodinations. This warrants further investigation. 
b. Optimizing Conditions for Radio-iodination with Iodine Monochloride. 
The efficiency and distribution of label when iodine mono chloride is used depends on 
pH and the concentrations of protein, ICL and radioactive I. 
c. Varying the protein concentration. 
To achieve reasonable iodination, the concentration of VLDL proteins needs to be high. 
Because sheep plasma contains low concentrations of VLDL, it was necessary to increase the 
amount of VLDL collected and concentrate the VLDL. Two methods of increasing the plasma 
VLDL concentration were evaluated. Soya-bean oil was infused intraduodenally at 5ml/h for 16h 
prior to blood collection (Gooden et ai., 1979). This markedly increased the chylomicron sized 
lipoproteins in the plasma illustrating that sheep can produce chylomicron sized particles and 
suggesting the size of the lipoproteins depended on the lipid availability. The increase in the 
concentration of 'VLDL-sized' particles however, was small. The second method, that consisted 
of intravenously injecting Triton WR 1339 (300mg/kg liveweight) to prevent VLDL catabolism, 
Table 4.6. Comparison of Iodine Monochloride and Iodo-gen Methods of Radio-iodinating 
Sheep VLDL at two protein concentrations. 
Reaction 
Method 
Reaction Condition 
Final 1251 VLDL Preparation 
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[prJ 
lAg/ml 
1 Mono-
chloride 429 
2 Iodo-gen 429 
3 Iodo-gen 429 
4 Mono-
chloride 206 
5 Iodo-gen 206 
6 Iodo-gen 206 
time Total TCAI TCAI 
(min) cpm ppt ppt 
E-8 % % 
RMix after 
dialysis 
10 2.14 59.4 
15 2.32 84.8 
30 2.32 85.1 
10 2.35 13.9 95.6 
15 2.74 23.2 
15 2.55 25.9 78.2 
I % counts bound to protein as precipitated by TCA. 
2 % counts bound to apoB as precipitated by isopropanol. 
Total incorp TCAI isop2 
cpm %3 ppt ppt 
E-6 % % 
7.105 2.26 68 34 
10.48 3.09 34 19.0 
5.299 1.38 30 11.3 
2.46 0.95 90.1 35.8 
12.5 0.54 11.8 6.7 
2.43 0.71 80.2 14.65 
3 %incorporation == TCA precipitable activity in final product/activity in reaction mixture x 100. 
lipid 
% 
3.78 
6.2 
12.0 
increased the VLDL concentration in plasma. In both methods the VLDL collected was not 
characteristic of normal VLDL and hence would not be a 'true' tracer. These methods of 
increasing the concentration of VLDL were, therefore, discontinued. 
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Various in vitro methods to concentrate the collected VLDL, namely, centrifugal 
flItration, mini con concentrators (Am icon Corp. MA, USA.) and ultracentrifugation were 
evaluated. The first two methods concentrated the lipoproteins but recovery was low. 
Ultracentrifugation with careful removal of the VLDL fraction with a fine pasteur pipette gave the 
most satisfactory results. Although the loss of small apoproteins during ultracentrifugation has 
been reported, these apoproteins may be replaced by exchange with endogenous lipoproteins on 
reinjection into the animal. 
Iodination with different protein concentrations demonstrated that incorporation of label 
increased as protein increased (e.g. Table 4.6.) Fidge and Poulis (1974) obtained similar results 
with rat VLDL. Unfortunately, although the incorporation increased, the specific activity was not 
increased. In this work, the specific activities obtained for sheep VLDL (0.4-1.4 x 107 cpm/mg) 
were similar to the values for iodinated human VLDL (0.175 - 2.5 x 107 cpm/mg; Sigurdsson et 
al,1975; Reardon et al., 1978; Janus et al., 1980a). The plasma VLDL pool in sheep is small, 
consequently the amount of VLDL reinjected should also be small; this necessitates a high 
specific activity tracer. 
d. Comparison of iodinating sheep and human VLDL and the effect of varying ICI 
concentrations. 
Human VLDL was isolated from plasma from 2 volunteers and iodinated alongside 
sheep VLDL in a series of reactions containing increasing amounts of 10 (11 to 220 nmole) and 
fixed amounts of protein and N a 125I, This allowed the comparison of iodinations using varying 
10 concentrations as well as of sheep and human VLDL. The method used was that described in 
section 3b, except that the dialysis against NaCl/EDTA was overnight. 
The incorporation and distribution of label in the final preparation of sheep and human 
VLDL are presented in Table 4.7. and the results at each stage of the iodination for sheep VLDL 
in Table 4.8. Incorporation of 1251, as measured by TCA precipitation of reaction mixture, ranged 
from 7-14% with the incorporation into sheep VLDL being slightly higher than for human. As 
the amount of 10 increased, the incorporation increased. This incorporation was similar to that 
previously reported for human VLDL (5-20%; Packard et al., 1980 and Janus et al. 1980a) and 
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Table 4.7 Incorporation and distribution of 12SI into sheep and human VLDL. 
REACfION WXTURE FINAL PRODUCf 
ICl TCA %incOrpl distribution oflabel (%) 
# species nmole ppt% free lipid protein apoB2 
1 human 220 8.91 0.90 13.0 1.7 85.3 42.7 
sheep 13.9 .94 12.2 3.8 84.0 35.8 
2 human 44 4.94 0.04 12.2 3.0 84.8 34.7 
sheep 6.6 0.19 14.0 4.0 82.0 26.8 
3 human 22 5.79 0.16 8.7 0.9 90.4 41.8 
sheep 7.7 0.17 47.0 5.2 48.8 16.2 
4 human 11 1.02 0.12 11.3 1.0 87.7 27.3 
sheep 7.5 0.05 22.2 2.7 75.1 18.0 
Reaction mixtures contained 276IJ.g protein and 3.37E8cpm 12SI for human VLDL and 
206IJ.g protein and 2.47E8cpml2SI for sheep VLDL. 
1 %incorp = TCA precipitable cpm/reaction mix cpm x 100. 
2 isopropanol precipitable cpm. 
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Table 4.8: The effects of varying the concentration of ICI on the iodination and purification of 
sheep VLDL. The preparations are compared as reaction mixture, after dialysis and after 
centrifugation. 
ICI (nmole) 220 44 22 11 
Reaction Mix 
VLDL-protein (",g) 206 206 206 206 
1251 (cpm x 10-8) 2.35 1.48 3.09 2.95 
IIP reactants 1 267 53 27 13.3 
Specific Activity 1251 
( x 10-6 cpm/nmole) 1.06 3.36 14.05 26.82 
%cpm TCAppt 13.9 6.6 7.7 7.5 
After Dialysis 
Total cpm (xlO-s) 30.818 4.63 4.09 3.236 
% cpm TCAppt 95.6 91.5 88.6 91.5 
% incorporation2 1.25 0.29 0.12 0.1 
After Centrifugation 
Total cpm (x 10-5) 24.576 3.179 2.972 2.071 
%cpmTCAppt 90.1 89.2 55.7 79.7 
% incorporation 0.94 0.19 0.17 0.05 
IIPproducf 2.51 0.10 0.05 0.01 
umole leI 
1 IIP reactants ::::: l.'IDole protein assuming mol wt 250000 
TCAQQtcQm 
2 % incorporation ::::: Reaction mix counts 
1251 bound x umol leI 
3 Product lIP ::::: 1251 added l.'IDol protein ::: % incorporation x IIP reactants 
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rat VLDL at similar protein concentrations (Fidge and Poulis, 1974; Eisenberg, 1973). The 
incorporation of 1251 into the final preparation of both sheep and human VLDL was inefficient as 
indicated by the small percentage ( < 1 %) incorporation. The difference between incorporation of 
label into reaction mixture and the final VLDL preparation reflects the loss of some VLDL-bound 
activity during purification, free label trapped in the TCA precipitate and radioactivity bound to 
the added albumin. 
In both sheep and human preparations, the radioactivity bound to apoB (isopropanol 
precipitable) represents about one third of the protein bound (TCA-lipid) activity although the 
fraction for sheep (29%) is lower than for human (41 %). The proportion of activity in apoB of 
human VLDL is similar to that previously reported by Reardon et ai. (1978) and Packard et ai. 
(1980). Huff and Telford (1985) found a similar propotion of label bound to apoB in pig VLDL 
(41 %). While in rabbit (Kushwaha and Hazzard, 1978), more than half the protein bound label 
(71 %) is on apoB. 
The percentage of label bound to lipid was low in both sheep (3.7%) and human (1.6%) 
VLDL. Since lipid labelling is related to pH of the reaction mixture (Langer et at., 1972), the low 
lipid incorporation demonstrated that pH 10 was a suitable reaction mixture pH. Substantial 
variations in the proportion of lipid labelling between species has been reported. Fidge and 
Poulis (1974) found low levels of lipid labelling with human VLDL and substantial amounts 
(>30%) with pig and rat VLDL. Sparks et ai. (1983) confirmed high lipid labelling in rat VLDL, 
but Huff and Telford (1985) recorded only 5-12% label in lipid of iodinated pig VLDL. 
Intermediate lipid labelling (17.2%) was reported in rabbit VLDL (Kushwaha and Hazzard, 
1978). The differences in lipid labelling between species may be due to differences in structural 
organization of the lipoproteins and hence the accessibility of the lipids and to the amount of 
unsaturated fatty acids (Fidge and Poulis, 1974). 
The present work showed no relationship between the ICI concentration and the 
proportion of lipid labelling. Fidge and Poulis (1974) found that increasing the lCI concentration 
decreased the label in lipid, although there were some inconsistencies. In contrast, Shepard et at. 
(1976) observed that in human LDL, lipid labelling increased with increasing lIP ratios ie. the 
molar ratio of iodine to protein. 
For sheep VLDL, the distribution oflabel was analysed several days after preparation, 
so the increase in free I (cf. Table 4.7) illustrates the deterioration of the tracer over time. The 
idea that lipoproteins labelled with higher concentrations of I Cl are more fragile is not supported 
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in this work because (1) no more labelled VLDL was lost on centrifugation, (2) the increases in 
free label on centrifugation was greater in samples produced with lower ICI and (3) increases in 
free counts (2-3%) were similar in all preparations on standing. 
Although it is desirable to have the specific activity of the iodinated VLDL (cpm/mg 
protein) as high as possible, non-radioactive I is incorporated along with the radioactive I. 
Consequently, increased incorporation of radioactivity results in increased incorporation oftota! I. 
To maintain biological activity it is generally accepted that the product should contain no more 
than about one atom of I per molecule of protein; although Fidge and Poulis (1974) found similar 
biolOgical activity with 1251 VLDL with I/P varing from 0.5-12. By varying ICI added to the 
reaction mixture, the lIP of the products was varied. Using the relationship between the lIP 
products and reactants, a suitable I/P ratio of reactants and hence amount of ICI in the reaction 
mixture can be selected to give a product with the desired characteristics. In the current work, to 
obtain a lIP ratio in the product of 1, the I/P ratio of the reactants needed to be 70. 
e. Purification of Radio-iodinated Lipoproteins 
The results in Table 4.8 show that dialysis was effective at removing free I although 
prolonged dialysis may have contributed to the loss of radioactivity bound to VLDL after 
ultracentrifugation. Only 60% of the radioactivity was recovered in VLDL, and in each case, 
TCA precipitable activity decreased. One sample (# 3) had an abnormally high amount of free 
label. 
To decrease the dialysis time required, a sephadex G column was tested. Although not 
greatly efficient as seen by TCA precipitation, gel flltration provided a rapid method of removing 
the bulk of the free I from the preparation. This decreased the time lipoproteins were exposed to 
high levels of radio-iodate and hence the likelihood of damage. Dialysis was efficient, provided 
frequent changes of dialysate were made, volumes were large and EDT A was added to the 
dialysate. A balance has to be struck between dialysing for enough time to remove all free I and 
preparing and using the tracer as quickly as possible after first collecting donor plasma. Since the 
specific activity of ApoB was determined, rather than plasma or lipoprotein cpm, total removal of 
free I was not necessary. If, however, additional information is required from analysing the 
cumulative urine radioactivity the amount of free iodine must be accounted for. 
During the final ultracentrifugation spin, particles of density greater than 1.006g/ml that 
may have arisen from denaturation during the iodination and purification procedures are removed. 
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The considerable loss (e.g.Table 4.8) of total radioactivity on ultracentrifugation of VLDL in this 
work indicated that denaturation had occurred and the importance of this purification step. In 
order to confirm that ultracentrifugation did not actually denature the lipoproteins, samples of 
iodinated VLDL and LDL were diluted with plasma and recentrifuged using the same centrifuge 
and conditions as used for samples (see 5). For 1251 VLDL, 76.4% of the counts were recovered 
and these were distributed among the isolated fractions as follows: VLDL 77.3%, IDL 7.0%, 
LDL 3.2%, 'HDL' 12.5%. The label in the 'HDL' fraction represents most of the free tracer in 
the 1251 VLDL preparation (13.5%) and perhaps some exchange of small labelled apoproteins. 
More than 90% of the label in the lower density fractions was isolated as VLDL. For 131 I LDL, 
77.6% of the radioactivity was recovered, and distributed as follows: VLDL 1.6%; IDL 2.2%; 
LDL 87.6% and 'HDL' 8.6%. These results indicate that ultracentrifugation did not cause the 
denaturation observed during purification of the tracer and that the fractions isolated were similar 
regardless of the centrifugation procedure used. 
f. Conclusion of the Iodination of Sheep Lipoproteins. 
The ICL method of McFarlane (1958) with the adaptions described (see 4.3.3) resulted 
in labelled lipoproteins with low free iodide, low lipid labelling and about a third of the protein 
bound counts of VLDL in apoB. The iodination for sheep VLDL was similar to that of human 
VLDL but differed in the distribution of label when compared to iodinated VLDL from other 
mammals. 
4.3.16 Selective precipitation of apoB. 
The choice of isopropanol to separate apoB from other apoproteins was based on 
effectiveness, availability, ease of preparation and cost. The applicability of isopropanol to 
selectively precipitate sheep apoB was determined by dissolving the resultant protein pellet in 
O.OIM NaOH, O.02M DTT, 1 % sodium dodecyl sulphate and electrophoresing on SDS-
polyacrylamide gels (7.5% and 3-20%) (Laemili, 1970). At least 90% of the Commassie blue 
staining protein for VLDL, IDL and LDL was found at the top of the 7.5% gel and only one band 
was visible on the 3-20% gel. 
4.3.17 Protein Assays 
All the protein assays were based on the Folin-Ciocalteu procedure of Lowry et al. 
(1951). To cater for small volumes of samples, a micro-assay with one quarter of the usual 
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volume was used. This allowed a sample volume of up to 250 JJ.1 in a total volume of 1.075 ml. 
The absorbance was read at 750 nm to increase sensitivity. 
The reagents were modified by including sodium dodecyl sulfate in the alkali reagent 
and increasing the concentration of copper sulphate as described by Markwell et al. (1978). This 
adaptation avoided the need for delipidation when measuring lipoprotein fractions. A typical 
standard curve is shown in Figure 4.5. 
When NaOH was included in the standards for assaying apoB after resolubilization, the 
absorbance was markedly depressed (Figure 4.5). This extra alkali could be titrated with HeI to 
give a standard curve that very closely approximated the normal standard curve (Figure 4.5). 
Consistent results were obtained if the HCI was added immediately after the alkali copper 
reagent 
When isopropanol-soluble proteins were prepared, centrifugation was often not 
sufficient to separate all the precipitated protein so the samples were filtered through a small plug 
of glass wool. The isopropanol soluble proteins were assayed by comparison to standards 
containing the same concentration of isopropanol. The presence of isopropanol in the assay 
slightly increased absorbance as shown in Figure 4.6 but did not alter the broad absorbance 
maximum around 700 nm. 
The cross reactivity of sheep apoB with commercial antibodies for human apoB (Sebia. 
France) was assesed in an attempt to fmd a simple, rapid apoB assay suitable for large numbers of 
samples. Sheep apoB did not react. Product information was not available on the source of the 
antibodies. 
4.3.18 Steady State and Homogeneity. 
Strictly speaking steady state occurs when the system is not recovering from 
perturbations and includes constant oscillations (Berman. 1982). For easier kinetics, the system is 
often said to be in steady state when the pool sizes are constant because the rates of entry and exit 
of each pool are equal. In this case the rate constants for the tracer are independent of time. The 
tracee should be homogeneous. In studying apoB kinetics, the lack of homogeneity presents 
further complications which needs to be catered for in the experimental design. The VLDL-IDL-
LDL spectrum is just that. a range of heterogeneous particles. Although the apoB remains with 
the particle, thus providing a useful marker for their metabolism, the environment of the apoB is 
Figure 4.5 
t2 
11 
to 
--- D.I E c 
oo.a 
L() 
r--
'-'" 0.7 
., 
0 o.a c 
0 
.D 
..... Q.5 
0 
., 
.D 0. • 
..: 
C).3 
0.2 
0.1 
0 
0 
Figure 4.6 
t2 
t1 
to 
___ D.I 
E 
c5o.a 
L() 
C 0.7 
., 
01).4 § 
.D 
..... 11.5 
o 
II> 
~ 0.' 
C).3 
0.1 
0 
Effect of NaOH on detennination of protein by the Lowry procedure. 
o 
)( Normal lowry aoooy 
+ additional NoOH 
o oddItiond NoOH ~ HCI 
+ 
I) 20 30 40 50 10 70 10 00 IlO 
Amount of protein (ug) 
Effect of isopropanol on the detennination of protein by the Lowry procedure. 
o )( norma standard a.rve 
O' $-~~ __ ~~-L~ __ ~~~~~~~~ __ ~~~~ __ L-~~ __ 
o ~ ~ » ~ ~ ~ ~ ~ ~ m 
Amount of protein (ug) 
127 
128 
heterogeneous with respect to lipids and other apoproteins. There are also two major sources of 
apoB, the intestines and the liver, and in many animals more than one form of apoB exists; each 
form may potentially exhibit different kinetics. 
Although in kinetic analysis, it is usually assumed the tracee is in steady state 
throughout the trial period, only a few authors (e.g. Huff and Telford, 1985; Janus et at., 1980b) 
actually assessed the validity of this. Many authors have attempted to maintain steady state of the 
lipoproteins and, in particular, control the contribution of intestinal apoB by fasting and/or 
maintaining a dietary regime. These diets have varied in fat content from fat-free to normal fat 
diets. An alternative to limiting the contribution of intestinal apoB (which will work in humans 
and rabbits whose liver only synthesises apoBh,) is to design experiments to study the apoB' s 
individually (Elovson et at., 1982; Sparks et al., 1983). 
a. Feeding regime. 
Because of the time required to empty the rumen and the length of the trial it was 
impractical to starve the lambs. Mamo et al. (1983a,b) reported that fasting increased the plasma 
triacylglycerollevels and, consequently, starving does not constitute a normal steady state. The 
lambs in the present trial were fed maintenance rations (1.3-2kg chaff per day) and had some feed 
available at all times to prevent gorging when food was offered. 
b. Animal Health. 
The general health of the animals was monitored daily with particular attention to food 
and water intakes. In general the animals were well accustomed to the conditions of the trial. 
Introduction of KI at l00mg/dl to the drinking water put all the animals off their food and water. 
The amount was reduced to 15mg/dl. Lamb C had a slight amount of scouring on day 7 of the 
trial. This was overcome quickly with a sprinkle of bicarbonate on the chaff. 
c. Assessment of Steady State. 
All animals' bodyweights remained within 5 % of their pretrial weights. Blood packed 
cell volumes and plasma concentrations of triacylglycerol and cholesterol were monitored (Figure 
4.7 a-d). The amounts ofVLDL-B, IDL-B and LDL-B isolated during the determination of 
specific activities are also shown. Results were averaged for each animal and are presented with 
standard deviation in Table 4.9. Small variations in the plasma triacylglycerol and cholesterol 
Figure 4.7 a-d Measurement of parameters to assess stability of steady state. Plasma 
triacy1glycerol and cholesterol concentrations, packed cell volumes and apoB 
isolated for detennination of specific activity in blood samples taken after the 
injection of 12S1 VLDL and 1311 LDL into lambs A. B. C and D. 
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Figure 4.7 C. 
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Table 8.9: Steady State Parameters. Mean (SD) of plasma triacylglycerol and 
cholesterol(mM), packed cell volumes(%) and the amount of apoB isolated from 
VLDL, IDL and LDL in samples taken following the injection of labelled VLDL 
andLDL. 
Plasma Concentration Packed cell Amount ApoB Isolated 
of volume from 
Triacy 19l ycerol Cholesterol VLDL-B IDL-B LDL-B 
(mM) (mM) (%) (lLg) 
A 0.17 1.46 26.14 32.9 45.6 89.6 
(0.01) (0.02) (0.49) (12.9) (25.4) (17.1) 
B 0.07 0.52 30.93 27.11 22.4 43.69 
(0.01) (0.07) (0.48) (15.56) (20.22) (14.03) 
C 0.16 1.16 29.57 52.5 43.8 76.9 
(0.03) (0.02) (0.58) (50.8) (22.3) (30.2) 
D 0.12 1.03 26.41 18.6 8.6 74.1 
(0.01) (0.02) (0.81) (5.4) (4.7) (43.9) 
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were seen in all lambs though no significant trends were seen apart from in lamb B where plasma 
cholesterol and triacylglycerol dropped at the beginning of the trial and subsequently recovered to 
normal levels. Similarly the packed cell volume showed small but random variations about the 
mean. The apoB results are more scattered. Although a consistent procedure was used 
throughout their preparation, no specific care was taken to ensure 100% recovery or to estimate 
the consistency of recovery, since this was not important in specific activity determinations. 
Some of the variation in the apoB amounts may be attributed to losses in the prolonged isolation 
and assay procedures. The differences seem to be random rather than suggesting an increasing or 
decreasing pool size. Assessment of the amount and composition of VLDL, IDL or LDL was not 
made as all the collected lipoprotein was required for estimation of apoB specific activity. 
Since systematic variations in these parameters were not observed, the system was 
assumed to be in steady state. 
d.Homogenelty. 
There are several points to consider when assessing the homogeneity of the fractions 
and apoprotein B. Although VLDL was isolated as d<1.oo6g1ml, no chylomicrons were 
detectable in sheep plasma so this larger density range effectively collected VLDL. The VLDL 
density range will include intestinally synthesised lipoproteins but feeding maintenance rations 
rather than growth or fattening rations probably reduced the intestinal synthesis of lipoproteins. 
On SDS-PAGE (7.5%,3-20%) only one form ofapoB was detectable in VLDL, IDL and LDL 
(comigrating with human VLDL-B). Similarly Forte et al. (1983) observed only one apoB 
component in lower density lipoproteins (d<1.063 glml) with a molecular weight similar to 
human apoB IOO' The similarity in molecular weights of apoB in sheep and human VLDL was also 
supported by Mamo (1986) although he considered everything greater than 65000 daltons as apoB 
and said they were degraded by the preparation procedures. 
It is also assumed that, although VLDL-B and LDL-B may be heterogenous with 
respect to the lipid and apoprotein environment within the lipoprotein. all possible subpopulations 
were isolated and labelled. The radioactivity injected was assumed to be proportional to the mass 
of apoB in each subpopulation. 
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4.4 RESULTS AND PRELIMINARY DISCUSSION. 
The results presented here are those obtained from the turnover studies of 1251 VLDL-B and 
131J LDL-B in 4 lambs. 
4.4.1 Plasma Lipid and Lipoprotein Composition. 
Plasma triacylglycerol and cholesterol concentrations and the composition of the 
lipoprotein fractions isolated from pre-trial plasma are in Table 4.10. The plasma concentrations 
oftriacylglycerol and cholesterol averaged 0.11 ± 0.02 mmole litre-1 and 1.21 ± 0.2 mmole litre-1 
respectively. Most of the triacylglycerol recovered was found in the VLDL fraction. LDL and 
'HDL' (d> 1.063g/ml) contained very little triacylg1ycerol. Total cholesterol was distributed more 
evenly between the 'HDL' and LDL fractions. VLDL carried very little cholesterol. Lamb B had 
low plasma concentrations of both triacylglycerol and cholesterol. 
The amount of protein associated with each isolated lipoprotein class increased with 
increasing density (Table 4.10) with LDL protein (148 ± 12 Itg/ml) being more than double 
VLDL and IDL protein (60.6 ± 6.1 Itg/ml and 74.5 ± 10.2 Itg/ml) respectively. The plasma 
concentrations ofVLDL-B, IDL-B and LDL-B were 37±4, 47±6 and 113±9 Itg/ml respectively. 
ApoB comprised 61 % of the VLDL protein, 63% IDL protein and 76% LDL protein. Protein and 
apoB concentrations were not measured in 'HDL' but PAGE ofHDL apoproteins revealed no 
significant apoB. 
4.4.2 Fate of 1251. 
Following the injection of 1251_ VLDL, plasma was sampled with time, the lipoprotein 
fractions were isolated and the total 125I-radioactivity in each fraction determined. The results 
from lamb D are presented in Figure 4.8. The radioactivity in the VLDL fraction showed an 
initial plateau followed by a rapid loss of activity as VLDL was metabolised. This decline 
represents the loss of the small apoproteins, the removal of lipid, and finally the movement of the 
remaining particle into a higher density fraction. IDL radioactivity increased almost immediately, 
representing a combination of (1) exchange of small apoproteins and perhaps lipids between 
VLDL and IDL, and (2) labelled particles entering this density range following the catabolism of 
VLDL by LPL. The radioactivity in IDL reached a maximum then declined as the IDL particles 
were catabolised. There was a slight delay in the appearance of radioactivity in LDL, after which 
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Table 4.10: Plasma lipids and lipoprotein composition. 
Lamb Triacylglycerol Cholesterol Protein ApoB 
# mmol/l mmol/l JLg/ml JLg/ml 
VLDL 
A 0.06 s 73.9 45 
B 0.015 s 49.4 30 
C 0.045 s 51.1 31 
~ -- -' . -' --".' -'--' D 0.045 s 67.8 41 
mean ± SE 0.041 ±0.009 60.6 ±6.09 37±4 
IDL 
A 0.03 0.006 93.4 59 
B s s 53.2 34 
C 0.024 s 90.3 57 
D 0.012 s 61.0 38 
mean ± SE 0.022±0.005 74.5±1O.2 47±6 
LDL 
A s 0.498 166.5 126 
B s 0.137 119.0 90 
C s 0.313 139.1 106 
D s 0.176 168.7 128 
mean ± SE 0.281 ±0.082 148.3±11.9 113±9 
HDL 
A s 0.508 
B s 0.235 
C s 0.391 
D s 0.352 
mean ± SE 0.371±0.06 
PLASMA 
A 0.17 1.61 
B 0.06 0.64 
C 0.11 1.54 
D 0.11 1.06 
mean ± SE 0.11±0.02 1.21 to.2 
S = insignificant 
Figure 4.8 IlSI radioactivity in VLDL, IDL, LDL and 'HDL' following the injection of IlSI_ 
labelled VLDL into lamb D. 
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the label increased more slowly to reach a maximum after 14 hrs. The subsequent decline in LDL 
radioactivity was slow. 
125I-activity appeared very rapidly in the HDL fraction. Since care was taken to inject 1251 
only in association with lipoproteins d<1.006 and since apoB did not exchange with, nor was it 
metabolised to, HDL (as the 1311 results illustrate later), the rapid appearance of 131I-activity in 
HDL represents the rapid exchange of small apoproteins between VLDL and HDL. Since 'HOL' 
was collected as plasma minus the lower density lipoproteins, HDL will also contain any free 1251. 
Eventually, the radioactivity from catabolised lipoproteins was recovered in the urine (Figure 
4.13). 
The appearance of label from 1251 VLDL in all the lipoprotein fractions illustrates the close 
relationships between the different lipoprotein classes. 
4.4.3 VLDL-apoB Metabolism. 
The total radioactivity in each lipoprotein fraction is a poor indicator of metabolic events 
because of the heterogeneous nature of the label. However, since apoB remains with the 
lipoprotein particle throughout its metabolism, apoB can be used to study the relationships 
between lipoprotein particles. In this study, apoB was separated from other apolipoproteins and 
lipids in each fraction by isopropanol precipitation. Specific activity was determined by 
measuring the radioactivity and protein in the redissolved apoB precipitate. 
4.4.3.1 Fate of apoB. 
ApoB specific activity - time curves (Figure 4.9 a-d) were constructed to investigate the 
precursor-product relationships between VLDL-B, IDL-B and LDL-B. The best-fitting curves 
were constructed visually by an independent artist to give the maximi and intersection times. 
Following the injection of 1251 VLDL, there was a rapid decline in the specific activity of 
VLDL-B with most of the activity disappearing by 48 hours. A precursor-product relationship 
was suggested by the subsequent appearance of 125I-apoB in IDL-B and then LDL-B. The 
specific activity of apoB in IDL reached a maximum at 2 h then declined at a rate similar to 
VLDL-B. The apoB specific activity in LDL was slower to reach a maximum (13.5 h) and 
declined more slowly than both IDL-B and VLDL-B. The times of maximum specific activities 
Figure 4.9: Specific activity of 125 I-apOB in VLDL. IDL and LDL with time following the 
injection of 12> 1-VLDL into four lambs. 
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Figure 4.9 continued 
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(Table 4.11) must be considered as estimates because of the limited number of time points and the 
variability of the results. 
4.4.3.2. Extent of precursor-product relationships 
The extent of this precursor-product relationship was further investigated using the specific 
activity-time curves using the criteria described by Zilversmit (1960) (see 4.3.9). If one fraction 
is derived solely from the precursor fraction, the specific activity of that fraction will reach a 
maximum at the time it crosses the precursor specific activity curve. 
In lambs A, B and C, the maximum specific activity of IDL-B occurred after this curve 
crossed the VLDL specific activity curve (Figure 4.9). This is consistent with VLDL-B being the 
exclusive precursor of IDL-B. Although the maximum specific activity of the product should be 
equal to or less than the specific activity of the precursor, curves such as this have been observed 
in rats (Fidge and Poulis, 1974, 1978). rabbits (Ghiselli. 1982) and humans (Janus et al., 1980a.b) 
and may be due to small amounts of label entering the plasma already in the IDL density range, 
heterogeneity in circulating IDL and LDL or a delay in lipoprotein conversion relating to the 
lipolytic mechanisms (Bennan et al., 1978). 
The specific activity of IDL-B in lamb D was always lower than the specific activity of 
VLDL-B suggesting there may be an alternative source ofIDL-B other than VLDL-B. The 
relative contribution of VLDL-derived apoB was calculated from the ratio of the specific activity 
of IDL-B at its maximum to the specific activity of VLDL-B at that time. For lamb D, 64-90% of 
the IDL turnover was derived from VLDL-B. 
The LDL-B specific activity curves (Figure 4.9 c,d) for lambs C and D reached their 
maximum after crossing the IDL-B specific activity curve while in lamb A the maximum LDL-B 
specific activity occurred before intersection with the IDL-B curve. Using the Zilversmit ratio, 
the fraction of LDL-B derived from IDL-B was 90% for lamb A. The results from lamb B are 
inconclusive but most ofLDL-B is probably derived from VLDL. Because of the limited number 
of time points the maximi can only be considered as estimates so the proportions of the product 
synthesised from its precursor are also estimates. Most of the LDL-B was derived from IDL-B 
and most IDL-B was derived from VLDL-B. 
The contributions to IDL-B and LDL-B flux from sources other than VLDL-B and IDL-B 
catabolism, respectively, were estimated by a second method described by Goldberg et al.(1983) 
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Table 4.11: Parameters derived from the graphs (Figure 4.9) of specific activity of apoB 
versus time following the injection of 1251 VLDL. 
Time to peak 
IDL specific 
Lamb Activity 
(h) 
A 2.75 
B 2.5 
c 1.75 
D 1.5 
Mean 2.13 ::1:0.03 
::I: sem 
Time to Peak 
LDL specific 
Activity 
(h) 
6.5 
15 
10.5 
22 
13.5 ::1:3.3 
1 Ratio of the areas under the specific activity curves. 
Area SAIDL1 
Area SAVLDL 
0.95 
0.89 
0.42 
0.75 ::1:0.17 
Area SATDL 
Area SAIDL 
1.22 
0.61 
1.29 
0.66 
0.94::1:0.18 
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and Le et al.(1986) (see 4.3.9a). If all the flux through the IDL-B pool was entirely derived from 
VLDL-B, the ratio of areas under the specific activity curves for IDL-B and VLDL-B should 
equal 1. If there was a direct input into IDL-B, other than from VLDL-B, the ratio of these areas 
would be less than 1. This method does not rely on the estimate of the maximum specific activity 
but uses the entire curve. The results from comparing the areas under the specific activity curves 
are presented in Table 4.11. 
Lambs A and B showed most (89-95%) of the IDL-B may have come from VLDL. In 
lamb D, 46% of the IDL-B originated from VLDL. Both lambs Band D, showed that 60% of 
LDL-B was derived from IDL-B. For lambs A and C, the ratios of LDL area to IDL area was 
greater than 1 which is not theoretically possible but could result if 1251 apoB from VLDL was 
transferred directly to LDL or passed rapidly through IDL and hence was not seen. This analysis 
is based on the assumption of a simple precursor/product relationship and this may not be valid. 
Le et al. (1986) reported that in most apoB turnover studies, the ratios of AIDJAVWL were greater 
than 1 (1-4.5) and suggested two possibile explanations: 1. Some of the label injected was in 
IDL. If this was correct, the ratio of areas should be proportional to the label in IDL but usually 
the amount of label in IDL is insufficent to account for the high ratio. 2. ApoB within VLDL is 
heterogeneous. For example, if VLDL is characterised by a series of pools (cascade process or 
delipidation steps) then the area of the IDL-B specific activity curve will be greater than the entire 
area for VLDL-B. 
The results, summarised in Table 4.12, show that most IDL-B originates from VLDL-B 
and most LDL-B is derived from IDL-B. Since apoB is indicative of the whole particle, the 
results also show most IDL is derived from VLDLand most LDL originates from IDL. 
4.4.3.3 Kinetics of VLDL-B Metabolism. 
The kinetic parameters of VLDL-B metabolism were calculated from the decline in log 
specific activity of 125I-apoB with time (Figure 4.10). In all the lambs, the decline could be 
explained adequately by a monoexponential equation. The log-linear regression analyses were 
significant at p<0.01. The curve was linear for at least 3 half-lives. This may have been 
responsible for the slight under-estimation of the turnover. 
The half-lives (Tlfl), fractional catabolic rates (FCR), and turnover rates are presented in 
Table 4.13. The mean half-life for VLDL-B turnover in the lambs was 8.55 ± 0.94 h and is 
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Table 4.12: Summary of evidence of sole precursor of IDL-B and LDL-B. The percentage of 
IDL-B and LDL-B derived from VLDL-B and IDL-B respectively, as calculated 
from specific activity versus time curves using the crossover method of Zilversmit 
(1960) and the ratio of areas under the specific activity curve method of Le et at. 
(1986) (see 4.3.9.a) 
Lamb From crossover analysis From area of SA curves 
IDL LDL IDL LDL 
A 100 90 95 >100 
B 100 >90 90 60 
C 100 100 >100 
D 79-90% 100 45 60 
Table 4.13: Kinetic parameters for VLDL-B metabolism 
Mean 
Lamb Weight 
(kg) 
A 28.4 
B 28.1 
C 27.4 
D 26.4 
Mean 27.6 
± sem 0.4 
4.5% bodyweight 
Plasma 
Volume1 
(ml) 
1276 
1265 
1231 
1188 
1240 
20 
Plasma 
[VLDL-B] 
(ILglml) 
45 
30 
31 
41 
37 
4 
(h) 
5.89 
10.00 
8.53 
9.77 
8.55 
0.94 
FCR 
0.1177 
0.0693 
0.0813 
0.0709 
0.0848 
0.0113 
ApoB 
Turnover 
(mg/D/kg) 
5.71 
2.25 
2.72 
3.14 
3.45 
0.77 
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Figure 4.10 Specific activities of "'I-apoB in VLDL and "'I-ap08 in LDL 
following injection of "'I-VLDL and "'I-LDL into lambs. 
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4.4.4 Fate of 1311. 
Figure 4.11 illustrates the distribution of 1311 in lipoproteins following the injection of 
1311 LDL. Radioactivity in LDL declined with time but very little appeared in VLDL, IDL and 
HDL suggesting that little exchange occurred between LDL and the other lipoprotein fractions 
and that LDL leaves the plasma directly. 
4.4.5 LDL-apoB Metabolism. 
4.4.5.1Kinetics of LDL-B Metabolism. 
The kinetics of LDL-B metabolism were calculated from the specific activity data 
(Figure 4.12 a.b). The data were fitted by mono and bi-exponential equations since visual 
assessment suggested lambs B and D may require an additional component. The parameters 
describing both fits are in Table 4.14. The two pools in lambs A and C are not the same as those 
in lambs B and D. There appears to be evidence for 3 pools although this was not demonstrated 
in anyone lamb. Lambs B and D had a small (less than one half-life) fast-turning over pool. This 
pool was not seen in lambs A and C where sampling was less frequent in the early period. 
Marcel et al. (1978) and Sniderman et al. (1975) noted a similar pool with a half-life of 
1-4 h in swine and suggested the pool represented an equilibrium phase with liver LDL-B since it 
disappears in hepatectomized swine. They discounted the idea that the pool represented 
denatured or damaged lipoproteins. Whether the fast turnover pool is real or due to damaged 
particles is difficult to assess. Assessment relies on careful preparation of a biologically active 
tracer and using a combination of other labels and techniques. The idea of biologically screening 
a tracer by injecting the tracer into an intermediate animal originated from the desire to remove 
any denatured material prior to kinetic studies. This may help to confirm whether there is an 
equilibrium with liver LDL-B but the procedure is fraught with difficulties, because (1) on re-
isolation some labelled LDL may be damaged or (2) if LDL is not homogenous and contains a 
discrete fast turning over pool which after screening and re-injection is no longer labelled. 
Indeed, we know that LDL is not homogeneous and that kinetic studies can distinguish between 
LDL1, LDL2 and LDL3 in terms of origin, rate of catabolism and fate of the particles (Fidge and 
Poulis, 1978). 
The fast turnover pool identified in this work has generally not been seen in human 
studies probably because in humans the sampling times are less frequent as in lambs A and C. 
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Figure 4.12. Specific activities of '''I apoS and "'I apoS in LDL 
following the simultaneous injection of "'I VLDL and "'I LDL 
into four lambs. Lambs A and C illustrate the relationship between 
total LDL and LDL derived from VLDL. 
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Figlre 4.12b Specific activity of '''I apoS in LDL foHowing the injection of "'I LDL. 
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Table 4.l4:Parameters (standard deviation) derived from fitting a. one exponential (log-linear 
regression using least squares log SA=I-St) or b. two exponentials (using curve peeling and 
SAAM SA=I1.e-Sl t + Iz.e-S2t) for LDL 1311_B specific activity data. 
(a). 
Lamb S I RZ 
A 0.01260 1.7394 0.99 
(0.00033) (0.0157) 
B 0.0246 2.008 0.80 
(0.0038) (0.051) 
C 0.01499 1.8210 0.99 
(0.00052) (0.0277) 
D 0.01832 1.8392 0.95 
(0.00156) (0.0197) 
(b). 
Lamb Sl Sz 11 Iz 
A 0.035 0.013 53 4 
(0.022) (0.060) (59) (60) 
B 0.272 0.0050 99 27 
(0.053) (0.0154) (36) (42) 
C 0.032 0.0346 20 41 
(0.045) (0.0099) (115) (114) 
D 0.267 0.043 66 2 
(1.011) (0.013) (24) (22) 
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The second pool in lambs A and C represents the tail of the decay curve but there were 
insufficient data points for it to be well defmed. It was not seen in lambs B and D because LDL 
was not isolated after 30 h due to freighting difficulties with centrifuge tubes. The tailing of the 
LDL decay curve has been documented in other animals (Langer et al., 1972; Huff and Telford, 
1985) and has a much longer half-life. If it is not included in the calculations there is a tendency 
to over-estimate LDL turnover. 
In this work, the pool that is 'common' to all 4 lambs has a mean half life of 21.7 h and 
accounts for 90% of the activity loss in lambs A and C, and greater than 50 % of the loss in lambs 
B andD. 
Significance of Different Fits. 
Although there appears to be evidence for 3 pools in ovine LDL metabolism, the 
inclusion of a second exponential to explain the decay curves for the lambs in this work does not 
improve the fit significantly, as assessed by errors of the parameters and the F-test. Since there is 
no direct evidence that the fast turnover pool in lambs B and D are due to denatured material, 
these points were included in the calculations of the lines of best fit. This made little difference to 
the FCR in lamb D (3%) but the effed was more marked in lamb B (50%). 
The FCR (Table 4.15) of LDL-B ranged from 0.0290 to 0'0567 h- I and averaged 
0'04058 ::I: 001202 h· t • The average turnover of LDL-B was 4.810 :I: 1.017 mg/d/kg. 
Table 4.15: Kinetic parameters for LDL-B metabolism calculated from specific activity of 
LDL-13II-B following the injection of 1311 - LDL. 
Lamb tIn FCR Turnover rate 
(h) (h.I) (mg/d) (mg/d/kg) 
A 23.88 .0290 111.9 3.94 
B 12.2 .0567 155.6 5.54 
C 20.08 .0345 107.7 3.93 
D 16.45 .0421 153.9 5.83 
____________________________________________________ m _________ Q _________________________________________________________ 
Mean 18.15 .04058 132.3 4.810 
:l:SD 5.00 .01202 26.0 1.017 
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4.4.6. Excretion of radioactivity in urine. 
The excretion of radioactive iodine during the trial is shown in figure 4.13 a-d as the 
cumulative 125I and 131I cpm in urine for each lamb. In each case, the total urinary activity 
reached a plateau and no further radioactivity was excreted. Table 4.16 shows the parameters for 
fitting a curve Y = A x (1 - exp(-Lx t») to the data. The plateau value (A) represents the total units 
excreted. The stability of this plateau is shown by the SEM. Lamb A still appears to be 
excreting a small amount of label but this may be a function of the curve fit. The proportion of 
the dose recovered in urine was variable and in no animal was this near 100%. In each lamb, the 
recovery of 125I was higher than that of 131 I. The rate constants (L), are a function of the time 
taken to reach a plateau and are measures of the rate of excretion of radioactivity. The excretion 
rates vary between animals. Lamb A had the lowest rate (0.005 h-1), lamb C intermediate and 
lambs B and D were similar and much higher (0.016 h-1). 
The iodinated lipoprotein preparations contain free iodine, iodine bound to lipid and 
iodine bound to protein. Following the catabolism of the lipoprotein particle, and hydrolysis of 
the apoproteins, free radioactive iodine enters the plasma. The thyroid avidly takes up iodine but 
if sufficient cold I is given, the majority of the radioactive iodine is excreted in urine. The results 
indicate that, following the injection of 125I VLDL and 131I LDL, radioactive iodine was excreted 
in urine. After 300 h very little further iodine was excreted. The proportion of the injected dose 
recovered in urine was variable and does not account for 100% of the dose. There were several 
difficulties associated with obtaining these measurements. Firstly the concentration of K.I given 
in the drinking water had to be reduced, compared to other species, for the sheep to drink and eat. 
This amount of iodine was probably insufficient to block the thyroid uptake of radioactive iodine 
and hence the urine radioactivity may not represent the total removal of plasma free iodine. On 
several occasions the metabolism crates were not effective in collecting all the urine since slight 
spillages occurred. On other occasions, the urine and faeces were not separated, the urine had to 
be decanted and, consequently, urinary radioactivity may have been lost on removal of the faeces. 
The activity bound to lipid may remain in the body but this would, at the most, account for a 
small proportion of the dose. 
The higher recovery of 125I than 1311 suggests that VLDL 125I is converted directly to free 
iodine rather than through LDL. This assumes that thyroid uptake of iodine is blocked or that 
there is no discrimination between 125I and 1311. An extended urinary collection period to ensure 
complete recovery of the isotopes may resolve whether the differences are due to difference in 
VLDL and LDL metabolism or differences in the thyroid uptake of 1311 or 1251. 
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If thyroid uptake is blocked, and urinary excretion of iodine is efficient (after the initial 
removal of free iodine introduced with the tracer), the rate constants provide a measure of the 
metabolism oflabelled lipoprotein. The large variation between lambs may indicate the 
differences in completeness of the thyroid block. Lambs B and D were given KI for several 
additional days before they were injected with the tracer. The higher rate of excretion of labels in 
these lambs may indicate more complete blockiing of the thyroid. For each lamb, the rate 
constants for the excretion of 1251 and 1311 are similar suggesting the fmal metabolism may be the 
same. If all VLDL was catabolised through LDL, the rates would be the same; while if all 
VLDL was catabolised independently of LDL, the rates would vary according to the metabolism 
of VLDL and LDL. If some VLDL is catabolised to LDL and a portion directly catabolised, the 
excretion rates may also be expected to differ but the sensitivity of using urinary excretion to 
determine this would depend on the proportion of VLDL being directly catabolised. 
Table 4.16: Cumulative Radioactivity in Urine: Parameters from Fitting the Curve 
Y=Ax(l-e(Lxt» 
Lamb Isotope A±SEM % Dose L±SEM 
A 125 4.444±0.742E6 62 0.0045 :1:0.0015 
131 2.810±0.334E6 21 0.0047±0.0012 
B 125 2.625 :l:0.0511E6 60 0.0176:1:0.00151 
131 8.312±0.088E6 56 0.0152±0.0006 
C 125 2.940±0.184E6 43 0.0083 ±0.0016 
131 2.391 ±0.087E6 18 0.0089:1:0.001 
D 125 1. 190±0.01OE6 29 0.0197:1:0.008 
131 3.443:1:0.063E6 25 0.0147±0.001 
lS5a 
Figure 4.13 The cumulative radioactivity in urine with time following the 
simlJtaneaus injection of "'1 VLDL and '''I LDL into lambs A. B. C ond D, 
LAMB A 
~ 3.S • E 
a. 
() 
G , 
3.D ~ 
X 
~ 
., 
c u 
'C 
::J 0 0 
,!;; 0 p-o 
>'2.0 0 
..----
~ 
'> ~ ~ / 
<> 
. / 0 \.5 0 
'6 
0 
.... 0 
., 
U> > 
~ 0 
'
20
1 0 :; 
E 
::J 
rus 
• 
0 "'I 
u 0 
0 ,., 200 200 JOO 400 
TIME (hours) 
LAMB C 
~ UI E • 
a. UI () 
G 2.4 , 
~ 0 
x 2.2 ~ 
'-' 
., 2.0 
,!;; 
• .... 
'" ::J 
0 
,!;; 
'" >. 0 
~ t4 
'> ~ 12 
<J 
0 
0 U> 
'6 
'
20
1 0 ~ .... 
., 
~ 0 "'I > 
~ 
0 0.. 
:; 
0 E D.2 
::J 
U 0 
0 ,., 200 200 JOO 400 
TIME (hours) 
155b 
Figure 4.13 continued. 
LAMB B 
........ [eo 
0 
" 
, 
0 711 ~ 
X 
'-' 
11> eo c 
.;: 
::> 0 
.f; !!O 
>. 
~ 
.> 
:;::; 
40 • '25, 0 
0 1311 0 0 
'0 
0 30 
"-
11> 
> 
• :;::; ~ 0 20 :; E ::> U 10 
0 !!O 100 .., 200 300 
TIME (hours) 
LAMB D 
........ 34 0 
[32 0 
0 
" 
30 , 
0 
~ 2lI x 
'-' 
11> 2lI 
C 
.~ 2' 0 
.f; 22 
~2O 0 13'1 
.> ,. :;::; 
0 
• '2', 0 ,. 0 
'0 ,. 
0 
"-
11> 12 • • 
> /' :;::; 10 0 :; • E ::> • U 
, 
0 50 100 .., 200 
TIME (hours) 
156 
4.5 DISCUSSION. 
This thesis describes for the first time the in vivo metabolism of lipoproteins in sheep 
using iodinated lipoproteins. The lipoprotein system is characterized by describing the 
relationships between lipoprotein fractions. The methods used to indicate direct synthesis of 
lipoproteins are critically assessed. The kinetics of VLDL-B and LDL-B are described and 
compared to those reported in other animals. The implications of the kinetic data on the role of 
lipoprotein metabolism in sheep are discussed. Finally, sheep plasma apoB concentrations are 
reported and compared to other species. 
4.5.1 Characteristics of the sheep lipoprotein system. 
The results of this thesis show that the relationships between VLDL, IDL and LDL in 
sheep are similar to those found in other animals. VLDL-B is catabolised to IDL-B and 
subsequently to LDL-B. On investigation of the stringency of these conversions, using the 
methods of Zilversmit (1960), Goldberg et at. (1983) and Le et al. (1986), most of the IDL-B was 
derived from VLDL-B and most of the LDL-B from IDL-B. The latter method suggests that up 
to 40% ofLDL-B is synthesised independently in 2 lambs. Further, comparisons ofVLDL-B 
and LDL-B turnover rates also indicate that some LDL may be synthesised independently of 
VLDL to account for the higher turnover ofLDL-B. 
Although in normal humans all the LDL-B may be derived from VLDL-B (Reardon et 
at., 1978; Sirgurdsson et al., 1975; Janus et al., 1980) direct synthesis ofIDL-B (Reardon et al., 
1982b) and LDL-B (Soutar et al., 1977) have been demonstrated in hyperlipidaemic patients. In 
animal systems, independent synthesis ofLDL-B is common but varies in extent between species. 
For example. 14% of LDL-B is synthesised independently of VLDL in the squirrel monkey 
(Illingworth. 1975),50-76% in the cynomologous monkey (Goldberg et at., 1983), greater than 
80% in the miniature pig (Huff and Telford, 1985) and as much as 85-94% of LDL is synthesised 
directly in rats l (Fidge and Poulis, 1978). The current findings suggest that in sheep the 
proportion of LDL independently synthesised in sheep is similar to that observed in the squirrel 
monkey but much lower than that found in rats and pigs. Interestingly the squirrel monkey also 
has very low plasma VLDL concentrations. 
1/ This calculation is based on total apoB. 
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4.5.2 Direct synthesis? 
The majority of evidence for direct synthesis of lipoproteins other than VLDL has been 
based on lipoprotein kinetic studies. However, interpretation of data as indicating direct or 
independent synthesis, must be made with care as a number of factors and assumptions impinge 
on the validity of the interpretation. Furthermore, it is always difficult to know whether 'direct 
synthesis' actually reflects real physiological pathways in the body. A number of the factors 
which influence the interpretation of data as direct synthesis are outlined below along with some 
tentative evidence of direct synthesis from physiological studies. 
One very important factor, especially when making comparisons between species, is the 
definition of each lipoprotein fraction. The importance of selecting the limiting density was 
emphasised by Reardon and Steiner (1982) who showed that by redefining the limiting density, 
studies that had demonstrated independent synthesis of IDL could then be interpreted as justifing 
a sole precursor-product relationship. The basic difficulty is that lipoproteins consist of a 
spectrum of particles differing in size and composition. It seems unrealistic to expect the body to 
produce particles of a discrete density. Indeed, we know that lipoproteins are synthesised in a 
variety of sizes differing in lipid composition. The diagram below illustrates this particular 
problem. If a continuum of particles are synthesized, as indicated by the arrows, then choosing a 
density of 1.006g/ml as the lowest density ofIDL, IDL would apparently be synthesised directly. 
In contrast, selecting a density of 1.008 would not support this conclusion. 
1.006 1.008 1.01 (g/ml) 
Given that the profiles of lipoproteins, as indicated by analytical ultracentrifugation, 
differ between species, then defining the densities of lipoproteins in any particular animal system 
is extremely important In some animal studies, the limiting densities used for isolating human 
lipoproteins have been used without checking their suitability for the species in question. Leat et 
al. (1976) showed, however, that in sheep the density prOfile of lipoproteins was similar to that in 
humans and that the limiting densities were acceptable. Similar observations have been made in 
this laboratory. It should be emphasised, however, that although the limiting densities were 
acceptable on analytical ultracentrifugation they were not evaluated kinetically. 
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Another factor is that 'direct synthesis' of a lipoprotein could arise if there is a fast-
turnover pool that is not labelled by the exogenous tracer. Such a pool would not be seen as a 
plasma precursor pool. This is most likely to occur if the pool size is small. Alternatively a 
proportion of nascent VLDL could be converted to LDL particles after secretion but prior to 
entering the circulation ie. VLDL is synthesised but actually enters the plasma as LDL. An 
example of this may be the 'newly synthesised' LDL-like particles released from the perfused pig 
liver as reported by Nakaya et at. (1977). 
Further factors include the ability of the experimental system to fulfil the criteria on 
which these interpretations are made. The descriptions of product-precursor relationships by 
Zilversmit (1960) and applied to ApoB by Reardon (1982), require the following four general 
criteria to be met: 
1. The system must be 'open' so radioactivity is continually lost from the system by 
dilution with unlabelled tracer and by excretion. 
2. The system is in steady state so inflow equals outflow. 
3. The turnover rates of precursor and product must remain constant. 
4. Random metabolism must prevail ie. the tracer and tracee must be random in terms 
of their likelihood to be converted to the product and the product must be random 
in its ability to be metabolised by any pathway ie. it must be metabolised 
independently of its origin or length of time in the pool. 
Observations in this work and from the literature, that suggest each of the 
above criteria were being met are: 
1. The radioactivity in plasma decreased with time indicating the system is 'open'. 
2. Estimates of body weight, packed cell volumes and plasma concentrations of 
triacylglycerol and cholesterol, during the turnover study, showed that although 
variable, there were no trends (see 4.3). This suggests the system is probably in 
steady state. 
3. In the ruminant, the rumen acts as a buffer and smooths out the availability of 
metabolites. It is assumed therefore, that, at least over the initial period, the 
turnover rates are reasonably constant It is difficult to see, however, that over the 
10 day trial period that this assumption would continue to apply. 
4. The parallelism of the specific activities of 1251 and 1311 LDL (Figure 4.12) suggests 
that LDL is homogeneous in that 1251 LDL produced from VLDL was metabolised 
in a similar manner to injected 1311 LDL. 
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It is this fourth criteria of random metabolism that complicates the estimation of 
precursor-product relationships by the Zilversmit and, indeed, the Le et at. methods. Both 
methods are based on a simple system of one precursor and one product pool. Clearly, the 
heterogeneity of apoB within VLDL and LDL, whether it be the physical form of apoB, the 
environment of apoB within the lipoprotein or the likely fate of the lipoprotein, can give rise to 
false interpretations. 
The metabolic heterogeneity of the two forms of apoB is well documented. In 
humans, apoB48 is synthesised in the intestinal epithelium, secreted as part of chylomicrons and 
catabolised as chylomicron remnants by the liver. ApoBlOO is synthesised in the liver as part of 
VLDL, which is subsequently catabolised to IDL and LDL mainly by peripheral tissues. In rats, 
VLDL contains three forms of apoB; PI (apoBlO<0, PH (apoB9s) and PIlI (apoB48). The synthesis, 
metabolic fate and turnover rate of apoB varies with the form of apoB (Elovson et al., 1981; 
Elovson, 1982; Sparks and Marsh, 1981; Sparks et al., 1983; Nestel et al., 1983). To overcome 
this heterogeneity problem, studies in humans and other animals have usually used fasting or 
feeding regimes to limit the contribution of intestinal apoB48 to plasma. More recent studies with 
rat VLDL have reported data on the individual forms of apoB. It needs to be recognised, 
however, that studies on apoB metabolism prior to 1981 were measured on combined forms of 
apoB. In this work, there was no evidence that there was apoB48 in any of the sheep lipoprotein 
fractions (4.3). This may have been a result of the maintenance rations only generating low 
concentrations of intestinally derived lipoproteins. 
The kinetic heterogeneity of VLDL was demonstrated in the experiments of 
Stalenhoef et al. (1984) and Musliner et al. (1987).· They showed that different subfractions of 
VLDL were cleared at different rates and differed in their ability to form LDL. Larger VLDL 
particles were cleared more rapidly and were less likely to become LDL than smaller particles. 
The concept of considering VLDL as a delipidation chain also implies heterogeneity. The 
heterogeneity ofLDL was demonstrated by Fidge and Poulis (1978) and Ghiselli (1982) who 
showed that different subfractions ofLDL were derived from different sources. It is now 
recognised that VLDL, IDL and LDL are structurally, functionally and kinetically heterogeneous 
(Lippel et ai., 1987). 
As the complexity of lipoprotein metabolism is recognised, it is more difficult to 
validate the above assumptions for the assessment of precursor-product relationships between 
particles by these means. Nevertheless, the described methods are useful in suggesting 
independent synthesis and do serve a role in showing differences in the metabolism of apoB in 
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various species. In contrast, multi-compartmental analysis does not require assumptions of 
homogeneity since the heterogeneity of VLDL, IDL and LDL can be included in models. This 
method therefore provides an alternative tool for assessing the precursor-product relationships 
between particles although it is not as simple as the methods of Zilversmit and Le et at. 
In any event, any suggestion of direct synthesis of lipoprotein needs to be supported 
by physiological data. Some tentative evidence is available. LDL-sized lipoproteins have been 
isolated from liver perfusates (eg. Nakaya et a1.1977) but there is still the question as to whether 
the LDL is newly synthesised, trapped LDL or newly synthesised VLDL rapidly metabolised to 
LDL. A novel approach using Triton WR 1339 to block the metabolism of VLDL whilst 
endogenously labelling newly synthesised lipoproteins allowed Illingworth (1975) to demonstrate 
that 10-15% of IDL and LDL may be newly synthesied in the squirrel monkey. Swift et al. 
(1980) also observed particles of the same size and composition as LDL in golgi ofhepatocytes 
from cholesterol-fed rats. 
In this work the source of the newly synthesised LDL suggested is unknown but one 
possibility is the liver as suggested in pig and rat. An alternative source could be the intestines as 
this is the major site of cholesterol synthesis in the sheep. Despite no apoB48 being seen in the 
present study, whether the intestines in sheep produce apoB48 still needs to be confirmed. One 
study in this laboratory has shown that well fed growing lambs have apoB48 (Davidson, unpubl 
observ). 
Subfractions ofVLDL and LDL were not analysed in this study. Such analysis may 
indicate changes in the precursor-product relationships, as described by the Zilversmit (1960) 
method or whether all the newly synthesised LDL-B is in one subfraction, as found in rats by 
Fidge and Poulis, (1978). 
4.5.3 VLDL kinetics. 
Following the injection of labelled VLDL, the metabolism ofVLDL-B was illustrated 
by the decline in specific activity of VLDL)25I-B. Even though blood sampling was continued 
for more than 48 hours, before the radioactivity became immeasurable, only one pool of VLDL-B 
was identified. In early studies on humans only one pool was observed but when the sampling 
period was extended a second pool was observed after 12 hours. In other animal studies, a second 
pool is usually observed but after 1-4 hours. The reason for this difference in sheep is unknown 
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but it may represent a real difference in metabolism, or as suggested by Reardon, a function of the 
activity of the tracer used. 
The FCR of sheep VLDL-B (0.0848:1:0.0113 hOi) was less than half that found in 
humans, rabbits or pigs (Table 4.2). The turnover rate of VLDL-B was also less reflecting the 
low VLDL-B concentration. This infers that less VLDL-B is produced and used in sheep than in 
any other animal species studied. The fate of the VLDL-B is, however, similar in that it is 
converted to IDL-B and LDL-B. 
The difference between sheep and human FCR could arise from differences in the 
composition of the lipoproteins. The FCR of sheep VLDL-B is similar to that found in 
hypertriglyceridaemic patients (Janus et at., 1980a). Sheep VLDL-B may, therefore, have 
potential to be used as a model for apoB metabolism in hypertriglyceridaemic although the 
concentrations of plasma lipoproteins are very different. Alternatively, the hypertriglyceridaemic 
patients may shed light on the ovine system. Hyperlipidaemic subjects have been shown to have 
a variety of abnormalities such as poor receptor binding or decreased LPL activity that are 
associated with defective proteins. It is possible that one or more of the sheep proteins, 
associated with lipid metabolism, differs sufficiently from the equivalent protein in normal human 
to produce the comparatively less efficient system in sheep. Indeed Tume and Thornton (1985) 
have shown that plasmas from sheep on different diets differ in their ability to activate LPL. 
The low turnover of VLDL-B suggests that lipoprotein metabolism plays a minor role 
in fat and perhaps energy metabolism in the normal animal. The low VLDL turnover could 
result from a decreased requirement for VLDL to carry lipids. Because of the nature of the 
ruminant digestive system, the intestinal epithelium has no need to produce large quantities of 
VLDL. This is supported by the absence of large chylomicrons in intestinal lymph (Gooden et at. 
1979) and the absence of apoB48 in lipoproteins from sheep fed maintenance diets. Furthermore, 
the liver does not synthesise fatty acids but uses plasma non-esterified fatty acids for re-
esterification into VLDL-triacylglycerol. In the sheep, the use of non-esterified fatty acids for 
energy production probably has priority over the synthesis of triacylglycerol. Consequently, the 
synthesis of VLDL in the liver is low. This, apparently, has little impact on the sheep. 
The tissue requirements for fatty acids may be catered for by the rapid turnover of 
NEFA. Smaller sized lipoproteins than VLDL may be synthesised to deliver cholesterol and a 
small amount of triacylglycerol to cells. In fact, in this work, analysis of the precursor-product 
relationships, from specific activity curves suggests that a fraction of IDL and LDL, may be 
derived independently of VLDL and that at least a quarter of the LDL may be independently 
synthesised as assessed from the turnover rates of VLDL-B and LDL-B. 
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The turnover of lipoproteins in various physiological states, other than normal, was 
not assessed in this study. In the case oflactation, the important contribution oflipoproteins to 
milk fat production has been demonstrated. In this instance, the hepatic production of VLDL by 
the liver may be increased by an increase in plasma NEF A influencing the hepatic uptake of 
NEF A. A study of lipoprotein kinetics in lactating sheep should provide an interesting 
comparison to the non-lactating sheep studied in this work. 
The possibility of a very fast turnover pool of VLDL-B cannot be totally dismissed as 
the sampling times and variability in the specific activities limit the ability to see such a pool. 
4.5.4 LDL-B kinetics. 
The FCR for sheep LDL-B (0.04058±0.01202 h-1) is intermediate between the low 
FCR in humans (0.015 h-1) and that in other animals (Table 4.2) such as the pig (0.055 h-1, Huff 
and Telford, 1985) and squirrel monkey (0.10 h-t, Portman and illingworth, 1974). The turnover 
rate of sheep LDL-B (4.81O±1.017 mg/d/kg) is approximately half that of humans and 'reflects' 
the lower concentration of plasma LDL-B since turnover was calculated as the product ofFCR 
and plasma pool size. 
In this work, LDL-B FCR was determined from the specific activity decay curves of 
1311 LDL-B using a monoexponential equation. There was, however, evidence for three LDL-B 
pools although all three did not occur in anyone lamb. As described earlier, three pools have also 
been noted in pigs. 
4.5.5 Comparison of VLDL-B and LDL-B kinetics. 
The FCR ofVLDL-B varied from 1.2 (lamb B) to 4.3 (lamb A) times that ofLDL-B; 
averaging twice the rate of LDL-B. The differences in VLDL-B and LDL-B FCR are emphasised 
in Figure 4.13. Similar observations have been made in other animals (Table 4.2a,b) although 
differences in the ratio of VLDL-B FCR to LDL-B FCR occur between species. For comparison, 
in humans the FCR ofVLDL-B is approximately twenty times the LDL-B FCR. As mentioned 
earlier, species differences may be due to differences in the lipid and apoproteins composition of 
the lipoprotein. 
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In lamb A, the turnover of LDL-B was less than that of VLDL-B but in the other 
lambs, LDL-B turnover exceeded that of VLDL-B. Comparison of the turnover rates, along with 
estimates of newly synthesised lipoproteins, can be used to define the other side of the precursor-
product relationships. That is, how much of the precursor is catabolised to the product? In lamb 
A, if all the LDL arose from VLDL (precursor-product investigation suggested >90%) then one 
third of the VLDL-B is removed from plasma as VLDL or IDL. In lambs B and D, the precursor-
product investigations suggest that there is some direct synthesis of smaller particles, especially 
LDL and that this is required to explain the greater turnover of LDL-B. Even if all the VLDL was 
converted to LDL-B, it would be insufficient to maintain steady state and the LDL-B turnover 
measured. In lamb C, the turnover rate would require the direct synthesis of IDL or LDL B but 
the analysis for precursor product relationships does not support this. Alternative procedures for 
estimating the conversion of precursor to product are deconvolution and the method of Reardon et 
al. (1978) where the areas between the specific activity curves of 1251 VLDL-B and 1251 LDL-B 
following the injection of labelled VLDL are measured. This method however assumes all LDL 
is derived from VLDL. 
4.5.6 Plasma apoB concentration in sheep. 
The total plasma apoB concentration was 19.7 mg/dl. This is similar to the plasma 
apoB concentration in bovine (13.3 mg/lOO ml- Marcos et ai., 1990) but much lower than that 
found in humans (80-120 mg/dl- Edelstein, 1986). The concentration is higher than that 
calculated from the data of Mamo (1986), the only other report of apoB in sheep. The 
contribution (%) of apoB to the apolipoproteins in each lipoprotein fraction (VLDL, 61; IDL,63; 
and LDL, 76) is also different from that reported in humans (25% VLDL, 95% LDL, Edelstein, 
1986) though is similar to the other report on sheep (49% VLDL and 73% LDL including IDL; 
Mamo, 1986). The estimates of apoB in sheep, both in the current work and by Mamo (1986) are 
based on a very limited number of samples and sheep from breeds. The marked differences in 
the contribution of apoB to apoprotein complement of lipoproteins probably contributes to the 
different rates of lipoprotein metabolism that are observed in sheep and humans. 
4.6 A KINETIC MODEL FOR APOB METABOLISM IN SHEEP. 
There is no doubt that modelling is a most useful research tool in the study of 
lipoprotein metabolism. A model represents an hypothesis describing the interactions among 
physiological and biochemical processes while the process of fonnulating the hypothesis and 
testing it is known as modelling. Because infonnation on a given parameter is spread over the 
entire data base, modelling provides a method of extracting more infonnation than using 
'simpler' mathematical functions and thus allows estimation of physiological values that were 
unmeasured or even unmeasurable. A model allows the integration of diverse data and 
infonnation; easier interpretation of changes in kinetics; and precise predictions of the 
consequences of complex hypothesis to be made. 
Models can be used to 
- quantitatively test known and proposed concepts against available data 
- help design new and innovative experiments 
- further validate existing notions about physiology 
- gain new insights and understandings of the system 
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The aim of kinetic studies is to detennine the behaviour of the tracee by describing the 
kinetics of the tracer as it is distributed by the flow of tracee between compartments. The analysis 
of tracer kinetic data initially requires the proposal of a model. In a non-linear system in steady 
state, the model can be represented by linear differential equations. The results predicted by the 
model are calculated. Then, by comparison, the model is fitted to the observed data by adjusting 
the model parameters. If the model is inconsistent with the data, the model must be revised and 
the process repeated. The model should satisfy all currently available infonnation about the 
system. The final stage is to interpret the model parameters into physiological parameters. Some 
components of the model may not be identified with known physiological processes and these can 
be considered either as new experimental findings or as discrediting the model. Further 
experiments may be required to distinguish between the two alternatives. 
Numerous computer programs are available to model data but lipoprotein kinetics are 
usually modelled using SAAM (see 4.3.10). By submitting the proposed structure of the model, 
the data, initial conditions and estimates of the parameter values, SAAM detennines the least 
squares solution by an iterative adjustment of the parameters. The fit of the model is assessed 
visually by plotting observed and calculated data, by checking the residuals are random and small 
or the ratio of the calculated to observed values are randomly distributed about 1 and the error 
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estimates on the parameters. CONSAM provides an interactive modelling package that allows 
the modeller to change the model and observe the effects on the predicted data and on the fit of 
the observed data. Solutions from different models can be stored and plotted on the same axis for 
comparison. 
Several useful texts are available on kinetics and modelling. The reader is referred to Shipley 
and Clark (1972) and MacIntosh and MacIntosh (1980) for general information and to Berman 
(1979) for more specific details on lipoprotein kinetics. 
This chapter describes the development of a model for the metabolism of sheep apoB. 
The data collected from the injection of 1251 VLDL and 1311 LDL into lambs was compared with 
data predicted by a model of human apoB metabolism. A model was then developed to improve 
the fit to the lamb data. 
4.6.2 Comparison of sheep data with a model for human apoB metabolism. 
SAAM was used to simulate the model of apoB metabolism in humans as proposed by 
Berman et al. (1978). The model-generated data was compared to the experimental sheep data to 
evaluate the appropriateness of the human model for apoB metabolism in sheep. 
4.6.2.1 Model description. 
The Berman model shown in Figure 4.14 proposes that apoB enters the plasma with 
newly synthesised VLDL (C7). VLDL may then be metabolised by either of 2 pathways: The Q!z 
pathway involves a series of delipidation steps (C7,11,12,16) resulting in particles with 
progressively less lipid and higher density (Sf400-Sf2o)' Further delipidation results in the 
formation ofIDL (C13) and subsequently LDL (Cl+C2). The {J pathway proposes the direct 
metabolism of the newly synthesised VLDL (C7) to {J VLDL (C21) which disappears from 
plasma without conversion to IDL or LDL and has a catabolic rate similar to LDL. The model 
also includes X-VLDL (C5), as this compartment was required to account for all the radioactive 
VLDL injected and may reflect label in lipid as well as VLDL altered or denatured during the 
preparation. This VLDL is removed from the plasma without conversion to other compartments. 
The model also proposes the possibility of direct synthesis of IDL (U 13) and direct metabolism of 
IDL without conversion to LDL but in normal individuals these rates are zero. 
Figure 4.14: Model for apoB metabolism in humans as described by Berman et al. (1978). 
Values next to arrows are rate constants (days'!) or if in parentheses steady state transport rates 
(mg.day-I). Values in parentheses inside circles are calculated steady state amounts of apoB in 
that compartment. The values are approximations for a normal individual. 
* 
15 day-I 
* 
0.15 0.5 
(5mg/day) 
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4.6.2.2 Input file for SAAM. 
The input file (Appendix 4) contained the structure of the model and the parameter 
values of Berman et al. (1978) for normal individuals (Figure 4.14) under H PAR. As the values 
for Ll,2 and L2•1 were unavailable, estimates from modelling sheep LDL metabolism were used. 
(By simulating data with various values of Ll,2 and LZ,I' the model was shown not to be sensitive 
to the value of these parameters.) The summer function, S(I,1) was used to combine all the VLDL 
pools (C5,7,11,12,16,21), with equal weighting, to give the plasma VLDL in C20. This 
represents 6 populations of labelled VLDL with the same space of distribution, the plasma. C20 
will contain the total sample counts and is calculated as 
QC(20) = S(20,5)*F(5)+ S(20,7)*F(7)+S(20,11)*F(11)+ S(20,12)*F(12) + 
S(20,16)*F(16)+ S(20,21)*F(21) 
The introduction of label was simulated using ICCC). The dose was administered to all 
VLDL pools in proportion to the mass of that pool. This meant IC(5)=0. Since the units of 
analysis are fractions of injected dose, the total of the initial conditions, IC(C), must equal 1. 
Under H DAT, SAAM was requested to generate data for VLDL, IDL,LDL and urine using the 
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data generation line. This line has a 2 in column 1 followed by the time interval between desired 
time points (columns 13-25) and the number of points to be generated (column 42). For 
comparison, data from each lamb were included in the deck (one lamb/deck). Because SAAM is 
designed to handle total radioactivity rather than specific activity, the specific activity data 
collected was converted to fraction of the radioactivity injected using plasma volume, the 
appropriate lipoprotein apoB concentration and dose. Since all the dose did not appear in the 
plasma an additional factor was incorporated so the data was presented as a fraction of the first 
sample. Time was converted to days. Both conversion factors were included in the field 
modification line starting with 1. 
4.6.2.3 Findings. 
The curves generated by simulating the model of human apoB metabolism are shown in 
Figure 4.15 along with the data from one representative animal (lamb D). Figure 4.15a gives a 
general view with the results of the simulation to 4 days, while Figure 4.15b illustrates the finer 
details of the model by concentrating on the first 3h. The activity in VLDL declines rapidly; 
activity in IDL increases rapidly to a maximum at approximately 7h then declines rapidly; the 
appearance of activity in LDL is slightly delayed, then is slower to reach a maximum (17h) then 
declines more slowly. 
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Figure 4.15 Curves derived by stimulating the injection of l2S1 VLDL using the model for humans 
of Berman et al. (1978). Data points arc experimentally observed data from lamb D. 
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The model for human apoB, with rate constants for normal individuals, is inconsistant 
with the experimental data obtained from any of the lambs as illustrated in Figure 4.15. In 
general, the initial decay of radioactivity in VLDL as simulated by the model, may be considered 
a reasonable fit, though a higher rate would fit the sheep data better. After this initial removal of 
the VLDL, the later phase was slower in sheep meaning a larger tail is required and this appeared 
earlier in sheep. The model did not fit the VLDL data for lamb C at all. Furthermore, the 
Berman model did not fit the bumps seen in the sheep VLDL-B data. 
The model predicted that the appearance of label in IDL was slower and resulted in a 
broader peak than observed in the sheep data. For lamb C, the simulated IDL curve fitted the data 
quite well although the rate of entry into IDL may have been a little slow. The model did not 
predict the possible bump or shoulder in IDL. 
The LDL peak predicted by the model was too large for all the lambs. The initial 
increase was slower but the peak was too high and too broad to fit the sheep data. 
The Berman model, using the rate constants from normal humans, did not fit the sheep 
data. When the parameters were allowed to adjust, parts of the data were more closely fitted, 
while other aspects did not fit as well. Simulation of the injection of 1311 LDL using IC(1)=1, 
predicted curves that were similar to the data. This is to be expected since the sub-model is much 
simpler and the rates included were already from sheep. 
In summary, some aspects of the proposed model seem appropriate for the sheep data 
while others do not. Simulating the model and then looking at individual aspects by setting the 
pathways to zero and observing the effects on the predicted curves and the fit of the model is 
beneficial in gaining experience in modelling. 
4.6.3 Model development and results. 
There are numerous approaches to developing a model. Having compared the data with 
the Berman model for human apoB and seen that some aspects fit the data while other do not, one 
approach is to modify the Berman model by the removal and addition of pathways and pools to 
obtain a better fit of the sheep data. An alternative approach is to model the data without 
constraints of a previous model. The second approach is described here. Because lambs B and D 
had more data points in the early stages of the decay curves, these lambs were used individually 
for the initial formulation of the model. Lambs A and C, who had more later time points were 
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then used to 'tighten up' this area of the model and to confirm details of the model. Initially only 
the 1251 data were used (Models 1-3), then as the model developed (Model 4-6), the 1311 and 1251 
data were modelled simultaneously and the data for tracer excretion in urine and masses of the 
compartments were included for comparison with model predicted values. The data were input as 
time in hours and specific activity was converted to fraction of the dose of radioactivity in apoB. 
The initial model structure (Figure 4.16) was simple and based on the initial 
observation of VLDL metabolism to IDL and the subsequent metabolism of IDL to LDL. VLDL 
was represented by CI, IDL by C2, LDL by C3 and urine by Cl2. The 1251 dose was modelled as 
entering Cl as 0.25 and initial estimates of parameters were given then allowed to adjust. The 
excretion of 1251 from VLDL (see 4.4.6) exceeded that of 1311 from LDL suggesting more label is 
lost from VLDL than through LDL. Further, from the simulation of the human model, the 
smaller size of the LDL peak suggested all VLDL may not be metabolised to LDL so the 
pathway, L(12,0, from IDL to urine was included. With L(2,I) set to 0.1, the curve generated for 
VLDL provided a reasonable fit, except for the "bump". This model, however, was inconsistent 
with the observed IDL and LDL data. The IDL and LDL curves were not high enough or sharp 
enough (ie.tracer was not entering these pools quickly enough). After allowing the parameters to 
adjust (Final values shown in Figure 4.16), the IDL and LDL curves closely approximated the 
data but the VLDL curve was far too steep and still didn't fit the bump. 
In order to get label into IOL more quickly (and hence LDL more quickly) and to have 
initial loss from VLDL but retain the slower overall rate of loss from VLDL, C5 and C6 were 
added and the dose was administered to C6 as well as Cl. Plasma VLDL was now represented as 
the sum of C1, C5 and C6 (Model 2 Figure 4.17) This was achieved in the SAAM input file 
using the G function XG(1)=F(1)+F(5)+F(6) under HDAT. The SAAM generated curves (Figure 
4.17) for VLDL, IDL and LDL more closely resembled the data though the model was still 
inconsistent with the VLDL data. 
In Model 3 (Figure 4.18), C7 and input of tracer into C7 were added to get the bump in 
VLDL. C8 was added to delay the appearance of this bump. C5, already in the model, gives the 
dip before the bump. With the initial dose into C6 equal to 0.3, the amount of tracer in VLDL was 
always too high, though the data generated for IDL and LDL are reasonable. IfIC(6)=0.1, the 
generated curve for VLDL starts off better but doesn't fall quickly enough hence the bump is too 
big. The model predicts too slow appearance of tracer in LDL and doesn't fit the little bump in 
IDL. 
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At this stage, the 1311 data and mass data were incorporated into the input deck as the 
additional information available from these should be useful. The 1311 and 1251 data were fitted 
simultaneously using the T -interrupt function. This function was used to reset the time to zero, 
clear the 1251 data from the compartments and to introduce the dose of 1311. A second T 
component is indicated in the deck using H ICC TC(t) followed by the instruction to clear all 
tracer from the previous initial conditions and to change the initial conditions as required at this 
break. The 1251 data is in TC(O), the default, while the 131 I data is input under HDA T TC(t). This 
card is followed by a 'T'card to reset the time to zero. 
The mass (mg) of apoB in each lipoprotein fraction in the plasma was calculated and 
included along with the steady state input function U(1) ie. steady state synthesis of apoB into 
compartment 1 under H STE. Only sufficient mass data required for the number of input 
functions was included. This allowed the comparison of the remaining mass data and the model-
generated pool sizes. A request for the steady state mass of each compartment and the transport 
rates R(I,J) was made under 120 (component 20). G functions were included to sum the masses 
of compartments within one lipoprotein fraction, ego G(lD)= M(1) + M(5) + M(6) for VLDL. 
To get the second peak in IDL, C9 and a pathway leading to it from C8 were added, 
Model 4, Figure 4.19. The tracer in C9 was modelled as leaving the plasma without conversion 
to LDL. CII was added between C3 (LDL) and C12 (urine) to delay the appearance of tracer in 
urine. 
The mass data predicted by Model 4 for IDL-B and LDL-B underestimated the mass of 
these pools when compared to that determined experimentally. Additional pools of IDL-B (C13) 
and LDL-B (C4) in eqUilibrium with C2 and C3 respectively, were included in the model to 
increase the mass ofIDL-B and LDL-B predicted by the model. These compartments were 
considered as slowly turning over pools. The fractional conversion rates of these slow-turnover 
pools were estimated and adjusted to fit the 1311 LDL-B data. Alternative approaches of 
introducing newly synthesised apoBinto IDL or a combination of newly synthesised apoS and a 
slow turnover pool would also increases the mass of plasma IDL and LDL. If supporting 
evidence from physiological studies was forthcoming, the model could be adjusted. 
The final model is depicted in Figure 4.20. The parameters (Table 4.17) were adjusted 
individually for each lamb (Figures 4.21-24) to obtain the best fit of the data as judged by visually 
comparing the experimental and model-predicted data and by the sum of squared deviations 
between the two. 
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Figure 4.20 Model for apoB metabolism in sheep. 
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Table 4.17: Parameters derived from final apoB model. 
LAMB 
A B C D 
Initial labelling 
IC (1) 0.065 .065 0.04 0.08 
IC (6) 0.50 0.5 0.6 0.3 
IC (7) 0.40 0.4 0.325 0.5 
IC(lO) 0.035 0.035 0.035 0.12 
VLDL 
L (5,1) 0.20 0.2 0.20 0.296 
L (6,5) 0.20 0.20 0.15 0.1 
L (8,7) 0.50 0.5 0.50 0.50 
L (5,8) 0.02 0.02 0.02 0.50 
L (9,8) 0.20 0.05 0.40 0.20 
L (2,6) 0.80 0.00 2.00 2.00 
IDL 
L(13,2) 0.015 (0.015) 0.015 0.015 
L (2,13) 5.5 E-4 5.5 E-4 5.5 E-4 5.5 E-4 
L (10,2) 0.62 1.155 0.10 1.2 
L(10,9) 0.20 0.20 0.25 0.2 
L (15,6) 2.2 
DN(15) 2.0 
DT(15) 1.0 
L (2,15) 1.0 
LDL 
L (4,3) 0.003 0.003 0.001 0.003 
L (3,4) 2.4 E-4 2.4 E-4 2.4 E-4 2.4 E-4 
L (3,2) 0.40 0.275 0.40 0.143 
L (11,3) 0.045 0.06 0.04 0.017 
PLASMA IODIDE and URINE 
L (0,10) 0.007 0.007 0.007 0.007 
L(12,11) 0.012 0.012 0.012 0.012 
L (0,11) 0.02 0.021 0.021 0.021 
L(12,1O) 0.018 0.018 0.018 0.018 
L (I,J) fractional rate of flow from compartment J to compartment I 
IC(I) initial condition in compartment I 
D (15) delay compartment 15. 
DN(15) number of cells in delay 
DT (15) time delay 
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Figure 4.21: Experimental data points and mode1-derived curves for 12SI_apoB in VLDL, IDL,and LDL following I2SI-VLDL injection and I3II-apoB in LDL following 
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Figure 4.22: Experimental data points and model-derived curves for 12SI_apoB in VLDL, IDL,and LDL following 1251_ VLDL injection and 1311_apoB in LDL following 
simultaneous injection of 1311 LDL into lamb B. 
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Figure 4.23: Experimental data points and model-derived curves for 12SI_apoB in VLDL, IDL,and LDL following 125I-VLDL injection and 1311_apeB in LDL following 
simultaneous injection of 1311 LDL into lamb C. 
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The distribution of initial label between the various compartments for each lamb are 
shown in Table 4.17 The amount of label introduced into each pool was adjusted in a similar 
manner to the other model parameters to give the best-fitting model. The labelled lipoproteins for 
reinjection were prepared from lipoproteins collected from plasma pooled from 2 sheep, A and C; 
Band D. The variation in the initial labelling of compartments between lambs is due to 
differences in the individuals both in the lipoprotein collected for labelling and the pattern of 
lipoproteins in plasma at the time of reinjection. Tracer unaccounted for in the initial conditions 
required for the fit of VLDL-B, IDL-B and LDL-B was modelled as going directly into the iodide 
pool and represents a loss oflabel from VLDL-B before the first sample time (10 min in Band 
D). As such it could represent fast-turning over VLDL-B or denatured particles. This input of 
tracer direct to the iodide pool could be considered to be similar to the additional pool, CS, in the 
human model of Berman et al. (1978). 
The fractional catabolic rates, L(ij), for each pool for each lamb are also given in Table 
4.17 In lamb B, an additional delay (CIS) was required between VLDL and IDL to account for 
the appearance of label in IDL. Such a discrete delay is difficult to explain physiologically. The 
rate constants for material finally leaving VLDL-B (ie from C6) varied from 0.8 to 2.2 h'l; for 
IDL-B (C2). O.S to 1.3 h'l and forLDL-B (C3). 0.017 to 0.06 h·l. 
Masses of each pool M(I), combined mass of VLDL-B, IDL-B and LDL-B, and the 
synthesis rate U(1)(mg/h) are given in Table 4.18. These steady state values were determined by 
inputing the mass ofLDL-B so they depend on the plasma concentration ofLDL-B as well as the 
model. The model under estimated the mass of VLDL-B but the mass of IDL-B was reasonably 
well estimated. The synthesis of new apoB was restricted in the model to compartment 1 in 
VLDL and ranged from 0.8 to 2.6 mg.h'l. The turnover ofLDL-B ranged from 0.187 to 1.014 
mg.h,l, 
The rates calculated by the model vary from those calculated in Section 4.3 because of 
the different models used. Both methods of calculation depend on different aspects of the data. 
Comparison of the curves fitted by the model and those fitted by hand previously illustrates where 
the differences arise. While the model uses combined information from all the data and allows 
different weighting of data points. the earlier estimates considered each pool individually and all 
data were given equal weighting. The model-derived VLDL-Band IDL-B 'FCR' are higher than 
those reported in humans and LDL-B 'FCR' is broadly similar. Since the number oflambs is 
small. the derived values are not necessarily typical of sheep. Since the data was collected as 
specific activity. it would have been better to model the specific activity rather than fraction of the 
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Table 4.18: Steady State parameters derived from apoB model. 
M(1) 
M (2) 
M(3) 
M (4) 
M(5) 
M(6) 
M(13) 
U (1) 
R(1O,2) 
R (3,2) 
R(11,3) 
R (2,6) 
M(VLDL) 
M(IDL) 
M(LDL) 
M(3) + M(4) 
M(I) 
M(VLDL) 
U(1) 
R (I,J) 
A B 
4.035 0.132 
1.345 1.840 
LAMB 
C 
6.339 
2.535 
D 
5.927 
1.306 
11.956 8.433 25.355 11.259 
149.44 105.417 105.645 140.74 
4.035 13.156 8.452 17.532 
1.009 1.196 0.634 0.877 
36.681 50.182 69.150 35.606 
0.807 2.631 1.268 1.753 
0.269 2.125 0.254 1.567 
0.538 0.506 1.014 0.187 
0.538 0.506 1.014 0.187 
0.807 2.631 1.268 1.753 
9.079 27.51 15.42 24.33 
38.027 52.02 71.685 36.912 
161.4 113.8 131 152 
supplied to SAAM as equal to mass ofLDL-B in plasma. 
mass of compartment I (mg) 
total mass of VLDL compartments, similarly M (IDL) and M(LDL) are total 
mass of IDL and LDL respectively. 
Synthetic rate of new apoB into compartment 1 (mg.h-I ). 
Steady state transport rates of material form compartment J to compartment I. 
(mg.h- I ). 
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dose. The structure of the model does not change but the parameter values may. In any case, the 
VLDL turnover rates for lambs are considerably lower than those reported by Berman et al. 
(1978) in normal humans (443 to 667 mg.d- l ). Clearly humans synthesise and metabolise more 
VLDL-apoB per day than sheep. 
4.6.5 Discussion. 
In this discussion, I first discuss the underlying assumptions of the model, and then 
describe and interpret the model of apoB metabolism in sheep. 
Assumptions. 
The major assumption is that the lambs were in steady state with respect to their 
lipoprotein metabolism because the linearity of tracer kinetics depends on this. If the system is 
not in steady state, the rates at which a substance moves through the system change and the data 
will reflect the changes in rate as well as the rate itself. Data on lipoprotein concentrations 
(Section 4.3), although somewhat variable, did not show systematic changes. Hence the 
assumption of steady state was made. Furthermore, the buffering action of the rumen and the 
continual, rather than intermittant, supply of digesta to the duodemum smooths out the supply of 
metabolites to the ruminant. Thus, although diurnal fluctuations undoubtedly occur, any effect of 
such variations are probably not as pronounced as in non-ruminants. To meet the steady state 
requirement, the dose of tracer must be small relative to the plasma mass so as not to perturb the 
system. In this study the doses ofVLDL-B and LDL-B were less than 10% of the plasma apoB 
since the label was prepared from the equivalant of 100mi blood and was subsequently reinjected 
into each lamb. If this amount was sufficient to alter the system, the structure of the model 
probably would not change, but the rate constants would. 
Description and interpretation of the model. 
The model for the metabolism of apoB in sheep is illustrated in Figure 4.20. VLDL is 
represented by compartments 1,5 and 6; IDL by compartments 2, 13 and 9; and LDL by 
compartments 3 and 4. The model proposes apoB enters the plasma as VLDL in Cl. The VLDL-
B is progressively metabolised presumably by delipidation through a series of steps (Cl, C5, C6) 
resulting in the formation of IDL (C2 + C13). IDL-B may be further catabolised to LDL (C3 + 
C4) or removed from plasma without conversion to LDL. Iodide released from the final 
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hydrolysis of apoB is represented by ClO and Cil. The iodide is either excreted in urine (C12) or 
lost from the system, presumably by being taken up by the incompletely blocked thyroid. The 
model also includes two precursor pools to plasma VLDL and IDL. ApoB from these pools enter 
the VLDL delipidation chain at C5 or is converted to an IDL pool (C9) which is then further 
metabolised and removed from the plasma without conversion to LDL. 
The proposed model (Figure 4.20) was generally compatible with the kinetic data from 
the four lambs studied (Figures 4.21-24). For the model to be a valid representation of apoB 
metabolism in sheep it should also be consistent with known physiology of lipoproteins. The 
current concepts of lipoprotein metabolism are based mainly on physiological and biochemical 
studies in humans and rats rather than sheep. Since, from this study, the general metabolism of 
lipoproteins seems similar to humans and rats, it can be expected although not assumed that the 
physiology of sheep lipoproteins is also similar. Thus the model should be compatible with these 
as far as possible. Ultimately each compartment and pathway in the model should be identified 
with a physiological or biochemical entity or process. Any model parameters that cannot be 
identified need to be treated as experimental findings and require further verification. The 
simplest scheme for lipoprotein metabolism is hepatic secretion of VLDL containing apoB, 
lipolysis of VLDL to IDL, metabolism of IDL either to LDL or by direct removal and removal of 
most LDL via LDL receptors. This undoubtedly is too simplistic but the proposed model is 
described in terms of each of these steps. 
VLDL-B is represented by a series of connected pools representing the removal of lipid 
following LPL hydrolysis and generation of smaller particles within the VLDL density range 
(Streja et at., 1977; Reardon et al., 1982; Fidge and Poulis, 1978). Delipidation chains were used 
in modeling apoB by Phair et al. (1975), Berman et al. (1978) and Beltz et al. (1985). ApoB is 
modelled as entering the chain in the first of the three pools and leaving VLDL from the last pool 
only. The restricted entry and exit from the delipidation chain has been used by these other 
modellers but may well be a simplification as VLDL B may well enter all pools of VLDL and 
also exit from all pools. 
The differences between the tracer kinetics of sheep lipoproteins and those predicted by 
the model of Berman et at. (1979) are illustrated in Figure 4.15 and 4.24 and are accounted for by 
the additional pools C7, 8, and 9. Since the bumps were apparent in all lambs, although to a 
lesser extent in lambs A and C, the model needs to fit the bump to be consistant with the 
experimental data. Similar bumps are observed in some of the data of Beltz et al.(1985) although 
these authors do not model them. Three possible reasons for the "blip" in VLDL and IDL are, 
apo C contamination; an artifact of preparation of the tracer; and a real feature of metabolism. 
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The bumps could represent contamination of the apoB pellet with apoC or some other 
labelled apoprotein that exchange between particles. Although the whole lipoprotein particles 
were iodinated, resulting in label in apoproteins other than apoB and lipid, apoB was isolated by 
isopropanol precipitation. This procedure was shown both in this work (4.3) and by Egusa et al. 
(1983) to yeild apoB free from other apoproteins. Thus it seems unlikely that contamination of 
the apoB pellet with another apoprotein which transfers back to VLDL and IDL, could account 
for the bumps in the decay curves of VLDL and IDL. 
In this model, the additional pools giving rise to the bumps in VLDL and IDL are 
considered to represent a characteristic of the tracer. With the input of new apoB only into the 
delipidation chain, these pools do not contain any mass. If in further studies, this difference 
between sheep and human lipoprotein kinetics was consistantly present the model could be 
adapted to have all the label entering the plasma as VLDL-B and having a pathway from Cl to C7 
outside the plasma and returning to C5. This loop could be similar to the variable delay loop 
between VLDL and LDL included by Packard et al., 1980. 
IDL is synthesised from VLDL either via the cascade or from an common precursor. 
The IDL in pool C9 represents IDL synthesised independently of the cascade chain though not 
necessarily independent of VLDL. The tracer data required three pools to represent IDL in sheep. 
In human studies mostly only one pool is used although Beltz et al. (1985) did note that 2 pools 
would be consistent with the data. The possibility of newly synthesised apoB entering the plasma 
as IDL, or LDL, would also be consistant with the data and physiological evidence for such 
synthesis is required to clarify this aspect of the model. The model allows IDL-B to be 
metabolised to LDL-B or cleared from the plasma directly. The relative importance of these 
pathways varied markedly in the lambs. In contrast to the human model (Berman et at., 1978) 
where the direct catabolic pathway was not required in normal individuals, at least a quarter of 
IDL-B in sheep is catabolised by this pathway. Recent studies in human and studies in animals 
indicate that VLDL or IDL may be removed directly apparently by the LDL receptor. In 
homozygous familial hypercholesterolemia and Watanabe Heritable hyperlipidemic rabbits who 
lack LDL receptors, more VLDL is converted to LDL (Goldstein et at., 1983; Bilhiemer et at., 
1982). 
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On further metabolism of IDL, LDL is formed. LDL is represented by two pools as in 
models for LDL-B metabolism in other animals. In this case both pools are considered to be in 
the plasma. Catabolism of LDL, mostly via LDL receptors, results in the release of free labelled 
iodide to the plasma. This is either excreted in urine or presumably taken up in the thyriod. 
The model for apoB metabolism in sheep shows many similarities to that proposed by 
Berman et al. (1978) for humans. Both include a delipidation chain for VLDL metabolism, 
resulting in the formation of IDL and the further catabolism of IDL to LDL. LDL is modelled by 
two pools in both species. While the model for human lipoprotein metabolism allows the direct 
catabolism of VLDL, the proposed model for sheep allows the direct catabolism of IDL. Thus 
the heterogeneity of the lipoprotein classes described in humans and other animals is also 
apparent in the sheep. 
Summary. 
Although models of greater complexity can not be excluded, the proposed model is 
considerably more complex than the simple scheme initially described. This model, like any 
other model, is a working model or hypothesis and requires continued testing under a variety of 
conditions. Further studies may build confidence in the model or require modification of the 
model for analysis of apoB kinetics in sheep. As it is, it represents a model for designing further 
investigations and for comparison of apoB metabolism in different physiological states. 
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5. GENERAL CONCLUSION. 
Lipid metabolism in ruminants, particularly fat deposition, has been of interest because 
of the importance of these animals in human nutrition. Lipoproteins and lipoprotein metabolism 
have been largely ignored, although in other animals this is the major means of transporting lipids 
around the body. Since the metabolism of lipids differs in ruminants from monogastrics, it cannot 
be assumed that the system for lipoprotein metabolism in ruminants will be the same, serve the 
same purposes and be regulated in the same fashion as in monogastrics. The general purpose of 
this thesis was to begin to redress this deficiency by investigating the metabolism of 
triacylglycerol-rich lipoproteins in sheep. 
In the first series of experiments, lambs were either weaned early or allowed to suckle 
to create differences in carcass composition. The activities of LPL in adipose tissue were 
measured to indicate a role for lipoprotein metabolism in fat deposition in sheep. The key 
fmdings of these experiments were that subcutaneous adipose tissue LPL activity (U/mg protein) 
was higher in the suckled lambs and that the suckled lambs also had increased deposition of 
subcutaneous fat. This was clearly demonstrated in Trial 3. The higher LPL activity allows the 
adipose tissue to utilize more fatty acids from lipoprotein-triacylglycerol. The possibility that, in 
sheep where adipose tissues are the major tissues synthesising fatty acids, lipoprotein-
triacylglycerols were not used for fat deposition, but spared for use in other tissues by changes in 
LPL activities, was thus discarded. 
In general, the effects of rearing on adipose tissue LPL activity and fat deposition were 
variable and depended on a number of factors including how LPL activity was expressed, the age 
of the lambs when LPL activity and body composition were measured, breed differences and 
differences in plane of nutrition relating to seasonal variation in pasture qUality. 
PHP-LPL was measured in weaned and suckled lambs in Trials 2 and 3 as an indicator 
of whole body metabolism of lipoproteins and in order to assess the usefulness of this 
measurement as a tool for selecting lambs of leaner carcass composition for breeding. In both 
trials, the suckled lambs had higher PHP-LPL activity than the weaned lambs indicating their 
greater ability to use lipoprotein -triacylglycerol than the weaned lambs. Since in Trial 2 the 
suckled lambs were leaner than the weaned lambs while in Trial 3, the reverse was true, PHP-LPL 
activity would not be a useful criteria to select lambs for leanness. Since the injection of heparin 
releases LPL from the capillary endothelium of all tissues, PHP-LPL activity does not give a 
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direct measure of adipose tissue LPL activity but reflects the total body use of lipoproteins. Thus 
PHP-LPL reflects the balance of changes in LPL activity through out the body. It also represents 
the particular state of the body at the time of collection of PHP rather than the potential of the 
animal at some later date. 
An additional aim of this study was to investigate the regulation ofLPL by insulin. 
This was achieved by using two methods of insulin administration in vivo. Firstly, exogenous 
insulin was infused for 7 or 18 weeks in weaned and suckled lambs in Trial 1 and LPL activities 
in adipose tissues were determined upon slaughter. Similarly in Trial 2, weaned lambs were 
continually infused with insulin for 8 weeks and PHP-LPL activities were determined. The 
infusion of insulin had no statistically significant effect on LPL activities in either adipose tissues 
orPHP. 
The second technique used to investigate the effects of insulin was the euglycemic 
clamp. By simultaneously infusing insulin and glucose to maintain plasma glucose at 
physiological levels, high concentrations of plasma insulin were achieved without counter 
regulatory hormonal changes induced by falling plasma glucose concentrations. Insulin was 
infused at O.629mU.kg-·75 .min-l for 3 hours followed by 6.29mU.kg-·75.min-l for 6 hours. LPL 
activities were measured in biopsied adipose tissue at the end of each infusion period. After 6 
hours at the higher insulin infusion rate, a two fold increase in adipose tissue LPL activity was 
achieved. This finding was broadly similar to results of euglycemic clamp experiments in 
humans (Sadur and Eckel, 1982). In euglycemic clamp experiments in lambs using the same 
infusions of insulin, Davey (1986) demonstrated an increase in the in vivo synthesis of glyceride 
glycerol in adipose tissue. These results suggest that the increased fat deposition is associated 
with increased LPL activity. 
That differences in response to insulin are dependant on the method insulin 
administration is undoubtedly due to the plasma insulin concentrations attained and the duration 
of the treatment. 
In summary, these studies demonstrated that differences in adipose tissue LPL activity 
occurs in suckled and weaned sheep and are related to changes in fat deposition. Increased 
adipose tissue LPL activity occurred in suckled compared to weaned lambs in Trial 3 and was 
associated with increased subcutaneous fat. In Trial 2, no differences in adipose tissue LPL 
activity or subcutaneous fat were noted. By implication, the metabolism of triacylglycerol-rich 
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lipoproteins may provide a source of fatty acids for the deposition of fat in sheep. LPL activity 
was also demonstrated to be regulated by insulin. 
In the second half of the thesis, the in vivo metabolism of lipoproteins in sheep was 
studied by injecting 1251_ VLDL and 1311_LDL into four sheep and following the changes in the 
specific activity of apoB in VLDL, IDL and LDL. This allowed the characterization of the 
lipoprotein system in sheep and the measurement of the turnover ofVLDL-B and LDL-B. On 
injection of 1251_ VLDL, apoproteins other than apoB were rapidly exchanged with HDL. VLDL-
B was catabolised to IDL-B and subsequently to LDL-B. The data were consistent with most of 
the IDL-B being derived from VLDL-B and most of the LDL-B being derived from IDL-B. 
Thus, the general relationships between lipoprotein particles were similar to those described in 
other mammals although, as noted previously, the indication of direct synthesis oflipoproteins, 
other than VLDL, varies with species. The turnover rate ofVLDL-B (3.45mg/d/kg) was less than 
those calculated in normal humans, rabbits and pigs. Similarly the turnover ofLDL-B 
(4.8mg/d/kg) was approximately half that determined in human studies. As indicated in other 
animal studies, the fractional catabolic rate ofVLDL-B was greater than that ofLDL-B. By 
comparison with other animals, the low plasma concentrations of VLDL in sheep are determined 
by the low synthetic rates. Although it is clear that triacylglycerol-rich lipoproteins play some 
role in the lipid and energy metabolism of the normal sheep, this role is limited by the turnover 
rates, in comparison to other animals. 
The data observed following the injection of labelled VLDL and LDL, were used to 
develop a model for the kinetics of apoB metabolism in sheep using the SAAM computer 
program. The model describes the synthesis of apoB as VLDL-B and VLDL metabolism through 
a delipidation chain to IDL. IDL may be further catabolised to LDL or directly cleared from the 
plasma. Both IDL and LDL are described by two pools, with the entrance and exit of apoB being 
confined to one pool and the second representing a pool with slower turnover. The model 
emphasises the similarities between lipoprotein metabolism in sheep and other animals, in 
particular, humans. The model provides a means of comparing lipoprotein metabolism in 
different physiological situations and a basis on which to design further experiments. 
It may be that in ruminants, although the contribution of lipoproteins to normal 
metabolism is low, lipoproteins fulfil a special role in other physiological states to direct fatty 
acids to tissues as required. For example, in stressed states such as fasting or early lactation, fatty 
acids are mobilised from the adipose tissue, taken up by the liver and re-exported as lipoprotein-
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triacylglycerol. Changes in the activity of LPL in various tissue, may then direct the fatty acids to 
the tissue that require them. In these situations lipoprotein metabolism may contribute 
significantly to the overall metabolism of the animal. The suckling lamb may be described as a 
special state. During suckling, the milk. diet gives rise to higher plasma lipoprotein and insulin 
concentrations. The increase in plasma insulin concentration stimulates adipose tissue LPL which 
results in the removal of more fatty acids from lipoprotein-triacylglycerol and an increase in fat 
deposition. 
Future Work. 
Since LPL and the metabolism of lipoprotein-triacylglycerol play some role in the 
deposition of fat, this area is one that may be further explored in the search for leaner lines of 
lambs. Decreased activity of LPL due to down regulation of the protein itself, reduced activation 
by apoC or the presence of an inhibitor should result in leaner carcass. Both the poultry and pig 
industries use strategies involving lipoprotein metabolism to select animals for breeding. This is 
an avenue, as yet, unexplored in the sheep meat industry. 
The kinetic studies and the model developed from the data provides a basis for further 
comparison oflipoprotein metabolism in different physiological situations. Sheep during 
lactation, after prolonged fast or during suckling would all provide interesting comparisons to the 
dry sheep. Further physiological evidence is required to assess the direct synthesis of lipoproteins 
in the IDL and LDL density fractions and to determine its origin. 
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APPENDIX!. 
ABBREVIATIONS. 
apoB 
B,E receptor 
BSA 
chylo 
CONSAM 
cpm 
dpm 
HDL 
IDL 
LCAT 
LDL 
LPL 
MW 
NADPH 
NEFA 
PCV 
PHP 
PPO 
r 
SA 
SAAM 
SD 
SEM 
t 
VFA 
VLDL 
VLDL 
apolipoprotein B 
receptor that recognises apolipoprotein B and apolipoprotein 
E. the LDL receptor. 
bovine serum albumin 
chylomicrons 
Conversational Version of Simulation, Analysis and Modeling 
program 
counts per minute of radioactivity. 
disintergrations per minute 
High density lipoproteins 
intermediate density lipoproteins 
Lecithin:cholesterol acyltransferase 
low density lipoproteins 
lipoprotein lipase 
molecular weight 
nicotine adenine dinucleotide phosphate 
non-esterified fatty acids 
packed cell volume 
post-heparin plasma 
2,3-diphenyloxazole 
correlation coefficient 
specific activity 
Simulation, analysis and modeling program. 
standard deviation 
standard error of the mean 
time 
volitile fatty acids 
very low density lipoproteins 
very low density lipoproteins 
VLDL-B 
VLDL-TG 
'" 
apolipoprotein B in very low density lipoprotein. similarly for 
other lipoprotein classes 
triacylglycerol in very low density lipoproteins. similary for 
other components and other lipoproteins. 
a labelled moiety e.g. VLDL-*B is the labelled apoB in VLDL 
while VLDL-B is all the apoB (labelled and unlabelled) and 
*VLDL is total label on VLDL 
Abbreviations used in modelling and using SAAM are in table 4.3.1 
APPENDIX 2 
MATERIALS 
Anaesthetic: 
"Halothane'; "Nembutal", phentobarbitone sodium. Abbott Laboratories (NZ) Ltd, Naenae, NZ 
"Xylocaine" or "Nopaine" .2% lignocaine hydrochloride. Astra Pharmaceuticals Pty (NZ), Australia 
Bovine Serum Albumin fraction V: Sigma Chemical Company (St Louis, U.S.A.) 
Catheters: 
16G, 24" (14G needle); 19G. 12" (17G needle). Intracath, Deseret (Utah, U.S.A.) 
2,3-diphenyloxazole (Liquid sintillation grade):J.T. Baker 
General Reagents: Ajax Chemicals (Sydney, Australia) 
BDH Chemicals (poole, U.K.) 
May & Baker Ltd (Dagenham, U.K.) 
Sigma Chemical Co. (St Louis, MO, U.S.A.) 
Ferric chloride (anhydrous): Fisons Scientific Apparatus (Leics., U.K.) 
Heparin: Evans Medical Ltd (Liverpool, U.K.) 
Leo Pharmaceutical Products, Ballerup, Denmark 
Infusion set (silas tic rubber catheter): Vygon (France) 
Insulin, ovine: Sigma Chemical Company 
Insulin, porcine: Velosulin, Nordisk 
Monotard, Novo 
Iodogen: Pierce Chemical Company 
Kits: 
Monotest Cholesterol CHOD-PAP, Boehringer Mannheim, Auckland, New Zealand 
Triacylglycerol GPO-PAP Boehringer Mannheim, Auckland, New Zealand 
Michel wound clips: Propper (U.S.A.) 
Needles: Terumo Corporation (Tokyo, Japan) 
L-o;-phoshotidyl choline type V-E Sigma Chemical Co., St Louis, MO, U.S.A. 
Radioactive isotopes: Tri[9,1O-3H]oleylglycerol, Na 1251, Na 131 I, The Radiochemical Centre (Amersham, 
Australia) 
Sephadex: Pharmacia 
Setonet: Setonet Products Ltd (U.K.) 
Solvents (redistilled, commercial): Shell Oil NZ Ltd., Wellington 
Syringes: Disposable Terumo Syringe. Terumo (Australia) Pty, Ltd, Melbourne, Australia 
Three-way stopcock. Unoplast (Denmark) 
Triolein: Sigma Chemical Company (St Louis, MO, U.S.A.) 
Triton-WR 1339: Sigma Chemical Company (St Louis, MO, U.S.A.) 
Triton-X-lOO: Rohm and Haas New Zealand Ltd (Auckland) 
APPENDIX 3.1 
LPL Activity in Subcutaneous, Omental and Perirenal Adipose Tissue from Lambs 
Slaughtered at 12 Weeks in Trial 1. 
Treatment Lipoprotein Lipase Activityl 
Lamb # Subcutaneous Omental Perirenal 
Weaned 
239 107 194 273 
251 216 451 236 
263 149 338 301 
266 304 506 339 
280 424 367 512 
292 104 235 187 
295 266 320 447 
304 73 99 230 
Weaned + Insulin 
252 32 109 190 
254 117 224 237 
289 207 362 439 
296 131 203 240 
Suckled 
236 64 155 219 
261 77 288 266 
271 35 63 105 
273 14 90 139 
274 715 541 662 
278 149 200 189 
285 446 292 507 
305 32 177 149 
Suckled + Insulin 
256 31 91 93 
259 23 142 152 
281 92 162 216 
299 65 173 313 
1 U.g-l wet weight tissue:: nmole fatty acid release.min-l.g- l wet weight tissue. 
Each number represents the mean of triplicate determinations of each extract. 
APPENDIX 3.2 
LPL Activity in Subcutaneous, Omental and Perirenal Adipose Tissue from Lambs 
Slaughtered at 23 Weeks in Triall. 
Treatment Lipoprotein Lipase Activityl 
Lamb # Subcutaneous Omental Perirenal 
Weaned 
238 130 28 41 
241 59 114 95 
264 26 14 73 
268 124 69 48 
277 91 
283 252 161 274 
284 351 226 316 
302 67 102 
Weaned + Insulin 
257 3 
260 72 
300 252 230 226 
306 381 249 205 
Suckled 
247 111 54 49 
255 52 7 43 
267 57 102 61 
269 43 44 60 
276 92 
282 114 106 165 
288 152 137 227 
298 34 
Suckled + Insulin 
249 29 
265 37 8 24 
279 128 117 100 
303 67 95 133 
1 V.g-l wet weight tissue:= nrnole fatty acid release.rnin-l.g-l wet weight tissue. 
Each number represents the mean of triplicate determinations of each extract. 
APPENDIX 3.3 
Empty body eight, GR, carcass, non-carcass and total body fat and total body protein in lambs 
slaughtered at 12 weeks in Triall. . 
Lamb 
No. 
Empty GR 
body (mM) 
weight 
(kg) 
Weaned 
239 25.26 5 
251 25.72 7 
263 22.69 
266 21.09 
280 23.55 
292 21.40 4 
295 20.36 
304 21.70 2 
Weaned + insulin 
252 25.04 6 
254 26.29 3 
289 23.03 5 
296 26.02 6 
Suckled 
236 28.77 11 
261 29.43 
271 29.18 11 
273 29.51 9 
274 20.20 
287 35.58 
285 30.72 
305 27.93 9 
Suckled + insulin 
256 28.30 14 
259 31.66 17 
281 25.43 12 
299 27.55 13 
Carcass 
fat 
(kg) 
2.43 
2.69 
1.97 
1.31 
2.28 
1.95 
1.38 
1.91 
2.04 
1.87 
1/49 
1.99 
4.06 
4.68 
4.48 
4.11 
2.00 
5.72 
4.69 
3.60 
4.13 
5.68 
4.28 
3.99 
Non-carcass 
fat 
(kg) 
0.86 
0.86 
0.64 
0.47 
1.02 
0.83 
0.57 
0.84 
0.70 
0.72 
0.71 
0.77 
1.59 
1.50 
1.44 
1.n2 
0.66 
2.12 
1.71 
1.26 
l.36 
1.55 
1.17 
1.35 
Total 
body fat 
(kg) 
3.29 
3.55 
2.62 
1.78 
3.30 
2.77 
1.95 
2.74 
2.73 
2.59 
2.20 
2.76 
5.65 
6.18 
5.92 
5.82 
2.65 
7.84 
6.40 
4.86 
5.49 
7.23 
5.45 
5.34 
Total 
body 
protein 
(kg) 
4.16 
4.00 
3.76 
3.58 
3.91 
3.68 
3.56 
3.72 
4.15 
4.18 
3.84 
4.19 
4.47 
4.36 
4.82 
4.54 
3.44 
5.31 
4.80 
4.44 
4.21 
4.61 
4.18 
5.34 
APPENDIX 3.4 
Empty body eight, GR, carcass, non-carcass and total body fat and total body protein in lambs 
slaughtered at 23 weeks in Triall. 
Lamb 
No 
Weaned 
238 
241 
264 
268 
277 
283 
284 
302 
Empty 
body 
weight 
(kg) 
25.13 
33.13 
40.25 
34.08 
37.16 
38.66 
37.06 
35.84 
Weaned + insulin 
257 37.27 
260 38.23 
300 35.67 
306 33.27 
Suckled 
247 43.58 
255 44.79 
267 40.72 
269 40.30 
276 45.34 
282 44.80 
288 38.15 
298 50.01 
Suckled + insulin 
249 47.59 
265 44.83 
279 43.48 
303 41.87 
GR Carcass 
(mM) fat 
(kg) 
5.79 
13 5.29 
6.35 
16 4.76 
19 5.85 
5.58 
5.73 
14 5.13 
18 6.12 
17 5.75 
9 4.67 
6 4.05 
22 9.62 
10.64 
24 8.70 
7.62 
320 9.71 
9.31 
8.60 
28 11.42 
26 9.85 
23 9.44 
25 9.56 
21 8.69 
Non-carcass 
fat 
(kg) 
2.09 
1.73 
2.84 
1.89 
2.32 
2.50 
2.36 
1.71 
2.19 
2.48 
1.92 
1.31 
3.28 
3.27 
2.59 
2.76 
3.38 
4.27 
2.55 
4.51 
3.05 
2.84 
2.44 
3.13 
Total 
body fat 
(kg) 
7.88 
7.02 
9.18 
6.65 
8.17 
8.09 
8.08 
6.84 
8.31 
8.22 
6.59 
5.36 
12.90 
13.91 
11.29 
10.38 
13.09 
13.59 
11.16 
15.93 
12.90 
12.28 
12.00 
11.82 
Total 
body 
protein 
(kg) 
5.24 
5.09 
5.91 
5.39 
5.52 
5.75 
5.68 
5.30 
5.64 
5.89 
5.49 
5.33 
6.12 
6.25 
5.80 
5.75 
6.36 
6.18 
5.30 
6.69 
6.62 
6.56 
6.29 
5.94 
APPENDIX 3.5 
Bodyweigbt and LPL activity (U/ml) in Post-Heparin Plasma from suckled, weaned and insulin 
infused weaned lambs at 14 weeks in Trial 2. 
Treatment Lamb # Live LPL Activity Treatment 
weight (U. mI-!) mean:l: sem 
(kg) (1) (2)* 
01 29.4 157 166 
Suckled 03 36.6 288 287 
06 33.0 208 213 
12 33.1 120 127 
18 31.0 174 188 
20 27.1 173 
24 31.0 221 230 
27 21.5 101 91 
Mean+sem 30.3:1:1.61 181+24 184+22 183±16b 
Weaned 09 30.0 
10 22.7 124 124 
15 21.8 49 48 
17 30.1 120 112 
21 27.5 109 93 
23 26.5 100 81 
29 28.7 127 115 
43 20.6 85 75 
Mean + sem 26.0:1:1.34 107±10 99+11 103±7a 
08 34.8 186 197 
Weaned + 16 30.8 139 139 
Insulin 22 28.8 200 203 
Infusion 28 24.4 120 125 
32 27.7 52 55 
33 23.2 73 101 
37** 23.6 90 90 
42 24.0 148 143 
Mean ± sem 27.2:1:1.47 126:1:18 134:1:18 129:1:12ab 
• Assay number; 
each value is the mean of triplicate determinations in one assay. 
U = nmol fatty acid released per min. 
•• this lamb had received no insulin for several days . 
a,b treatment means with different letters are significantly different. 
APPENDIX 3.6 
Adipose tissue LPL activity in biopsy and slaughter samples taken from weaned and suckled lambs 
~fiW~ . 
Lamb No. LPL activity 
U/g tissue U/mgpr 
Biopsy samples 
Suckled 
1001 138 17.7 
1006 1.6 
1012 1.9 
1024 103 8.0 
Weaned 
1009 79 5.6 
1010 51 3.9 
1017 65 6.6 
1043 42 2.6 
. Slaughter samples 
Suckled 
1003 87 42.4 
1018 104 18.6 
1020 177 17.2 
1027 246 30.2 
Weaned 
1021 244 32.0 
1023 271 27.6 
1029 195 24.5 
Each value represents the mean of triplicate tissue samples. 
U/g lipid 
212 
129 
93 
66 
77 
43 
119 
126 
238 
309 
306 
309 
215 
APPENDIX 3.7 
LPL activity (expressed per mg protein and per g tissue) in subcutaneous adipose tissue taken during 
an euglycemic damp at two insulin infusion levels. Biopsy 1 was taken after infusing insulin at 
O.629mU.kg",75.min for 3 hours. Biopsy 2 was taken after infusing insulin at 6.29mU.kg-.7s.min for 6 
hours. A further sample was taken at slaughter. 
Lamb Biopsy sample Slaughter 
# 1 2 sample 
LPL activity (U/mg protein) 
Suckled 
1001 1. 256 3.231 8.756 
1006 3.760 8.496 
1012 8.09 4.865 
1024 2.222 5.974 9.638 
Weaned 
1009 2.185 2.673 7.891 
1010 3.113 3.353 10.530 
1017 1. 626 7.303 7.322 
1043 1.461 3.243 5.938 
LPL activity (U/g tissue) 
Suckled 
1001 26.823 46.636 98.236 
1006 'It 39.555 66.734 
1012 'It 50.335 35.355 
1024 21.040 73.282 86.642 
Weaned 
1009 18.118 28.439 63.305 
1010 16.232 28.076 63.342 
1017 22.613 60.866 71.679 
1043 24.428 33.277 41. 501 
APPENDIX 4.1 
SUMMARY OF DATA FROM TURNOVER STUDIES 
Lamb A 
Bodyweight (kg) initial 29.0 Final 27.7 
Plasma Volume (ml) 
(4.5% av Bwt) 
Plasma [VLDL·B] 
[IDL ·B] 
[LDL .B] 
Dose 1251 • VLDL ApoB 
Dose 1311 • LDL ApoB 
Difference <5% 
1278 ml 
45 tAg/ml 
59 tAg/ml 
126.5 tAg/ml 
3.08 E6cpm 
9.829 E6cpm 
Specific Activities (cpm/ tAg) of *1 ApoB in VLDL, IDL, LDL following injection of 1251 VLDL and 
131JLDL 
Time(b) VLDL IDL 
0.42 16.22 3.81 
1.83 12.66 11.63 
5.08 6.26 8.37 
7.00 1.53 6.05 (7.79) 
9.08 3.96 6.22 
11.87 1.96 5.09 
19.00 1.82 0.54 
24.17 0.31 0.54 
30.00 0.53 0.47 
50.05 0.16 
143.8 0.22 
Recovery of 1251 and 1311 in urine. 
Time 
(b) 
30 
100 
144 
190 
243 
289 
339 
386 
431 
Cumulative Activity (cpm xlO-5) 
1251 
0.4709 
1.1656 
1.5096 
3.1475 
3.3768 
3.466 
3.4987 
3.5149 
3.5278 
LDL 
0.423 
3.750 
6.040 
5.900 
5.50 
5.53 
3.05 
3.80 
2.85 
1.78 
0.55 
131ILDL 
52.89 
58.54 
49.80 
45.58 
40.01 
41.7 
22.05 
30.30 
19.70 
11.30 
0.90 
0.2955 
0.8474 
1.1325 
1.9588 
2.1367 
2.2001 
2.2565 
2.2882 
2.2991 
APPENDIC 4.1 continued. 
Lamb B 
Bodyweight (kg) 27 initial Final 29.2 Difference 7.5% 
Plasma Volume (ml) 1265 ml 
Plasma 
Dose 1251 • VLDL Apo8 
Dose 1311 0 LDL ApoB 
(4.5% av Bwt) 
[VLDL·B] 
[IDL ·8] 
[LDL ·8] 
1.9159 E6 cpm 
1.074 E7 cpm 
30 /Jg/ml 
33.5 /Jg/ml 
90 /Jg/ml 
Specific Activities (cpm/ /Jg) of ·1 ApoB in VLDL, IDL, LDL following injection of 1251 VLDL and 
131ILDL 
Time (h) VLDL IDL 
0.17 7.29 
0.52 4.94 1.41 
1.02 12.81 3.8 
1.67 3.26 4.89 
2.27 3.8 11.03 
3.07 3.75 4.3 
6.17 3.4 1.14 
9.13 1.48 3.18 
11.83 1.77 0.08 
16.62 1.33 0.03 
24.02 0.96 1.47 
30.35 0.65 
Recovery of uSI and 1311 in urine. 
Time 
(h) 
24 
77 
123 
173 
220 
265 
337 
Cumulative Activity (cpm xlO-5) 
1251 
10.530 
18.497 
22.83 
24.98 
25.98 
26.19 
26.375 
LDL 
0 
0.61 
0.11 
0.78 
1.02 
1.25 
0.93 
0.81 
l.5 
0.77 
0.97 
0.62 
131ILDL 
93.27 
143.4 
102.27 
128.45 
75.78 
112.37 
47.75 
41.83 
20.92 
66.30 
29.70 
23.75 
27.170 
55.190 
70.550 
77.870 
80.676 
81.538 
82.146 
LambC 
Bodyweight (kg) 27 initial Final 27.7 Difference 2.6% 
Plasma Volume (ml) 
Plasma 
Dose 1251 • VLDL ApoB 
Dose 1311 • LDL ApoB 
1233 m} 
(4.5% av Bwt) 
[VLDL-B] 
[IDL ·B] 
[LDL -B] 
2.2880 E6 cpm 
9.343 E6 cpm 
31 ~g/ml 
57 ~g/ml 
106 ~g/ml 
Specific Activities (cprn/ lAg) of '1 ApoB in VLDL, IDL, LDL following injection of 1251 VLDL and 
131ILDL 
Time (h) VLDL IDL 
0.38 17.35 3.86 
1.72 2.2 16.3 
5.05 2.33 7.37 
6.87 1.17 
9.05 2.08 2.27 
11.72 1.91 3.30 
18.88 1.52 1.30 
23.98 0.425 0.69 
29.8 0.35 
49.88 0.1 0.07 
95.85 0.39 
143.63 0.28 
Recovery of 1251 and 1311 in urine. 
Time 
(h) 
30 
100 
144 
190 
243 
289 
339 
389 
431 
Cumulative Activity (cpm xlO·S) 
1251 
0.0473 
1.8321 
2.1465 
2.3907 
2.6006 
2.7040 
2.7480 
2.7674 
2.7793 
LDL 
0.39 
3.63 
4.79 
3.68 
6.98 
5.78 
4.63 
4.43 
3.46 
1.75 
0.59 
0.13 
1311 LDL 
75.28 
70.59 
51.97 
32.58 
56.88 
46.4 
35.0 
31.6 
23.68 
11.27 
2.45 
0.466 
1311 
.2679 
1.5241 
1.7664 
1.9620 
2.1219 
2.1979 
2.2677 
2.3056 
2.3115 
Lamb D 
Bodyweight (kg) 26 initial Final 26.8 Difference 3% 
Plasma Volume (ml) 
Plasma 
Dose 1251 • VLDL ApoB 
Dose 1311. LDL ApoB 
1188 ml 
(4.5% av Bwt) 
[VLDL.B] 
[IDL ·B] 
[LDL ·B] 
1.77 E6 cpm 
9.95 E6 cpm 
41.3 SAg/ml 
38.4 JAg/ml 
128 SAg/ml 
Specific Activities (cpm/ SAg) of *1 ApoB in VLDL, IDL, LDL following injection of 1251 VLDL and 
131ILDL 
Time (h) VLDL IDL LDL 131ILDL 
0.17 9.5 3.3 0.12 80.97 
0.51 9.18 4.5 0.51 67.9 
1.03 8.48 3.78 0.099* * 
1.65 6.70 5.00 0.24 58.94 
2.28 7.24 3.16 0.33 59.36 
3.08 7.8 2.59 0.5 54.18 
6.18 9.4 3.75 0.626 (62.30) 
9.22 3.58 1.97 0.95 52.16 
11.95 2.04 0.61 0.86 39.08 
16.68 3.18 0.61 0.97 36.05 
24.02 2.07 0.3 1.24 * 
30.33 0.92 0.5 18.87 
52.52 0.05 
99.33 0.0 
Recovery of 1251 and 1311 in urine. 
Time Cumulative Activity (cpm dO's) 
(h) 1251 1311 
24 4.62 8.61 E5 
77 9.377 24.2 
123 10.507 28.47 
173 11.5115 32.4 
220 11.8139 33.2 
265 11.9369 33.5 
337 11.9950 33.7 
APPENDIX 4.C: 
Input file to fit the sum of two exponentials to data using SAAM. 
A SAAM30 LAMB A LDL DATA 
C 
C FIT A SUM OF EXPONENTIALS TO THE DATA 
C 
H DAT 
C 
C G(30) IS THE INITIAL CONDITIONS 
C 
G(30)=K(60)+K(61) 
C AREA UNDER CURVE 
G(31)=K(60)/p(1)+K(61)/p(2) 
C NORMALIZED AREA UNDER CURVE-RESID TIME PLASMA 
G(32)=G(31)/G(30) 
C FCR OF PLASMA POOL 
G(33)=1/G(32) 
C 
XG(23)=K(60)*EXP(-P(1)*T)+K(61)*EXP(-P(2)*T) 
C 
101G(23) FSD=.1 
C LDL 131-I INJECTION 
C DOSE in ApoB 9.829E6 CPM 
C [LDL apoB]126.5ug/ml 
C hours specific activity 
HPAR 
o 
0.42 
1.83 
5.08 
7.00 
9.08 
11.87 
19.00 
24.17 
30.00 
50.05 
143.8 
52.89 
58.54 
49.80 
45.58 
40.01 
41. 7 
29.53 
30.30 
19.70 
11.30 
0.90 
C provide initial estimates and limits 
C parameter estimate minimum 
K(60) 3.983618E+OO 1.000000E+00 
K(61) 5. 362239E+01 O.OOOOOOE+OO 
P(1) 1. 380281E-02 6.000000E-03 
P(2) 3.496519E-02 1.000000E-02 
y 
maximum 
1.500000E+02 
1.500000E+02 
6.000000E-02 
1.200000E-Ol 
APPENDIX 4.C: 
Input file to simulate the model of apoB metabolism described by Berman et al. (1978) for human. 
Data from lamb D is included in the deck to enable comparison. 
A SAAM30 simutation of 
CBERMAN ET AL MODEL FOR APOB JLR 78 
C comparison to lamb D data 
H PAR 
C SUMMING ALL VLDL COMPARTMENTS TOGETHER 
C 
S 20,5) 1 
S 20(21) 1 
S 20,7) 1 
S 20'11~ 1 S 20,12 1 
S 20,16 1 
C INITIAL INPUT INTO ALL VLDL 
IC 71 .22 IC 5 O.OOOOOOE+OO 
IC 11 .22 
IC 12 .22 
IC 16 .22 
IC 2 l .11 
C VLDL section 
C 
C 
C 
C 
C 
C 
L!21,71 0.15 L 11,7 15 
L 12,1 ) 15 
L 16,12) 15 
IDL SECTION 
L(13,16) 15 
LDL SECTION 
L~1,13) 3.5 L 2,1) .2 
POOLS 
C 
C 
C 
C 
C 
L 1,2) .2 
VALUES ESTIMATED FROM SHEEP AS VALUES UNAVAILABLE 
IN BERMAN PAPER 
IODIDE POOL SECTION 
C 
L~3,5) 15 L 3,21) 0.5 
L 3,1) 0.45 
C CUMULATIVE URINE 
L(4,3) 2 
H DAT 
C SIMULATE DATA FOR MODEL 
120 
2 
113 
2 
101 
2 
.01 
.02 
.03 
.04 
.08 
.16 
.2 
.24 
.25 
.01 
.02 
.03 
.04 
.08 
.16 
.2 
.24 
.25 
.01 
.02 
.03 
.04 
.08 
.16 
.2 
.24 
.25 
16 
16 
16 
104 
.01 
.02 
.03 
.04 
.08 
.16 
• 2 
.24 
2 .25 16 
C For comparison data from 
C 125I VLDL INJECTION IN LAMB D is included. 
C 125-I DOSE = 1.77E6 CPM 
C vldl-b concentration = 41.3 ug/ml 
C plasma vol 1188ml 
C CPM/ug * 41.3/1.77E6*1188 - fraction of dose 
C factor*.25 
C days fraction of dose 
120 /24 *1.108E-l 
C IDL 
113 
C 
C PLASMA LDL 
C 
101 
C 
C CUMULATIVE 
104 
y 
o 
.17 9.5 
.51 9.18 
1.03 8.48 
1.65 6.70 
2.28 7.24 
3.08 7.8 
9.22 3.58 
11.95 2.04 
16.68 3.18 
24.02 2.07 
30.33 0.92 
52.52 0.05 
99.33 0.0 
6.18 9.4 
}24 *1.031E-1 
o 
.17 3.3 
.51 4.5 
1.03 3.78 
1.65 5.0 
2.28 3.16 
3.08 2.59 
6.18 3.75 
9.22 1.97 
11.95 0.61 
16.68 0.61 
24.02 0.3 
I-125 
}24 
o 
.17 
.51 
1. 03 
1. 65 
2.28 
3.08 
6.18 
9.22 
11. 95 
16.68 
24.02 
30.33 
COUNTS 
~24 
24 
77 
123 
173 
220 
265 
337 
IN URINE 
*3.436E-l 
0.12 
0.58 
.099 
.24 
.33 
• 5 
.626 
.95 
.86 
.97 
1. 24 
.5 
125I 
/1.77E6 
4.62 
9.377 
10.507 
11.5115 
11. 8139 
11.9369 
11.99497 
FSD=.2 
FSD=.2 
FSD=.2 
1"5D=.2 
Appendix 4 C 
Input file for modelling apoB kinetics using the model decribed 
in text. This example includes the data and parameter values for Lamb 
A SAAM30 APO B final MODEL in sheep. lambD 
C 
C 
441 
H PAR 
C VLDL SECTION 
c VLDL tracer injected at t=O, TC(O) 
C 
C 
IC(1) B.Oe-2 
IC ( 5 ) 
IC(6) 3.0E-1 
IC(7) 5.0E-l 
IC(B) 
IC(10) .12 
IC(12) 
L(7,1) 
L(B,7) 
L(l,B) 
L(5,B) 
L(9,B) 
L(0,9) 
L(10,9) 
L(12,10) 
L(3,9) 
L(5,1) 
L(6,5) 
L(2,6) 
L(13,2) 
L(2,13) 
L(3,2) 
L(0,2) 
L(10,2) 
L(O,lO) 
L(11,3) 
L(11,1) 
L(12,11) 
L(0,11) 
L(12,3) 
L(4,3) 
L(3,4) 
estimate 
5.0E-1 
0.0 
5.0-1 
2.0E-1 
0.0 
2.0E-1 
1.BE-2 
0.1 
.1 
2.0 
1.5E-2 
5.5E-4 
2.7E-1 
0.0 
1.2 
7.0E-3 
4.0E-2 
1.2E-2 
2.1E-2 
.013 
3.0E-3 
2.4E-4 
H STE 
U(l) 3.530143E+00 
M(1)+M(5)+M(6)=49 
H DAT 
XG(1)=F(1)+F(5)+F(6) 
XG(2)=F(2)+F(13)+F(9) 
XG(3)=F(3)+F(4) 
C 
XG(10)=M(1)+M(5)+M(6) 
XG(20)=M(2)+M(13)+M(9) 
XG(30)=M(3)+M(4) 
100 
minimun 
100 
maximum 
C generating extra points for graph 
101G(1) 
o . 
2 . 1 10 
2 1 10 
2 2 10 
2 5 14 
102G(2) 
O. 
2 .1 10 
2 1 20 
103G(3) 
o . 
2 .1 10 
2 1 20 
103G(3) 
o. 
2 1 10 
2 2 10 
112 
o . 
2 24 10 
H DAT TC(2) 
T 
113G(3) 
O • 
2 . 1 10 
2 1 10 
2 2 10 
122F(12) 
o . 
2 24 10 
H ICC TC(2) 
I I 
1 o. 
7 O. 
6 O. 
10 O. 
3 1. 
C************END OF MODEL********** 
H DAT 
120 FSD=.2 
M ( 1 ) 
M(2) 
M( 3) 
M ( 4) 
M(5) 
M(6) 
M(7) 
M( 8) 
M(9) 
G(10) 49 
G(20) 45.6 
G(30) 152 
C 125-1 DOSE"" 1.77E6 CPM 
C vldl-b concentration = 41.3 ug/ml 
C CPM/ug * 41.3/1.77E6 = fraction of dose/ml 
C PLASMA VOL 1188ML 
C VLDL 125-1 
101G(1) *.0277 
c 1DL 
o 
.17 
.51 
1. 03 
1. 65 
2.28 
3.08 
9.22 
11. 95 
16.68 
24.02 
30.33 
52.52 
99.33 
6.18 
C plasma 1DL_B 38.4ug/ml 
102G(2) 
C 
o 
.17 
.51 
1. 03 
1. 65 
2.28 
3.08 
6.18 
9.22 
11. 95 
16.68 
24.02 
C PLASMA LDL 1-125 
C 
103G(3) 
C 
o 
.17 
.51 
1. 03 
1.65 
2.28 
3.08 
6.18 
9.22 
11. 95 
16.68 
24.02 
30.33 
9.5 
9.18 
8.48 
6.70 
7.24 
7.8 
3.58 
2.04 
3.18 
2.07 
0.92 
0.05 
0.0 
9.4 
*.02577 
3.3 
4.5 
3.78 
5.0 
3.16 
2.59 
3.75 
1. 97 
0.61 
0.61 
0.3 
.0859 
0.12 
0.58 
.099 
.24 
.33 
.5 
.626 
.95 
.86 
.97 
1. 24 
.5 
C CUMULATIVE COUNTS IN URINE 1251 
112 /17.7 
o 
24 
77 
123 
173 
220 
265 
4.62 
9.377 
10.507 
11.5115 
11.8139 
11.9369 
FSD .... 2 
FSD .... 2 
FSD .... 2 
FSD=.2 
337 
H DAT 
T O. 
C DOSE 1311 LDL B 9.95E6 
C PLASMA LDL~B I28ug/m1 
11.99497 
TC(2) 
c spec activity*128/9.95E6-fraction 
C LDL 131-1 
dose/ml 
113G(3) *.0152 
C 
o 
.17 
.3 
.51 
1.65 
2.28 
3.08 
6.18 
9.22 
11.95 
16.68 
30.33 
Curine 1311 cumulative cpm as 
122F(12) 
y 
24 
77 
123 
173 
220 
265 
337 
67.90 
58.94 
59.36 
54.18 
62.30 
52.16 
39.08 
36.05 
18.87 
fraction dose 
/9.95E6 
8.61E5 
24.2E5 
28.47E5 
32.4ES 
33.2ES 
33.SES 
33.7ES 
FSD-.2 
FSD-.2 
